

Statins and the risk of dementia

Lancet, The

356, 1627-1631

DOI: [10.1016/s0140-6736\(00\)03155-x](https://doi.org/10.1016/s0140-6736(00)03155-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Statins reduce dementia risk by 70%. Current Controlled Trials in Cardiovascular Medicine, 2000, 2, 1.	1.5	0
3	Statins associated with reduced risk of dementia. Inpharma Weekly, 2000, &NA;, 9.	0.0	0
4	Use of statins in CNS disorders. Journal of the Neurological Sciences, 2001, 187, 81-89.	0.3	116
6	A Cholesterol-Lowering Drug Reduces β -Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. Neurobiology of Disease, 2001, 8, 890-899.	2.1	505
7	Clinically relevant differences between the statins: implications for therapeutic selection. American Journal of Medicine, 2001, 111, 390-400.	0.6	177
8	Essential fatty acids as possible mediators of the actions of statins. Prostaglandins Leukotrienes and Essential Fatty Acids, 2001, 65, 37-40.	1.0	69
9	Dementia and statins. Lancet, The, 2001, 357, 880.	6.3	3
10	Dementia and statins. Lancet, The, 2001, 357, 880-881.	6.3	3
11	Dementia and statins. Lancet, The, 2001, 357, 881.	6.3	9
12	Dementia and statins. Lancet, The, 2001, 357, 881.	6.3	3
13	Dementia and statins. Lancet, The, 2001, 357, 881.	6.3	4
14	Dementia and statins. Lancet, The, 2001, 357, 882.	6.3	2
15	Cerebrovascular structure and dementia: new drug targets. Trends in Pharmacological Sciences, 2001, 22, 630-635.	4.0	20
16	Cholesterol, $A\beta$ and Alzheimer's disease. Trends in Neurosciences, 2001, 24, S45-S48.	4.2	88
17	Cholesterol, $A\beta$ and Alzheimer's disease. Trends in Neurosciences, 2001, 24, 45-48.	4.2	65
18	Dementia and its associations in type 2 diabetes mellitus: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2001, 53, 165-172.	1.1	41
19	Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet, The, 2001, 357, 455-462.	6.3	230
20	Dementia and statins. Lancet, The, 2001, 357, 880.	6.3	9

#	ARTICLE	IF	CITATIONS
21	Estatinas: ¿estÃ¡ justificada su prescripciÃ³n para indicaciones distintas a la hipercolesterolemia?. FMC Formacion Medica Continuada En Atencion Primaria, 2001, 8, 404-413.	0.0	0
22	Do Statins Afford Neuroprotection in Patients with Cerebral Ischaemia and Stroke?. CNS Drugs, 2001, 15, 589-596.	2.7	30
23	Medication Use in Alzheimer's Disease and Healthy Aging. Clinical Gerontologist, 2001, 24, 75-84.	1.2	0
24	Joint Effect of the <i>APOE</i> Gene and Midlife Systolic Blood Pressure on Late-Life Cognitive Impairment. Stroke, 2001, 32, 2882-2889.	1.0	126
26	11: Disorders of memory and intellect. Medical Journal of Australia, 2001, 175, 433-439.	0.8	3
27	Facts and Ideas from Anywhere. Baylor University Medical Center Proceedings, 2001, 14, 117-122.	0.2	0
28	Issues surrounding age: vascular disease in the elderly. Current Opinion in Lipidology, 2001, 12, 601-609.	1.2	29
29	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 253-256.	1.5	4
30	Pleiotropic effects of statins: do they matter?. Current Opinion in Lipidology, 2001, 12, 391-394.	1.2	71
31	Community studies of psychogeriatric disorders. Current Opinion in Psychiatry, 2001, 14, 383-386.	3.1	3
32	Statins for the prevention of Alzheimer's disease and dementia. , 2001, , CD003160.		56
33	Diagnosis and management of lipid disorders. Clinics in Family Practice, 2001, 3, 757-780.	0.3	1
34	Drug treatment in dementia. Current Opinion in Psychiatry, 2001, 14, 349-353.	3.1	11
35	Alzheimer Disease Therapeutics. Journal of Neuropathology and Experimental Neurology, 2001, 60, 923-928.	0.9	42
36	Pravastatin Improves Cerebral Vasomotor Reactivity in Patients With Subcortical Small-Vessel Disease. Stroke, 2001, 32, 2817-2820.	1.0	110
41	Alzheimer's disease: molecular concepts and therapeutic targets. Die Naturwissenschaften, 2001, 88, 261-267.	0.6	51
42	Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses. Current Atherosclerosis Reports, 2001, 3, 156-162.	2.0	8
43	Pharmacotherapy for Alzheimerâ€™s disease. Current Neurology and Neuroscience Reports, 2001, 1, 428-434.	2.0	20

#	ARTICLE	IF	CITATIONS
44	What Heterogeneity Among Centenarians Can Teach Us About Genetics, Aging, and Longevity. <i>Journal of the American Geriatrics Society</i> , 2001, 49, 1568-1569.	1.3	4
45	Serum Cholesterol and Cerebrospinal Fluid Amyloid β Protein in Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 2001, 49, 1738-1739.	1.3	8
46	Folate Deficiency and Risk of Pneumonia in Older People. <i>Journal of the American Geriatrics Society</i> , 2001, 49, 1739-1741.	1.3	40
48	Alzheimer's amyloid-beta as a preventive antioxidant for brain lipoproteins. <i>Cellular and Molecular Neurobiology</i> , 2001, 21, 299-315.	1.7	29
49	Emerging perspectives on lipid management: international approaches and global challenges. <i>American Journal of Cardiology</i> , 2001, 88, 876-881.	0.7	2
50	Compartmentalization of β -secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. <i>Current Biology</i> , 2001, 11, 1288-1293.	1.8	300
51	Amyloid- β : an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. <i>Free Radical Biology and Medicine</i> , 2001, 31, 1120-1131.	1.3	155
52	Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. <i>Drug Discovery Today</i> , 2001, 6, 1049-1055.	3.2	63
53	Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease. <i>Drug Discovery Today</i> , 2001, 6, 1207-1219.	3.2	31
54	A fluid connection: Cholesterol and β . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 5371-5373.	3.3	187
55	Use of Statins and Risk of Fractures. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 1850.	3.8	232
56	The Prevention of Dementia. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2001, 8, 253-256.	3.1	3
57	Treatment with controlled-release lovastatin decreases serum concentrations of human β -amyloid ($A\beta$) peptide. <i>International Journal of Neuropsychopharmacology</i> , 2001, 4, 127-30.	1.0	87
58	Nutritional Factors and Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2001, 56, M675-M680.	1.7	49
59	Dementia at old age: a clinical end-point of atherosclerotic disease. <i>European Heart Journal Supplements</i> , 2001, 3, N16-N19.	0.0	11
60	Is sticky blood a treatable determinant of cognitive decline and of dementia?. <i>Age and Ageing</i> , 2001, 30, 101-103.	0.7	17
61	Statins: effects beyond cholesterol lowering. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1738-1741.	0.4	45
62	Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the β -secretase ADAM 10. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 5815-5820.	3.3	744

#	ARTICLE	IF	CITATIONS
63	Simvastatin strongly reduces levels of Alzheimer's disease β -amyloid peptides A β 42 and A β 40 in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5856-5861.	3.3	1,050
64	Cholesterol and Alzheimer's disease. Neurology, 2001, 57, 1089-1093.	1.5	260
65	Statins and neuroprotection. Expert Opinion on Investigational Drugs, 2001, 10, 1847-1853.	1.9	29
68	The Devil Is in the Details. The American Journal of Geriatric Cardiology, 2001, 10, 64-65.	0.7	0
69	Bone growth stimulators New tools for treating bone loss and mending fractures. Vitamins and Hormones, 2002, 65, 1-80.	0.7	14
70	Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physiological Reviews, 2002, 82, 637-672.	13.1	391
71	Induction of the Cholesterol Transporter ABCA1 in Central Nervous System Cells by Liver X Receptor Agonists Increases Secreted A β Levels. Journal of Biological Chemistry, 2002, 277, 48508-48513.	1.6	139
72	ABCA1 and Scavenger Receptor Class B, Type I, Are Modulators of Reverse Sterol Transport at an in Vitro Blood-Brain Barrier Constituted of Porcine Brain Capillary Endothelial Cells. Journal of Biological Chemistry, 2002, 277, 42781-42789.	1.6	177
73	Use of Lipid-Lowering Agents, Indication Bias, and the Risk of Dementia in Community-Dwelling Elderly People. Archives of Neurology, 2002, 59, 223.	4.9	495
74	Antioxidant strategies for Alzheimer's disease. Proceedings of the Nutrition Society, 2002, 61, 191-202.	0.4	166
75	Function of β -amyloid in cholesterol transport: a lead to neurotoxicity. FASEB Journal, 2002, 16, 1677-1679.	0.2	109
76	Reduction of Plasma 24S-Hydroxycholesterol (Cerebrosterol) Levels Using High-Dosage Simvastatin in Patients With Hypercholesterolemia. Archives of Neurology, 2002, 59, 213.	4.9	154
77	Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women. Archives of Neurology, 2002, 59, 378.	4.9	420
78	The Risk of Obesity and the Trp64Arg Polymorphism of the β -Adrenergic Receptor: Effect Modification by Age. Annals of Nutrition and Metabolism, 2002, 46, 152-158.	1.0	32
79	A safety look at currently available statins. Expert Opinion on Drug Safety, 2002, 1, 269-274.	1.0	19
80	Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Report, 2002, 7, 199-206.	1.4	167
81	No Association of Paraoxonase Genotype or Atherosclerosis With Cerebral Amyloid Angiopathy. Stroke, 2002, 33, 896-900.	1.0	13
82	Alzheimers Disease: An Overview of Current and Emerging Therapeutic Strategies. Current Topics in Medicinal Chemistry, 2002, 2, 343-352.	1.0	28

#	ARTICLE	IF	CITATIONS
83	Clinical Significance of Pleiotropic Effects of Statins: Lipid Reduction and Beyond. <i>Current Medicinal Chemistry</i> , 2002, 9, 1831-1850.	1.2	54
84	Diet and risk of dementia: Does fat matter?. <i>Neurology</i> , 2002, 59, 1915-1921.	1.5	280
85	Einsatz der Statine in der Neurologie. <i>Aktuelle Neurologie</i> , 2002, 29, 254-261.	0.1	4
86	Apolipoprotein E (ApoE) Isoform-dependent Lipid Release from Astrocytes Prepared from Human ApoE3 and ApoE4 Knock-in Mice. <i>Journal of Biological Chemistry</i> , 2002, 277, 29919-29926.	1.6	183
87	Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 423-437.	1.8	64
88	Pharmacologic Agents Associated with a Preventive Effect on Alzheimer's Disease: A Review of the Epidemiologic Evidence. <i>Epidemiologic Reviews</i> , 2002, 24, 248-268.	1.3	56
89	A Cross-Sectional Study of Lipids and ApoC Levels in Alzheimer's Patients With and Without Cardiovascular Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2002, 57, M757-M761.	1.7	12
90	The Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2002, 57, M414-M418.	1.7	158
91	Prevalence and Impact of Medical Comorbidity in Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2002, 57, M173-M177.	1.7	213
92	Statin Therapy in Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1524-1534.	1.1	146
93	Do persons with dementia vote?. <i>Neurology</i> , 2002, 59, 149-149.	1.5	8
94	Risk Factors for Alzheimer's Disease: Role of Multiple Antioxidants, Non-Steroidal Anti-inflammatory and Cholinergic Agents Alone or in Combination in Prevention and Treatment. <i>Journal of the American College of Nutrition</i> , 2002, 21, 506-522.	1.1	65
95	Regulation of Cholesterol Homeostasis by the Liver X Receptors in the Central Nervous System. <i>Molecular Endocrinology</i> , 2002, 16, 1378-1385.	3.7	182
96	Evolution and the Plasticity of Aging in the Reproductive Schedules in Long-Lived Animals. , 2002, , 799-820.		5
97	Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. <i>Journal of Lipid Research</i> , 2002, 43, 1078-1085.	2.0	132
98	Ischemic stroke and active migraine. <i>Neurology</i> , 2002, 59, 149-150.	1.5	3
99	Neurodegenerative diseases. , 2002, , 210-236.		3
100	Aging and dementia: principles, evaluation and diagnosis. , 2002, , 237-251.		1

#	ARTICLE	IF	CITATIONS
102	The significance of environmental factors in the etiology of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2002, 4, 179-189.	1.2	187
103	Statins in the Prevention and Treatment of Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2002, 16, 131-136.	0.6	80
104	Statins and stroke: evidence for cholesterol-independent effects. <i>European Heart Journal</i> , 2002, 23, 1908-1921.	1.0	77
105	Cholesterol and Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2002, 30, 525-529.	1.6	51
106	Treatment of Dyslipidaemia in the Elderly. <i>Journal of Pharmacy Practice and Research</i> , 2002, 32, 188-193.	0.5	1
107	Long Term Administration of Hypericum perforatum Improves Spatial Learning and Memory in the Water Maze.. <i>Biological and Pharmaceutical Bulletin</i> , 2002, 25, 1289-1294.	0.6	31
108	Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. <i>Neurology</i> , 2002, 59, 1257-1258.	1.5	115
109	Cognitive Pharmacotherapy of Alzheimer's Disease and other Dementias. <i>Canadian Journal of Psychiatry</i> , 2002, 47, 715-722.	0.9	14
110	Non-familial Alzheimer's disease is mainly due to genetic factors. <i>Journal of Alzheimer's Disease</i> , 2002, 4, 169-177.	1.2	132
111	Chapter 20. Searching for Alzheimer's disease therapies in your medicine cabinet: The epidemiological and mechanistic case for NSAIDs and statins. <i>Annual Reports in Medicinal Chemistry</i> , 2002, 37, 197-208.	0.5	0
112	Recent developments: Recent developments in neurology. <i>BMJ: British Medical Journal</i> , 2002, 324, 656-660.	2.4	6
113	Is ACAT a novel pharmacological target for the treatment of Alzheimer's disease?. <i>Drugs of the Future</i> , 2002, 27, 863.	0.0	1
114	Hypertension and Hypercholesterolaemia as Risk Factors for Alzheimer's Disease. <i>CNS Drugs</i> , 2002, 16, 435-444.	2.7	66
115	Alzheimer Disease as a Vascular Disorder. <i>Stroke</i> , 2002, 33, 1152-1162.	1.0	788
116	Cholesterol-Dependent β -Secretase Activity in Buoyant Cholesterol-Rich Membrane Microdomains. <i>Neurobiology of Disease</i> , 2002, 9, 11-23.	2.1	406
117	Interactions of $A\beta$ with Endogenous Anti-Inflammatory Agents: A Basis for Chronic Neuroinflammation in Alzheimer's Disease. <i>Neurobiology of Disease</i> , 2002, 10, 187-200.	2.1	7
118	Microvascular damage and platelet abnormalities in early Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2002, 203-204, 189-193.	0.3	43
119	Pharmacodynamic activity of drugs and ecotoxicology" can the two be connected?. <i>Toxicology Letters</i> , 2002, 131, 105-115.	0.4	135

#	ARTICLE	IF	CITATIONS
120	Statins inhibit A β ¹⁻² -neurotoxicity in vitro and A β ¹⁻² -induced vasoconstriction and inflammation in rat aortae. <i>Atherosclerosis</i> , 2002, 161, 293-299.	0.4	32
121	Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors. <i>Clinical Pharmacokinetics</i> , 2002, 41, 719-739.	1.6	303
122	Cholesterol attenuates the membrane perturbing properties of A β ¹⁻² -amyloid peptides. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2002, 9, 149-160.	1.4	29
123	The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics. <i>Science</i> , 2002, 297, 353-356.	6.0	12,113
124	Apolipoprotein E ϵ 4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease. <i>Annals of Internal Medicine</i> , 2002, 137, 149.	2.0	561
125	Health-Related Quality of Life and Long-Term Therapy with Pravastatin and Tocopherol (Vitamin E) in Older Adults. <i>Drugs and Aging</i> , 2002, 19, 793-805.	1.3	33
126	Could statins prevent age-related macular degeneration?. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 803-807.	0.9	10
127	HYPOLIPEMIC AGENTS FOR STROKE PREVENTION. <i>Clinical and Experimental Hypertension</i> , 2002, 24, 573-594.	0.5	8
128	Is pharmacological prevention of Alzheimer's a realistic goal?. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 365-380.	0.9	16
129	Non-Cholinergic Strategies for Treating and Preventing Alzheimer's Disease. <i>CNS Drugs</i> , 2002, 16, 811-824.	2.7	123
130	Case-control studies: research in reverse. <i>Lancet, The</i> , 2002, 359, 431-434.	6.3	352
131	MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. <i>Lancet, The</i> , 2002, 360, 7-22.	6.3	7,542
132	Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. <i>Lancet, The</i> , 2002, 360, 1623-1630.	6.3	3,147
133	High-risk elderly patients PROSPER from cholesterol-lowering therapy. <i>Lancet, The</i> , 2002, 360, 1618-1619.	6.3	35
134	Lipoprotein Receptors in the Nervous System. <i>Annual Review of Biochemistry</i> , 2002, 71, 405-434.	5.0	402
135	Aluminum accumulation and membrane fluidity alteration in synaptosomes isolated from rat brain cortex following aluminum ingestion: effect of cholesterol. <i>Neuroscience Research</i> , 2002, 44, 181-193.	1.0	42
136	Biogenesis and metabolism of Alzheimer's disease A β ¹⁻² amyloid peptides. <i>Peptides</i> , 2002, 23, 1285-1297.	1.2	149
137	Brain membrane cholesterol domains, aging and amyloid beta-peptides. <i>Neurobiology of Aging</i> , 2002, 23, 685-694.	1.5	139

#	ARTICLE	IF	CITATIONS
138	Neuroprotective and neurorestorative signal transduction mechanisms in brain aging: modification by genes, diet and behavior. <i>Neurobiology of Aging</i> , 2002, 23, 695-705.	1.5	89
139	Policosanol safely down-regulates HMG-CoA reductase " potential as a component of the Esselstyn regimen. <i>Medical Hypotheses</i> , 2002, 59, 268-279.	0.8	46
140	Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. <i>Trends in Pharmacological Sciences</i> , 2002, 23, 324-330.	4.0	63
141	Statins as novel therapies for osteoporosis?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2002, 101, 4-5.	0.5	6
142	Possible association between genetic variability at the apolipoprotein(a) locus and Alzheimer's disease in apolipoprotein E2 carriers. <i>Neuroscience Letters</i> , 2002, 331, 60-62.	1.0	12
143	Should Hypercholesterolemia Be Treated in Frail Elders?. <i>Journal of the American Medical Directors Association</i> , 2002, 3, 66-70.	1.2	1
144	Prevention of brain aging and dementia. <i>Clinics in Geriatric Medicine</i> , 2002, 18, 485-503.	1.0	32
145	Vascular dementia revisited: Diagnosis, pathogenesis, treatment, and prevention. <i>Medical Clinics of North America</i> , 2002, 86, 477-499.	1.1	128
146	Estatinas en el tratamiento de la hipertensi3n arterial. <i>Hipertension Y Riesgo Vascular</i> , 2002, 19, 400-405.	0.3	3
147	Inhibition of Intracellular Cholesterol Transport Alters Presenilin Localization and Amyloid Precursor Protein Processing in Neuronal Cells. <i>Journal of Neuroscience</i> , 2002, 22, 1679-1689.	1.7	232
148	Nutrition and Cognition in Older Persons. , 2002, 6, 121-134.		1
149	Pharmacological concentrations of the HMG-COA reductase inhibitor lovastatin decrease the formation of the Alzheimer b-amyloid peptide in vitro and in patients. <i>Frontiers in Bioscience - Landmark</i> , 2002, 7, a50.	3.0	40
150	Maladie d'Alzheimer : vision ensemble, aspects cliniques, facteurs de risque et prvention. <i>Medicine/Sciences</i> , 2002, 18, 689-696.	0.0	0
151	Pharmacological concentrations of the HMG-COA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta -amyloid peptide em in vitro em and in patients. <i>Frontiers in Bioscience - Landmark</i> , 2002, 7, a50-59.	3.0	41
152	Implications of Amyloid Precursor Protein and Subsequent 12-Amyloid Production to the Pharmacotherapy of Alzheimer's Disease. <i>Pharmacotherapy</i> , 2002, 22, 1547-1563.	1.2	9
153	Pharmacogenomics in cardiovascular diseases. <i>Progress in Cardiovascular Diseases</i> , 2002, 44, 479-498.	1.6	27
155	Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins. <i>Brain Research</i> , 2002, 958, 100-111.	1.1	40
156	Subcortical ischaemic vascular dementia. <i>Lancet Neurology, The</i> , 2002, 1, 426-436.	4.9	958

#	ARTICLE	IF	CITATIONS
158	Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis. This article is part of a series of reviews on "Causes and Consequences of Oxidative Stress in Alzheimer's Disease." The full list of papers may be found on the homepage of the journal. Free Radical Biology and Medicine, 2002, 33, 173-181.	1.3	70
159	Estrogen, statins, and polyunsaturated fatty acids: similarities in their actions and benefits? "is there a common link?". Nutrition, 2002, 18, 178-188.	1.1	46
160	Association between high-density lipoprotein and cognitive impairment in the oldest old. Annals of Neurology, 2002, 51, 716-721.	2.8	164
161	Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Annals of Neurology, 2002, 52, 346-350.	2.8	372
162	Mevastatin induces degeneration and decreases viability of cAMP-induced differentiated neuroblastoma cells in culture by inhibiting proteasome activity, and mevalonic acid lactone prevents these effects. Journal of Neuroscience Research, 2002, 68, 627-635.	1.3	32
163	Amyloid β -protein affects cholesterol metabolism in cultured neurons: Implications for pivotal role of cholesterol in the amyloid cascade. Journal of Neuroscience Research, 2002, 70, 438-446.	1.3	53
164	Cholesterol and pathological processes in Alzheimer's disease. Journal of Neuroscience Research, 2002, 70, 361-366.	1.3	69
165	Neuroplasticity in Alzheimer's disease. Journal of Neuroscience Research, 2002, 70, 402-437.	1.3	102
166	Thinking preventively about dementia: a review. International Journal of Geriatric Psychiatry, 2002, 17, 895-906.	1.3	12
167	Vascular risk factors, ApoE ϵ 4 allele, and gender and the risk of Alzheimer's disease: perspectives on prevention. Drug Development Research, 2002, 56, 85-94.	1.4	9
168	Therapeutic strategies of Alzheimer's disease through manipulation of A β metabolism: a focus on A β -degrading peptidase, neprilysin. Drug Development Research, 2002, 56, 171-183.	1.4	6
169	Targeting APP metabolism for the treatment of Alzheimer's disease. Drug Development Research, 2002, 56, 211-227.	1.4	15
170	Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease. Drug Development Research, 2002, 56, 415-420.	1.4	4
171	Statin therapy for Alzheimer's disease. Journal of Molecular Neuroscience, 2002, 19, 155-161.	1.1	152
172	Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated?. Journal of Molecular Neuroscience, 2002, 19, 209-212.	1.1	3
173	Prevention of Alzheimer's disease: Where we stand. Current Neurology and Neuroscience Reports, 2002, 2, 392-399.	2.0	9
175	Kosten-Effektivität der KHK-Prävention. Clinical Research in Cardiology, 2002, 91, 1-1.	1.2	5
176	Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Research in Cardiology, 2002, 97, 105-116.	2.5	187

#	ARTICLE	IF	CITATIONS
177	Use of Lipid-Lowering Drugs in Older Adults With and Without Dementia: A Community-Based Epidemiological Study. <i>Journal of the American Geriatrics Society</i> , 2002, 50, 1852-1856.	1.3	93
178	New Possible Role of Statins in Age-Related Diseases. <i>Journal of the American Geriatrics Society</i> , 2002, 50, 2099-2100.	1.3	11
179	Second-Generation Issues in the Management of Depression in Nursing Homes. <i>Journal of the American Geriatrics Society</i> , 2002, 50, 2100-2101.	1.3	9
180	Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. <i>Molecular Psychiatry</i> , 2002, 7, 899-902.	4.1	139
181	Alzheimer's disease: treatments in discovery and development. <i>Nature Neuroscience</i> , 2002, 5, 1055-1057.	7.1	154
182	Therapeutic strategies for Alzheimer's disease. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 859-866.	21.5	167
183	Prospects for the prevention of dementia. <i>Australasian Journal on Ageing</i> , 2002, 21, 9-13.	0.4	12
184	Vascular Basis of Alzheimer's Pathogenesis. <i>Annals of the New York Academy of Sciences</i> , 2002, 977, 196-215.	1.8	217
185	Cholesterol and Cognition. <i>Annals of the New York Academy of Sciences</i> , 2002, 977, 356-366.	1.8	26
186	Cholesterol in Alzheimer's Disease and Tauopathy. <i>Annals of the New York Academy of Sciences</i> , 2002, 977, 367-375.	1.8	116
187	Apolipoproteins and ? Amyloid Transport Pathway. <i>Psychogeriatrics</i> , 2002, 2, 149-155.	0.6	0
188	Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. <i>Biochemistry (Moscow)</i> , 2002, 67, 85-91.	0.7	17
189	Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. <i>Cellular and Molecular Neurobiology</i> , 2002, 22, 545-563.	1.7	65
190	Changes in Apolipoprotein E Expression in Response to Dietary and Pharmacological Modulation of Cholesterol. <i>Journal of Molecular Neuroscience</i> , 2003, 20, 395-406.	1.1	47
191	The Role of Cholesterol in Pathogenesis of Alzheimer's Disease: Dual Metabolic Interaction between Amyloid β -Protein and Cholesterol. <i>Molecular Neurobiology</i> , 2003, 27, 1-12.	1.9	81
192	Use of in vivo models to study the role of cholesterol in the etiology of Alzheimer's disease. <i>Neurochemical Research</i> , 2003, 28, 979-986.	1.6	21
193	Plasticity and the spread of Alzheimer's disease-like changes. <i>Neurochemical Research</i> , 2003, 28, 1715-1723.	1.6	9
194	Beta-amyloid and cholinergic neurons. <i>Neurochemical Research</i> , 2003, 28, 499-506.	1.6	26

#	ARTICLE	IF	CITATIONS
195	Pharmacoeconomics of lipid-lowering drugs. <i>Current Atherosclerosis Reports</i> , 2003, 5, 67-72.	2.0	0
197	Brain region-dependent increases in β -amyloid and apolipoprotein E levels in hypercholesterolemic rabbits. <i>Journal of Neural Transmission</i> , 2003, 110, 641-649.	1.4	37
199	Vascular cognitive impairment. <i>Lancet Neurology, The</i> , 2003, 2, 89-98.	4.9	1,130
200	Treatment of Alzheimer's disease; current status and new perspectives. <i>Lancet Neurology, The</i> , 2003, 2, 539-547.	4.9	664
201	Cognitive Impairment Associated with Atorvastatin and Simvastatin. <i>Pharmacotherapy</i> , 2003, 23, 1663-1667.	1.2	123
202	The Role of Lipid-Lowering Drugs in Cognitive Function: A Meta-Analysis of Observational Studies. <i>Pharmacotherapy</i> , 2003, 23, 726-730.	1.2	61
203	Statin-Associated Memory Loss: Analysis of 60 Case Reports and Review of the Literature. <i>Pharmacotherapy</i> , 2003, 23, 871-880.	1.2	308
204	Pharmacogenomics in cardiovascular diseases. <i>Current Problems in Cardiology</i> , 2003, 28, 317-347.	1.1	10
205	Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. <i>Developmental Brain Research</i> , 2003, 146, 87-98.	2.1	148
207	Statin effects on cholesterol micro-domains in brain plasma membranes. <i>Biochemical Pharmacology</i> , 2003, 65, 843-856.	2.0	162
208	Expression of acetoacetyl-CoA synthetase, a novel cytosolic ketone body-utilizing enzyme, in human brain. <i>Biochemical Pharmacology</i> , 2003, 65, 989-994.	2.0	25
209	Prevention of stroke and dementia with statins. <i>American Journal of Cardiology</i> , 2003, 91, 23-29.	0.7	119
210	Stress proteins and glial functions: possible therapeutic targets for neurodegenerative disorders. , 2003, 97, 35-53.		55
211	Is degenerative calcification of the native aortic valve similar to calcification of bioprosthetic heart valves?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 126, 939-941.	0.4	33
212	ADAMs family members as amyloid precursor protein β -secretases. <i>Journal of Neuroscience Research</i> , 2003, 74, 342-352.	1.3	402
213	Medicinal chemistry approaches for the treatment and prevention of Alzheimer's disease. <i>Medicinal Research Reviews</i> , 2003, 23, 48-88.	5.0	86
214	Association of the C766T polymorphism of the low-density lipoprotein receptor-related protein gene with Alzheimer's disease. , 2003, 121B, 128-130.		38
216	Treatment of mild cognitive impairment: rationale, present and future strategies. <i>Acta Neurologica Scandinavica</i> , 2003, 107, 83-93.	1.0	19

#	ARTICLE	IF	CITATIONS
217	Arterial hypertension and ischaemic stroke. <i>Acta Neurologica Scandinavica</i> , 2003, 107, 241-251.	1.0	41
218	Cholesterol is necessary both for the toxic effect of A β peptides on vascular smooth muscle cells and for A β binding to vascular smooth muscle cell membranes. <i>Journal of Neurochemistry</i> , 2003, 84, 471-479.	2.1	90
219	An Outbreak of Severe Acute Respiratory Syndrome in a Nursing Home. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 1504-1505.	1.3	9
220	Benefits of Statins in the Elderly. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 1509-1510.	1.3	0
221	Pathology and Pathways of Alzheimer's Disease with an Update on New Developments in Treatment. <i>Journal of the American Geriatrics Society</i> , 2003, 51, S314-S320.	1.3	39
223	Recent trends in lipid management: raising the bar and shifting the goalposts?. <i>Internal Medicine Journal</i> , 2003, 33, 95-102.	0.5	0
224	Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2003, 17, 93-102.	1.2	87
225	Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 288-298.	1.1	14
227	Alzheimer's disease: the cholesterol connection. <i>Nature Neuroscience</i> , 2003, 6, 345-351.	7.1	751
228	Tratamiento farmacolÃ³gico del riesgo cardiovascular metabÃ³lico. <i>Medicine</i> , 2003, 8, 6382-6395.	0.0	0
229	Long-term statin use and psychological well-being. <i>Journal of the American College of Cardiology</i> , 2003, 42, 690-697.	1.2	121
230	The Pleiotropic Effects of HMG-CoA Reductase Inhibitors. <i>Drugs</i> , 2003, 63, 139-152.	4.9	47
231	Pravastatin inhibits pro-inflammatory effects of Alzheimer's peptide A β 1-42 in glioma cell culture in vitro. <i>Pharmacological Research</i> , 2003, 47, 119-126.	3.1	18
232	Will a Healthy Lifestyle Help Prevent Alzheimer's Disease?. <i>Annual Review of Public Health</i> , 2003, 24, 111-132.	7.6	106
233	Amyloidogenic processing of the Alzheimer β -amyloid precursor protein depends on lipid rafts. <i>Journal of Cell Biology</i> , 2003, 160, 113-123.	2.3	992
234	Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. <i>Progress in Neurobiology</i> , 2003, 71, 83-248.	2.8	176
235	Association of Aortic Atherosclerosis with Cerebral β -Amyloidosis and Learning Deficits in a Mouse Model of Alzheimer's Disease. <i>American Journal of Pathology</i> , 2003, 163, 2155-2164.	1.9	125
236	ALZHEIMER'S DISEASE: Molecular Understanding Predicts Amyloid-Based Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2003, 43, 545-584.	4.2	785

#	ARTICLE	IF	CITATIONS
237	NSAIDs and enantiomers of flurbiprofen target β -secretase and lower $A\beta_{42}$ in vivo. <i>Journal of Clinical Investigation</i> , 2003, 112, 440-449.	3.9	476
238	Alzheimer's disease and angiogenesis. <i>Lancet</i> , The, 2003, 361, 605-608.	6.3	263
239	Alzheimer's disease and angiogenesis. <i>Lancet</i> , The, 2003, 361, 1299.	6.3	62
240	Alzheimer's disease and angiogenesis. <i>Lancet</i> , The, 2003, 361, 1300.	6.3	1
241	Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2003, 1610, 281-290.	1.4	145
242	β -Amyloid-specific upregulation of stearyl coenzyme A desaturase-1 in macrophages. <i>Biochemical and Biophysical Research Communications</i> , 2003, 303, 302-305.	1.0	23
243	Transcriptional regulation of farnesyl pyrophosphate synthase by liver X receptors. <i>Steroids</i> , 2003, 68, 685-691.	0.8	14
244	Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease. <i>Neuroscience Letters</i> , 2003, 343, 213-215.	1.0	29
245	Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid- β ($A\beta$) 40 or $A\beta$ 42 in humans. <i>Neuroscience Letters</i> , 2003, 350, 161-164.	1.0	46
246	Serum cholesterol, precursors and metabolites and cognitive performance in an aging population. <i>Neurobiology of Aging</i> , 2003, 24, 147-155.	1.5	76
247	ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003, 24, 421-426.	1.5	148
248	$A\beta_{42}$ generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3 β signaling-dependent mechanism. <i>Neurobiology of Aging</i> , 2003, 24, 437-451.	1.5	71
249	Lovastatin enhances $A\beta$ production and senile plaque deposition in female Tg2576 mice. <i>Neurobiology of Aging</i> , 2003, 24, 637-643.	1.5	131
250	High cholesterol affects platelet APP processing in controls and in AD patients. <i>Neurobiology of Aging</i> , 2003, 24, 631-636.	1.5	24
251	Co-localization of cholesterol, apolipoprotein E and fibrillar $A\beta$ in amyloid plaques. <i>Molecular Brain Research</i> , 2003, 110, 119-125.	2.5	108
252	Identification of neuronal plasma membrane microdomains that colocalize β -amyloid and presenilin: implications for β -amyloid precursor protein processing. <i>Neuroscience</i> , 2003, 120, 291-300.	1.1	25
253	The cholesterol-lowering drug ProbucoI increases apolipoprotein e production in the hippocampus of aged rats: implications for Alzheimer's disease. <i>Neuroscience</i> , 2003, 121, 99-110.	1.1	64
254	Can the premises of the altered homeostatic theory permit improvement in the prevention of ischemic heart disease?. <i>Medical Hypotheses</i> , 2003, 60, 12-25.	0.8	3

#	ARTICLE	IF	CITATIONS
255	Molecular Mechanisms of Amyloidosis. <i>New England Journal of Medicine</i> , 2003, 349, 583-596.	13.9	1,629
256	Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. <i>Trends in Molecular Medicine</i> , 2003, 9, 94-101.	3.5	149
257	Evolution by Phenotype: A Biomedical Perspective. <i>Perspectives in Biology and Medicine</i> , 2003, 46, 159-182.	0.3	32
258	Is Breakdown of the Blood-Brain Barrier Responsible for Lacunar Stroke, Leukoaraiosis, and Dementia?. <i>Stroke</i> , 2003, 34, 806-812.	1.0	551
259	Cyp46 (24S-Cholesterol Hydroxylase). <i>Archives of Neurology</i> , 2003, 60, 16.	4.9	40
260	Statins stimulate arachidonic acid release and prostaglandin I ₂ production in rat liver cells. <i>Lipids in Health and Disease</i> , 2003, 2, 1.	1.2	43
261	Benefits of Optimising Drug Treatment in Home-Dwelling Elderly Patients with Coronary Artery Disease. <i>Drugs and Aging</i> , 2003, 20, 585-595.	1.3	6
262	Dietary Lipids in the Aetiology of Alzheimer's Disease. <i>Drugs and Aging</i> , 2003, 20, 399-418.	1.3	36
263	HMG-CoA Reductase Inhibitors in Osteoporosis. <i>Drugs and Aging</i> , 2003, 20, 321-336.	1.3	11
264	Statin Therapy in the Elderly. <i>Drugs and Aging</i> , 2003, 20, 263-275.	1.3	19
265	Vaccines for Alzheimer's Disease. <i>CNS Drugs</i> , 2003, 17, 457-474.	2.7	39
266	Reduction of Serum LDL-C Levels. <i>American Journal of Cardiovascular Drugs</i> , 2003, 3, 271-281.	1.0	16
267	Preventing and treating Alzheimer's disease: strategies and prospects. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 565-569.	1.4	5
268	Reduction in Levels of 24S-Hydroxycholesterol by Statin Treatment in Patients With Alzheimer Disease. <i>Archives of Neurology</i> , 2003, 60, 510.	4.9	155
269	Serum lipids and memory in a population based cohort of middle age women. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 1530-1535.	0.9	73
270	Cholesterol. <i>Journal of Lipid Research</i> , 2003, 44, 1423-1430.	2.0	68
271	Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 2651.	3.8	1,843
272	Association of 3'-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer's disease. <i>Journal of Medical Genetics</i> , 2003, 40, 424-430.	1.5	37

#	ARTICLE	IF	CITATIONS
273	Expression of Liver X Receptor Target Genes Decreases Cellular Amyloid β Peptide Secretion. <i>Journal of Biological Chemistry</i> , 2003, 278, 27688-27694.	1.6	160
274	Dietary fat modulation of apoA-II metabolism and prevention of senile amyloidosis in the senescence-accelerated mouse. <i>Journal of Lipid Research</i> , 2003, 44, 762-769.	2.0	17
275	Early Embryonic Lethality Caused by Targeted Disruption of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Gene. <i>Journal of Biological Chemistry</i> , 2003, 278, 42936-42941.	1.6	94
276	Drugs and Vascular Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 1-6.	0.7	10
277	Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE). <i>Journal of Biological Chemistry</i> , 2003, 278, 38829-38839.	1.6	332
278	Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease. <i>Journal of Lipid Research</i> , 2003, 44, 2019-2029.	2.0	69
279	Treatment with Simvastatin in Patients with Alzheimer's Disease Lowers Both β - and β -Cleaved Amyloid Precursor Protein. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 25-30.	0.7	102
280	Rapid Effects of Statins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 156-157.	1.1	27
281	Dietary Fats and the Risk of Incident Alzheimer Disease. <i>Archives of Neurology</i> , 2003, 60, 194.	4.9	436
282	Anti-Amyloidogenic Effect of <i>Allium sativum</i> in Alzheimer's Transgenic Model Tg2576. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2003, 3, 95-107.	0.1	32
283	A Novel Anti-Inflammatory Role for Simvastatin in Inflammatory Arthritis. <i>Journal of Immunology</i> , 2003, 170, 1524-1530.	0.4	399
284	Progenitor endothelial cell involvement in Alzheimer's disease. <i>Neurological Research</i> , 2003, 25, 617-624.	0.6	6
285	Alzheimer's disease: from molecular pathogenesis to innovative therapies. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 619-630.	1.4	11
286	Association of Abnormal Serum Lipids in Elderly Persons With Atherosclerotic Vascular Disease and Dementia, Atherosclerotic Vascular Disease Without Dementia, Dementia Without Atherosclerotic Vascular Disease, and No Dementia or Atherosclerotic Vascular Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> . 2003, 58, M859-M861.	1.7	23
287	Cholesterol Distribution in the Golgi Complex of DITNC1 Astrocytes Is Differentially Altered by Fresh and Aged Amyloid β -Peptide-(1-42). <i>Journal of Biological Chemistry</i> , 2003, 278, 17150-17157.	1.6	26
288	Cholesterol, β -amyloid, and Alzheimer's disease. <i>Advances in Cell Aging and Gerontology</i> , 2003, 12, 163-175.	0.1	0
289	Exclusively targeting β -secretase to lipid rafts by GPI-anchor addition up-regulates β -site processing of the amyloid precursor protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 11735-11740.	3.3	346
291	Autosomal Recessive Hypercholesterolemia Protein Interacts with and Regulates the Cell Surface Level of Alzheimer's Amyloid β Precursor Protein. <i>Journal of Biological Chemistry</i> , 2003, 278, 31843-31847.	1.6	27

#	ARTICLE	IF	CITATIONS
292	Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease. Archives of Internal Medicine, 2003, 163, 1053.	4.3	250
293	Hypertension, hypertension-clustering factors and Alzheimer's disease. Neurological Research, 2003, 25, 675-680.	0.6	98
294	Cerebrovascular risk factors in Alzheimer's disease: Brain hemodynamics and pharmacogenomic implications. Neurological Research, 2003, 25, 567-580.	0.6	69
295	The risk of dementia in relation to statins and other lipid lowering agents. Neurological Research, 2003, 25, 601-604.	0.6	24
296	Brain Cholesterol, Statins and Alzheimer's Disease. Pharmacopsychiatry, 2003, 36, 113-119.	1.7	41
297	Cholesterol Modulates Amyloid Beta-peptide's Membrane Interactions. Pharmacopsychiatry, 2003, 36, 136-143.	1.7	42
299	Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology, 2003, 61, 199-205.	1.5	291
301	24S-Hydroxycholesterol: a Marker of Brain Cholesterol Metabolism. Pharmacopsychiatry, 2003, 36, 102-106.	1.7	61
302	Cholesterol and Tau Protein - Findings in Alzheimer's and Niemann Pick C's Disease. Pharmacopsychiatry, 2003, 36, 120-126.	1.7	41
303	Cholesterol, Synaptic Function and Alzheimer's Disease. Pharmacopsychiatry, 2003, 36, 107-112.	1.7	28
304	Pharmacotherapy for Alzheimer's Disease: 2002. Clinical Neuropharmacology, 2003, 26, 93-101.	0.2	16
305	Vascular factors and cognition: toward a prevention of dementia?. Journal of Hypertension, 2003, 21, S15-S19.	0.3	3
306	Melanoma Chemoprevention: A Role for Statins or Fibrates?. American Journal of Therapeutics, 2003, 10, 203-210.	0.5	42
307	Is Cholesterol a Culprit in Alzheimer's Disease?. International Psychogeriatrics, 2003, 15, 153-159.	0.6	15
308	Clinical Features of MRI-Defined Subcortical Vascular Disease. Alzheimer Disease and Associated Disorders, 2003, 17, 236-242.	0.6	60
309	Statins as potential therapeutic agents in neuroinflammatory disorders. Current Opinion in Neurology, 2003, 16, 393-401.	1.8	97
310	Dementia Update 2003. Alzheimer Disease and Associated Disorders, 2003, 17, 245-258.	0.6	32
311	Neuropsychiatric Effects of Cardiovascular Drug Therapy. Cardiology in Review, 2003, 11, 73-93.	0.6	68

#	ARTICLE	IF	CITATIONS
312	Vascular Factors and Risk of Dementia: Design of the Three-City Study and Baseline Characteristics of the Study Population. <i>Neuroepidemiology</i> , 2003, 22, 316-325.	1.1	570
313	ALZHEIMER DISEASE: GENES AND ENVIRONMENT; THE VALUE OF INTERNATIONAL STUDIES. , 2003, , .		0
314	The Role of Cardiovascular Risk Factors in Alzheimer's Disease. <i>CNS Spectrums</i> , 2003, 8, 824-831.	0.7	18
315	Current Concepts in the Prevention of Alzheimer's Disease. <i>CNS Spectrums</i> , 2003, 8, 846-853.	0.7	16
316	The incorporation and metabolism of amyloid- β^2 into chylomicron-like lipid emulsions. <i>Journal of Alzheimer's Disease</i> , 2003, 5, 179-188.	1.2	29
317	Statins and Stroke. <i>Therapie</i> , 2003, 58, 49-58.	0.6	3
319	Cerebrovascular Disease in Italy and Europe: It Is Necessary to Prevent a "Pandemia". <i>Gerontology</i> , 2003, 49, 69-79.	1.4	8
320	Prevention of Alzheimer's Disease and Other Dementias. <i>Journal of Pharmacy Practice and Research</i> , 2003, 33, 138-143.	0.5	2
321	Increased Brain β^2 -Amyloid Load, Phosphorylated Tau, and Risk of Alzheimer Disease Associated With an Intronic CYP46 Polymorphism. <i>Archives of Neurology</i> , 2003, 60, 29.	4.9	210
322	Emerging Therapeutics for Alzheimer's Disease: An Avenue of Hope. <i>CNS Spectrums</i> , 2003, 8, 834-845.	0.7	8
323	2 Epidemiologie psychischer Störungen im Alter. , 2003, , .		0
324	Statins as potential therapeutic agents in neuroinflammatory disorders. <i>Current Opinion in Neurology</i> , 2003, 16, 393-401.	1.8	78
326	Presenilin Redistribution Associated with Aberrant Cholesterol Transport Enhances β^2 -Amyloid Production <i>In Vivo</i> . <i>Journal of Neuroscience</i> , 2003, 23, 5645-5649.	1.7	170
327	Pharmacological Treatment of Dementia: A Review. , 2003, , 199-278.		1
328	NATURAL PRODUCTS AS PHARMACEUTICALS AND SOURCES FOR LEAD STRUCTURES. , 2003, , 91-109.		7
329	Molecular Mechanisms of Neurodegenerative Disorders. , 0, , 377-409.		1
330	Lipid Rafts in the Maintenance of Synapses, Dendritic Spines, and Surface AMPA Receptor Stability. <i>Journal of Neuroscience</i> , 2003, 23, 3262-3271.	1.7	527
331	3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Protect Cortical Neurons from Excitotoxicity. <i>Journal of Neuroscience</i> , 2003, 23, 11104-11111.	1.7	236

#	ARTICLE	IF	CITATIONS
332	Dietary Fats and the Risk of Incident Alzheimer Disease—Correction. Archives of Neurology, 2003, 60, 1072.	4.9	3
333	Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia. Journal of Atherosclerosis and Thrombosis, 2004, 11, 253-264.	0.9	92
334	Statins in the Primary Prevention of Atherosclerosis-Related Events. , 2004, , 53-92.		1
335	Statins and Reduction of Stroke: Cholesterol-Lowering versus Pleiotropic Effects. , 2004, , 113-141.		0
336	Could Lipoprotein Lipase Play a Role in Alzheimer's Disease?. Scientific World Journal, The, 2004, 4, 531-535.	0.8	7
338	Linking lipids, Alzheimer's and LXRs?. Nuclear Receptor Signaling, 2004, 2, nrs.02001.	1.0	9
340	ADAM Proteases: Protective Role in Alzheimers and Prion Diseases ?. Current Alzheimer Research, 2004, 1, 165-174.	0.7	20
341	Association between Statin Use and Alzheimer's Disease. Neuroepidemiology, 2004, 23, 94-98.	1.1	183
343	Molecular Mechanisms, Emerging Etiological Insights and Models to Test Potential Therapeutic Interventions in Alzheimers Disease. Current Alzheimer Research, 2004, 1, 295-306.	0.7	6
344	The Effects of Gender and CYP46 and Apo E Polymorphism on 24S-Hydroxycholesterol Levels in Alzheimers Patients Treated with Statins. Current Alzheimer Research, 2004, 1, 71-77.	0.7	20
345	Secretases as therapeutic targets in Alzheimer's disease: patents 2000 - 2004. Expert Opinion on Therapeutic Patents, 2004, 14, 1403-1420.	2.4	16
346	Brain Cholesterol: Long Secret Life Behind a Barrier. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 806-815.	1.1	866
347	Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. Journal of Lipid Research, 2004, 45, 1375-1397.	2.0	865
348	Differential Expression of Cholesterol Hydroxylases in Alzheimer's Disease. Journal of Biological Chemistry, 2004, 279, 34674-34681.	1.6	238
349	Causes and Consequences of Disturbances of Cerebral Glucose Metabolism in Sporadic Alzheimer Disease: Therapeutic Implications. Advances in Experimental Medicine and Biology, 2004, 541, 135-152.	0.8	156
350	Statin Therapy: Having the Good Without the Bad. Hypertension, 2004, 43, 1171-1172.	1.3	9
351	Vascular cognitive impairment. Reviews in Clinical Gerontology, 2004, 14, 45-53.	0.5	3
352	Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. Journal of Lipid Research, 2004, 45, 186-193.	2.0	277

#	ARTICLE	IF	CITATIONS
353	Membrane cholesterol interferes with neuronal apoptosis induced by soluble oligomers but not fibrils of the amyloid β peptide. <i>FASEB Journal</i> , 2004, 18, 836-838.	0.2	82
354	Mixed Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2901.	3.8	293
355	The Role of Cholesterol and Statins in Alzheimer's Disease. <i>Annals of Pharmacotherapy</i> , 2004, 38, 91-98.	0.9	61
356	SREBP-1a Polymorphism Influences the Risk of Alzheimer's Disease in Carriers of the ApoE4 Allele. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 18, 245-249.	0.7	23
357	Genetic Association of CYP46 and Risk for Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 18, 257-260.	0.7	34
358	Mouse Models of Alzheimer's Disease: Insight into Treatment. <i>Reviews in the Neurosciences</i> , 2004, 15, 353-370.	1.4	101
359	Inhibition of Geranylgeranylation Mediates the Effects of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Inhibitors on Microglia. <i>Journal of Biological Chemistry</i> , 2004, 279, 48238-48245.	1.6	63
360	Patients with Alzheimer's Disease May Be Particularly Susceptible to Adverse Effects of Statins. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 109-116.	0.7	24
361	BACE1 and Presenilin: Two Unusual Aspartyl Proteases Involved in Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2004, 1, 168-174.	0.8	25
362	Plasmin Deficiency in Alzheimer's Disease Brains: Causal or Casual?. <i>Neurodegenerative Diseases</i> , 2004, 1, 205-212.	0.8	22
363	Utilizing combination therapy in the treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 799-808.	1.4	18
364	Transgenic mouse models of Alzheimer's disease: How useful have they been for therapeutic development?. <i>Briefings in Functional Genomics & Proteomics</i> , 2004, 3, 47-59.	3.8	90
365	Pleiotropic Effects of Statins. <i>Annual Reports in Medicinal Chemistry</i> , 2004, 39, 239-258.	0.5	2
366	Neuronal membrane cholesterol loss enhances amyloid peptide generation. <i>Journal of Cell Biology</i> , 2004, 167, 953-960.	2.3	308
367	Hypercholesterolemia, HMG-CoA Reductase Inhibitors, and Risk of Intracerebral Hemorrhage. <i>Stroke</i> , 2004, 35, 1360-1364.	1.0	73
368	Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia. <i>Pharmacogenomics</i> , 2004, 5, 1049-1105.	0.6	29
369	Statin therapy and risk of dementia in the elderly. <i>Neurology</i> , 2004, 63, 1624-1628.	1.5	243
370	Dietary fat intake and 6-year cognitive change in an older biracial community population. <i>Neurology</i> , 2004, 62, 1573-1579.	1.5	270

#	ARTICLE	IF	CITATIONS
371	Genetic aspects of Alzheimer's disease, Pick's disease, and other dementias. American Journal of Alzheimer's Disease and Other Dementias, 2004, 19, 219-225.	0.9	4
372	The care gap: underuse of statin therapy in the elderly. International Journal of Clinical Practice, 2004, 58, 777-785.	0.8	22
373	Do statins slow down Alzheimer's disease? A review. Journal of Clinical Pharmacy and Therapeutics, 2004, 29, 209-213.	0.7	49
374	Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clinical Endocrinology, 2004, 61, 182-189.	1.2	14
375	Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. Journal of Neurochemistry, 2004, 89, 939-950.	2.1	201
376	Epidemiology and prevalence of Alzheimer's disease and risk factors. Psychogeriatrics, 2004, 4, 120-123.	0.6	1
377	Cholesterol at the crossroads: Alzheimer's disease and lipid metabolism. Clinical Genetics, 2004, 66, 1-16.	1.0	56
378	Strategies for disease modification in Alzheimer's disease. Nature Reviews Neuroscience, 2004, 5, 677-685.	4.9	409
379	Increased iron staining in the cerebral cortex of cholesterol fed rabbits. Mechanisms of Ageing and Development, 2004, 125, 305-313.	2.2	18
380	Dietary factors and Alzheimer's disease. Lancet Neurology, The, 2004, 3, 579-587.	4.9	379
383	Alzheimer's Disease Therapeutics: New Approaches to an Ageing Problem. IUBMB Life, 2004, 56, 203-208.	1.5	5
384	Proteases and Lipoprotein Receptors in Alzheimer's Disease. Cell Biochemistry and Biophysics, 2004, 41, 139-178.	0.9	6
385	<I>APOE</I> Genotype Effects on Alzheimer's Disease Onset and Epidemiology. Journal of Molecular Neuroscience, 2004, 23, 157-166.	1.1	199
386	ApoE-Dependent Plasticity in Alzheimer's Disease. Journal of Molecular Neuroscience, 2004, 23, 167-180.	1.1	47
387	Cholesterol Efflux as a Critical Component of Alzheimer's Disease Pathogenesis. Journal of Molecular Neuroscience, 2004, 23, 219-224.	1.1	41
388	Drug Discovery for Alzheimer's Disease: The End of the Beginning. Journal of Molecular Neuroscience, 2004, 24, 001-008.	1.1	13
389	Loss of Apolipoprotein E Receptor LR11 in Alzheimer Disease. Archives of Neurology, 2004, 61, 1200-5.	4.9	286
390	Clinical medicine and successful aging. Geriatrics and Gerontology International, 2004, 4, S3-S5.	0.7	1

#	ARTICLE	IF	CITATIONS
391	Links Between the Pathology of Alzheimer's Disease and Vascular Dementia. <i>Neurochemical Research</i> , 2004, 29, 1257-1266.	1.6	89
392	Effects of Lovastatin and Pravastatin on Amyloid Processing and Inflammatory Response in TgCRND8 Brain. <i>Neurochemical Research</i> , 2004, 29, 1897-1911.	1.6	70
393	Common ancestors: Chronic progressive diseases have the same pathogenesis. <i>Clinical Cardiology</i> , 2004, 27, 186-190.	0.7	9
394	Iron, Atherosclerosis, and Neurodegeneration: A Key Role for Cholesterol in Promoting Iron-Dependent Oxidative Damage?. <i>Annals of the New York Academy of Sciences</i> , 2004, 1012, 51-64.	1.8	74
395	Cardiovascular risk factors and Alzheimer's disease. <i>Current Atherosclerosis Reports</i> , 2004, 6, 261-266.	2.0	197
396	Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: Beyond cardiovascular diseases. <i>Current Atherosclerosis Reports</i> , 2004, 6, 36-41.	2.0	10
397	Hypertension and dementia: Does blood pressure control favorably affect cognition?. <i>Current Hypertension Reports</i> , 2004, 6, 357-362.	1.5	10
398	Statins as potential therapeutic agents in multiple sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2004, 4, 237-244.	2.0	11
399	Vascular depression: Recent advances. <i>Current Psychosis & Therapeutics Reports</i> , 2004, 2, 27-32.	0.1	1
400	Amyloid β -peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. <i>Journal of Peptide Science</i> , 2004, 10, 229-248.	0.8	251
401	Life long changes in cognitive ability are associated with prescribed medications in old age. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 327-332.	1.3	53
402	Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to β -amyloid metabolism. <i>Human Mutation</i> , 2004, 23, 358-367.	1.1	120
403	Differential effects of lipid-lowering agents on human cholinesterases. <i>Clinical Biochemistry</i> , 2004, 37, 42-49.	0.8	32
404	Cholinesterase Inhibitors and Vascular Dementia. <i>CNS Drugs</i> , 2004, 18, 79-92.	2.7	21
405	Combination Therapy in Alzheimer's Disease. <i>CNS Drugs</i> , 2004, 18, 827-844.	2.7	152
406	Proteolytic Antibody Light Chains Alter β -Amyloid Aggregation and Prevent Cytotoxicity. <i>Biochemistry</i> , 2004, 43, 9999-10007.	1.2	37
407	Toward Alzheimer Therapies Based on Genetic Knowledge. <i>Annual Review of Medicine</i> , 2004, 55, 15-25.	5.0	39
410	The Risk of Cancer in Users of Statins. <i>Journal of Clinical Oncology</i> , 2004, 22, 2388-2394.	0.8	475

#	ARTICLE	IF	CITATIONS
411	Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. <i>Gastroenterology</i> , 2004, 127, 1044-1050.	0.6	326
412	Single Chain Variable Fragments against $\text{A}\beta$ Can Inhibit $\text{A}\beta$ Aggregation and Prevent $\text{A}\beta$ -Induced Neurotoxicity. <i>Biochemistry</i> , 2004, 43, 6959-6967.	1.2	111
413	Biomarkers of Alzheimer disease in plasma. <i>NeuroRx</i> , 2004, 1, 226-234.	6.0	241
414	Treatment Strategies in Alzheimer's Disease with a Focus on Early Pharmacological Interventions. <i>Drugs and Aging</i> , 2004, 21, 415-426.	1.3	15
415	On the horizon: pathways for drug development in Alzheimer's disease. <i>Clinics in Geriatric Medicine</i> , 2004, 20, 141-152.	1.0	3
416	Influence of Insulin-Like Growth Factor-1 and Hepatocyte Growth Factor on Carotid Atherosclerosis and Cognitive Function in the Elderly. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 18, 67-74.	0.7	16
417	Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. <i>Cancer Treatment Reviews</i> , 2004, 30, 609-641.	3.4	270
418	Cholesterol modulates ligand binding and G-protein coupling to serotonin _{1A} receptors from bovine hippocampus. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2004, 1663, 188-200.	1.4	220
419	High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. <i>Steroids</i> , 2004, 69, 431-438.	0.8	108
420	Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2004, 71, 263-269.	1.0	73
421	Association analysis of genes involved in cholesterol metabolism located within the linkage region on chromosome 10 and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, 1305-1308.	1.5	14
422	ApoA1 Deficiency Results in Marked Reductions in Plasma Cholesterol But No Alterations in Amyloid- β Pathology in a Mouse Model of Alzheimer's Disease-Like Cerebral Amyloidosis. <i>American Journal of Pathology</i> , 2004, 165, 1413-1422.	1.9	52
423	Small dense low-density lipoprotein and carotid atherosclerosis in relation to vascular dementia. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 476-482.	1.5	72
424	A role for lipoprotein lipase during synaptic remodeling in the adult mouse brain. <i>Neurobiology of Disease</i> , 2004, 15, 510-519.	2.1	33
425	APP intracellular domain is increased and soluble $\text{A}\beta$ is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. <i>Neurobiology of Disease</i> , 2004, 16, 124-132.	2.1	80
426	An association study of the cholesteryl ester transfer protein TaqI B polymorphism with late onset Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 357, 152-154.	1.0	23
427	Exclusion of CYP46 and APOM as candidate genes for Alzheimer's disease in a French population. <i>Neuroscience Letters</i> , 2004, 363, 139-143.	1.0	40
428	Effects of high cholesterol diet on gliosis in apolipoprotein E knockout mice. <i>Neuroscience Letters</i> , 2004, 369, 87-92.	1.0	45

#	ARTICLE	IF	CITATIONS
429	Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 367, 228-231.	1.0	36
430	APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 368, 148-150.	1.0	63
431	Association between a T/C polymorphism in intron 2 of cholesterol 24S-hydroxylase gene and Alzheimer's disease in Chinese. <i>Neuroscience Letters</i> , 2004, 369, 104-107.	1.0	38
432	Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. <i>Neuroscience Letters</i> , 2004, 368, 303-308.	1.0	112
433	Rosuvastatin reduces caspase-3 activity and up-regulates β -secretase in human neuroblastoma SH-SY5Y cells exposed to $A\beta$. <i>Neuroscience Letters</i> , 2004, 371, 209-214.	1.0	29
434	Increased caveolin-1 expression in Alzheimer's disease brain. <i>Neurobiology of Aging</i> , 2004, 25, 753-759.	1.5	110
435	Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: from risk factors to disease modulators. <i>Neurobiology of Aging</i> , 2004, 25, 747-751.	1.5	78
436	Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, 977-989.	1.5	90
437	Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. <i>American Journal of Ophthalmology</i> , 2004, 137, 615-624.	1.7	84
438	Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. <i>American Journal of Medicine</i> , 2004, 117, 823-829.	0.6	216
439	Cholesterol and the Biology of Alzheimer's Disease. <i>Neuron</i> , 2004, 41, 7-10.	3.8	263
440	Pharmacotherapeutic approaches to the prevention of Alzheimer's disease. <i>American Journal of Geriatric Pharmacotherapy</i> , 2004, 2, 119-132.	3.0	39
441	Evidence-based pharmacotherapy of Alzheimer's disease. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 351-369.	1.0	70
442	Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. <i>Lancet, The</i> , 2004, 363, 757-767.	6.3	1,016
443	Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. <i>Lancet, The</i> , 2004, 363, 1139-1146.	6.3	510
444	Methods of Regulating Alzheimer Pathogenesis: Diet, Oxidative Damage and Inflammation. , 2004, , 1-16.		0
445	Clinical Assessment of the Genetic Risk Functions in Alzheimer's Disease. , 2004, , 71-78.		0
446	Plasma Levels of β -Amyloid(1-40), β -Amyloid(1-42), and Total β -Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins. <i>Archives of Neurology</i> , 2004, 61, 333.	4.9	109

#	ARTICLE	IF	CITATIONS
447	Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration*1. American Journal of Ophthalmology, 2004, 137, 615-624.	1.7	127
448	Cholesterol, statins and dementia. Current Opinion in Lipidology, 2004, 15, 667-672.	1.2	76
449	Conceptual Foundations of the UCSD Statin Study. Archives of Internal Medicine, 2004, 164, 153.	4.3	47
450	Hypolipidemic Drugs Can Change the Composition of Rat Brain Lipids. Tohoku Journal of Experimental Medicine, 2004, 204, 299-308.	0.5	15
451	Pathogenesis of Alzheimer Disease: Metabolic Factors. , 2004, , 303-353.		0
452	Alzheimer's Disease, Genes, and Environment: The Value of International Studies. Canadian Journal of Psychiatry, 2004, 49, 92-99.	0.9	32
454	Iron, neuroinflammation, and Alzheimer's disease. Journal of Alzheimer's Disease, 2005, 8, 183-200.	1.2	112
455	Is there a characteristic lipid profile in Alzheimer's disease?. Journal of Alzheimer's Disease, 2005, 6, 585-589.	1.2	50
456	Strategies to reduce the risk of cognitive decline and dementia. Aging Health, 2005, 1, 107-116.	0.3	16
457	Alzheimer's disease amyloid-beta peptide modulates apolipoprotein E isoform specific receptor binding. Journal of Alzheimer's Disease, 2005, 7, 303-314.	1.2	25
458	The bad news and the bad news. BMJ: British Medical Journal, 2005, 330, 1063.	2.4	0
459	Therapy of vascular dementia: perspectives and milestones. Therapy: Open Access in Clinical Medicine, 2005, 2, 649-658.	0.2	5
460	Neuroprotection and Neurodegenerative Diseases. Alzheimer Disease and Associated Disorders, 2005, 19, 226-239.	0.6	27
461	Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression?. Current Opinion in Lipidology, 2005, 16, 619-623.	1.2	23
462	Dementia Update 2005. Alzheimer Disease and Associated Disorders, 2005, 19, 100-117.	0.6	58
463	Serum Cholesterol and Cognitive Performance in the Framingham Heart Study. Psychosomatic Medicine, 2005, 67, 24-30.	1.3	148
464	Clinical implications for statin pleiotropy. Current Opinion in Lipidology, 2005, 16, 624-629.	1.2	123
465	Cosmetic neurology: The controversy over enhancing movement, mentation, and mood. Neurology, 2005, 64, 1320.	1.5	7

#	ARTICLE	IF	CITATIONS
466	Statins and Cognition: What Can We Learn from Existing Randomized Trials?. <i>CNS Spectrums</i> , 2005, 10, 867-875.	0.7	22
467	APP23 Mice as a Model of Alzheimer's Disease: An Example of a Transgenic Approach to Modeling a CNS Disorder. <i>CNS Spectrums</i> , 2005, 10, 207-222.	0.7	51
468	The Future of Statins: Alzheimer's Disease?. <i>The Consultant Pharmacist</i> , 2005, 20, 663-673.	0.4	2
469	Stroke-related dementia. , 2005, , 538-555.		0
471	“Nature-inspired” drug“protein complexes as inhibitors of A β aggregation. <i>Biochemical Society Transactions</i> , 2005, 33, 543-547.	1.6	22
472	Is Hypercholesterolemia a Risk Factor for Alzheimer's Disease?. <i>Molecular Neurobiology</i> , 2005, 31, 185-192.	1.9	32
473	Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. <i>Journal of Neurochemistry</i> , 2005, 92, 1386-1398.	2.1	185
474	Contributors to white matter damage in the frontal lobe in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2005, 31, 623-631.	1.8	49
475	Statins “a cure-all for the brain?. <i>Nature Reviews Neuroscience</i> , 2005, 6, 325-331.	4.9	104
477	Different localization in rat brain of the novel cytosolic ketone body-utilizing enzyme, acetoacetyl-CoA synthetase, as compared to succinyl-CoA:3-oxoacid CoA-transferase. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2005, 1729, 147-153.	2.4	13
478	Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. <i>Brain Research</i> , 2005, 1045, 229-233.	1.1	48
479	Cholesterol in Alzheimer's disease. <i>Lancet Neurology, The</i> , 2005, 4, 841-852.	4.9	292
480	Cognitive function in dialysis patients. <i>American Journal of Kidney Diseases</i> , 2005, 45, 448-462.	2.1	154
481	Mild cognitive impairment. <i>Psychiatry (Abingdon, England)</i> , 2005, 4, 64-66.	0.2	70
482	Cancer risk among statin users: A population-based cohort study. <i>International Journal of Cancer</i> , 2005, 114, 643-647.	2.3	254
483	APOA1 polymorphism influences risk for early-onset nonfamilial AD. <i>Annals of Neurology</i> , 2005, 58, 436-441.	2.8	68
484	Lovastatin stimulates up-regulation of $\alpha 7$ nicotinic receptors in cultured neurons without cholesterol dependency, a mechanism involving production of the β -form of secreted amyloid precursor protein. <i>Journal of Neuroscience Research</i> , 2005, 82, 531-541.	1.3	24
486	Statin treatment and a disease-specific pattern of $\beta 2$ -amyloid peptides in Alzheimer's disease. <i>Experimental Brain Research</i> , 2005, 164, 205-214.	0.7	30

#	ARTICLE	IF	CITATIONS
487	Alzheimer's associated inflammation, potential drug targets and future therapies. Journal of Neural Transmission, 2005, 112, 429-453.	1.4	92
488	Influence of peroxisome proliferator-activated receptor β gene polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients. Journal of Neural Transmission, 2005, 112, 1381-1389.	1.4	25
489	Statins: drugs for Alzheimer's disease?. Journal of Neural Transmission, 2005, 112, 1057-1071.	1.4	54
490	The Serotonin 1A Receptor: A Representative Member of the Serotonin Receptor Family. Cellular and Molecular Neurobiology, 2005, 25, 553-580.	1.7	222
491	Alzheimer's Disease - A Dysfunction in Cholesterol and Lipid Metabolism. Cellular and Molecular Neurobiology, 2005, 25, 475-483.	1.7	43
492	Potential Role of Acyl-Coenzyme A:Cholesterol Transferase (ACAT) Inhibitors as Hypolipidemic and Antiatherosclerosis Drugs. Pharmaceutical Research, 2005, 22, 1578-1588.	1.7	69
493	The "Statint" wonder of the world: a panacea for all illnesses or a bubble about to burst. Journal of Negative Results in BioMedicine, 2005, 4, 3.	1.4	8
494	Post-translational processing of beta-secretase in Alzheimer's disease. Proteomics, 2005, 5, 1533-1543.	1.3	23
495	Neurodegeneration. , 2005, , 335-355.		0
496	A genetic outline of the pathways to cell death in Alzheimer's disease, Parkinson's disease, frontal dementias and related disorders. , 2005, , 222-226.		0
497	Relationship between Dementia and Nutrition-Related Factors and Disorders: An Overview. International Journal for Vitamin and Nutrition Research, 2005, 75, 83-95.	0.6	37
498	Treatment of Alzheimer's disease. , 2005, , 459-470.		1
499	Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology, 2005, 64, 1320-1320.	1.5	3
500	Atorvastatin Therapy Lowers Circulating Cholesterol but not Free Radical Activity in Advance of Identifiable Clinical Benefit in the Treatment of Mild-to-Moderate AD. Current Alzheimer Research, 2005, 2, 343-353.	0.7	69
501	Sporadic Creutzfeldt-Jakob disease: Magnetic resonance imaging and clinical findings. Neurology, 2005, 64, 1318-1318.	1.5	2
502	Do Statins Reduce Risk of Incident Dementia and Alzheimer Disease?< subtitle>The Cache County Study</ subtitle>. Archives of General Psychiatry, 2005, 62, 217.	13.8	300
503	Cholesterol and Amyloid β Fibrillogenesis. , 2005, 38, 179-202.		22
504	ATP-Binding Cassette Transporter A1: A Cell Cholesterol Exporter That Protects Against Cardiovascular Disease. Physiological Reviews, 2005, 85, 1343-1372.	13.1	443

#	ARTICLE	IF	CITATIONS
505	The Dualistic Nature of Immune Modulation In Alzheimers Disease: Lessons from the Transgenic Models. <i>Current Pharmaceutical Design</i> , 2005, 11, 3335-3352.	0.9	3
506	Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case-control analysis. <i>Heart</i> , 2005, 92, 752-758.	1.2	35
507	Modulation of Statin-Activated Shedding of Alzheimer APP Ectodomain by ROCK. <i>PLoS Medicine</i> , 2005, 2, e18.	3.9	134
508	The Role of Aβ42 Peptides in Alzheimers Disease. <i>Protein and Peptide Letters</i> , 2005, 12, 513-519.	0.4	24
509	Recombinant hepatitis B vaccine and the risk of multiple sclerosis: A prospective study. <i>Neurology</i> , 2005, 64, 1317.	1.5	15
510	Statins and cognitive function in the elderly. <i>Neurology</i> , 2005, 65, 1388-1394.	1.5	140
511	Association of active γ-secretase complex with lipid rafts. <i>Journal of Lipid Research</i> , 2005, 46, 904-912.	2.0	127
512	Alzheimer's Aβ40 Studied by NMR at Low pH Reveals That Sodium 4,4-Dimethyl-4-silapentane-1-sulfonate (DSS) Binds and Promotes β-Ball Oligomerization. <i>Journal of Biological Chemistry</i> , 2005, 280, 3675-3685.	1.6	34
513	Serum cholesterol and risk of Alzheimer disease: A community-based cohort study. <i>Neurology</i> , 2005, 65, 1045-1050.	1.5	140
514	Season of birth and risk of brain tumors in adults. <i>Neurology</i> , 2005, 64, 1317-1317.	1.5	18
515	APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study. <i>Neurology</i> , 2005, 64, 1531-1538.	1.5	223
516	Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease. <i>Archives of Neurology</i> , 2005, 62, 753.	4.9	385
517	Biochemical Markers and Risk Factors of Alzheimers Disease. <i>Current Alzheimer Research</i> , 2005, 2, 47-64.	0.7	64
518	Statin Use and the Risk of Incident Dementia. <i>Archives of Neurology</i> , 2005, 62, 1047.	4.9	261
519	High total cholesterol levels in late life associated with a reduced risk of dementia. <i>Neurology</i> , 2005, 64, 1689-1695.	1.5	346
520	Implications of statin adverse effects in the elderly. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 389-397.	1.0	34
521	Lipid-Lowering Therapy for Elderly Patients at Risk for Coronary Events and Stroke. <i>The American Heart Hospital Journal</i> , 2005, 3, 256-262.	0.2	10
522	Drug Insight: using statins to treat neuroinflammatory disease. <i>Nature Clinical Practice Neurology</i> , 2005, 1, 106-112.	2.7	27

#	ARTICLE	IF	CITATIONS
523	Aggregation of vascular risk factors and risk of incident Alzheimer disease. <i>Neurology</i> , 2005, 65, 545-551.	1.5	691
524	3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Attenuate β -Amyloid-Induced Microglial Inflammatory Responses. <i>Journal of Neuroscience</i> , 2005, 25, 299-307.	1.7	164
527	Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 18700-18705.	3.3	242
528	Statin therapy and risk of dementia in the elderly. <i>Neurology</i> , 2005, 64, 1319-1319.	1.5	4
529	Statins Cause Intracellular Accumulation of Amyloid Precursor Protein, β -Secretase-cleaved Fragments, and Amyloid β -Peptide via an Isoprenoid-dependent Mechanism. <i>Journal of Biological Chemistry</i> , 2005, 280, 18755-18770.	1.6	133
530	Regulated expression of endothelial lipase by porcine brain capillary endothelial cells constituting the blood-brain barrier. <i>Journal of Neurochemistry</i> , 2005, 94, 109-119.	2.1	37
531	Translational Research on the Way to Effective Therapy for Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2005, 62, 1186.	13.8	50
532	No Genetic Association between ATP Binding Cassette Proteins and Japanese Sporadic Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 95-98.	0.7	2
533	Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1624-1629.	0.9	101
534	Cholesterol and apolipoprotein E in Alzheimer's disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2005, 20, 91-96.	0.9	37
535	Outcomes in 45 Patients With Statin-Associated Myopathy. <i>Archives of Internal Medicine</i> , 2005, 165, 2671.	4.3	224
536	Treatment with statins in the acute phase of ischemic stroke. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 211-221.	1.4	21
537	Statins and Thrombin. <i>Current Drug Targets Cardiovascular & Haematological Disorders</i> , 2005, 5, 115-120.	2.0	14
538	The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 256-265.	0.7	86
539	Vascular Dementia Prevention: A Risk Factor Analysis. <i>Cerebrovascular Diseases</i> , 2005, 20, 91-100.	0.8	128
540	Cholesterol and ApoE: A Target for Alzheimers Disease Therapeutics. <i>CNS and Neurological Disorders</i> , 2005, 4, 553-567.	4.3	9
541	LRP and Alzheimer's Disease. <i>Reviews in the Neurosciences</i> , 2005, 16, 123-35.	1.4	55
542	Mechanisms of Statin-mediated Inhibition of Small G-protein Function. <i>Journal of Biological Chemistry</i> , 2005, 280, 34202-34209.	1.6	205

#	ARTICLE	IF	CITATIONS
543	Report from the Neurology Scientific Integrity Advisor. <i>Neurology</i> , 2005, 64, 588-589.	1.5	8
544	Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. <i>BMJ: British Medical Journal</i> , 2005, 330, 1059-1063.	2.4	118
545	Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. <i>BMJ: British Medical Journal</i> , 2005, 331, 1310-1316.	2.4	201
547	Estatinas y enfermedad de Alzheimer: ¿son concluyentes los estudios actuales?. <i>Clínica E Investigación En Arteriosclerosis</i> , 2005, 17, 2-6.	0.4	0
548	Cholesterol and Alzheimer's Disease: Statins, Cholesterol Depletion in APP Processing and A β Generation. , 2005, 38, 365-380.		17
549	Effects of statins on microglia. <i>Journal of Neuroscience Research</i> , 2005, 82, 10-19.	1.3	45
550	Lowering the risk of Alzheimer's disease: Evidence-based practices emerge from new research. , 2005, 1, 152-160.		32
551	Preoperative Statin Therapy Does Not Reduce Cognitive Dysfunction After Cardiopulmonary Bypass. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2005, 19, 294-299.	0.6	34
552	Statins and Modulation of Oxidative Stress. <i>Toxicology Mechanisms and Methods</i> , 2005, 15, 61-92.	1.3	39
553	The link between cholesterol and Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 85-97.	1.3	54
554	Evaluation of HMG-CoA Reductase Inhibitors for Multiple Sclerosis. <i>CNS Drugs</i> , 2005, 19, 833-841.	2.7	17
555	Use of Statins and Breast Cancer: A Meta-Analysis of Seven Randomized Clinical Trials and Nine Observational Studies. <i>Journal of Clinical Oncology</i> , 2005, 23, 8606-8612.	0.8	214
556	Chronic Administration of Statins Alters Multiple Gene Expression Patterns in Mouse Cerebral Cortex. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 786-793.	1.3	179
557	ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease. <i>Neurobiology of Disease</i> , 2005, 18, 119-125.	2.1	109
558	Association between acyl-coenzyme A: cholesterol acyltransferase gene and risk for Alzheimer's disease in Chinese. <i>Neuroscience Letters</i> , 2005, 388, 17-20.	1.0	15
559	Cholesterol depletion inhibits the degradation of amyloid β -peptide in rat pheochromocytoma (PC12) cells. <i>Neuroscience Letters</i> , 2005, 391, 71-75.	1.0	8
560	Amyloid beta peptide-induced cholinergic fibres loss in the cerebral cortex of the rat is modified by diet high in lipids and by age. <i>Journal of Chemical Neuroanatomy</i> , 2005, 29, 31-48.	1.0	21
561	A review of uses of health care utilization databases for epidemiologic research on therapeutics. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 323-337.	2.4	1,041

#	ARTICLE	IF	CITATIONS
562	High-cholesterol diets impair short-term retention of memory in alloxan-induced diabetic mice, but not acquisition of memory nor retention of memory in prediabetic mice. <i>Life Sciences</i> , 2005, 77, 481-495.	2.0	28
563	Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women. <i>Maturitas</i> , 2005, 50, 312-320.	1.0	4
564	Lovastatin-induced PC-12 cell differentiation is associated with RhoA/RhoA kinase pathway inactivation. <i>Molecular and Cellular Neurosciences</i> , 2005, 29, 591-602.	1.0	18
565	Statins lower the risk of developing Alzheimer's disease by limiting lipid raft endocytosis and decreasing the neuronal spread of Herpes simplex virus type 1. <i>Medical Hypotheses</i> , 2005, 64, 53-58.	0.8	22
566	Persistence of inflammatory cytokines cause a spectrum of chronic progressive diseases: Implications for therapy. <i>Medical Hypotheses</i> , 2005, 65, 227-231.	0.8	13
567	Tau phosphorylation: physiological and pathological consequences. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2005, 1739, 280-297.	1.8	379
568	Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid β -infused rats relates to the decreases of amyloid β and cholesterol levels in detergent-insoluble membrane fractions. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2005, 1738, 91-98.	1.2	109
569	Statins downregulate myeloperoxidase gene expression in macrophages. <i>Biochemical and Biophysical Research Communications</i> , 2005, 331, 442-451.	1.0	86
570	Response to "The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes". <i>Contemporary Clinical Trials</i> , 2005, 26, 417-418.	0.8	0
571	Molecular biology and genetics of Alzheimer's disease. <i>Comptes Rendus - Biologies</i> , 2005, 328, 119-130.	0.1	163
572	Molecularly targeted agents: Their promise as cancer chemopreventive interventions. <i>European Journal of Cancer</i> , 2005, 41, 2003-2015.	1.3	28
573	Alpha-tocopherol: roles in prevention and therapy of human disease. <i>Biomedicine and Pharmacotherapy</i> , 2005, 59, 380-387.	2.5	190
574	Simvastatin treatment does not protect retinal ganglion cells from degeneration in a rat model of autoimmune optic neuritis. <i>Experimental Neurology</i> , 2005, 193, 163-171.	2.0	14
575	Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 81-84.	1.1	37
576	HMG CoA Reductase Inhibitors (Statins): Do They Have a Role in Age-related Macular Degeneration?. <i>Survey of Ophthalmology</i> , 2005, 50, 194-206.	1.7	52
577	Developmental origins of aging in brain and blood vessels: an overview. <i>Neurobiology of Aging</i> , 2005, 26, 281-291.	1.5	64
578	Cardiovascular functional phenotypes and pharmacological responses in apolipoprotein E deficient mice. <i>Neurobiology of Aging</i> , 2005, 26, 309-316.	1.5	40
579	Alzheimer disease and Down syndrome: factors in pathogenesis. <i>Neurobiology of Aging</i> , 2005, 26, 383-389.	1.5	187

#	ARTICLE	IF	CITATIONS
580	Genetic association of low density lipoprotein receptor and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2005, 26, 1-7.	1.5	44
581	Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. <i>Neurobiology of Aging</i> , 2005, 26, 355-361.	1.5	148
582	Cholesterol homeostasis in neurons and glial cells. <i>Seminars in Cell and Developmental Biology</i> , 2005, 16, 193-212.	2.3	184
583	Statin therapy in the treatment of Alzheimer disease: what is the rationale?. <i>American Journal of Medicine</i> , 2005, 118, 48-53.	0.6	41
584	Neuroinflammation: a potential therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 887-900.	1.5	97
585	Optimal lipids, statins, and dementia: Reply. <i>Journal of the American College of Cardiology</i> , 2005, 45, 964-965.	1.2	3
586	Optimal lipids, statins, and dementia. <i>Journal of the American College of Cardiology</i> , 2005, 45, 963-964.	1.2	6
587	A study of statin use in the prevention of cognitive impairment of vascular origin in the UK. <i>Journal of the Neurological Sciences</i> , 2005, 229-230, 147-150.	0.3	14
588	PLEIOTROPIC EFFECTS OF STATINS. <i>Annual Review of Pharmacology and Toxicology</i> , 2005, 45, 89-118.	4.2	1,574
589	Guidelines for the Treatment of Alzheimer's Disease from the Italian Association of Psychogeriatrics. <i>Drugs and Aging</i> , 2005, 22, 1-26.	1.3	44
590	Development of Beta-Amyloid-induced Neurodegeneration in Alzheimer's Disease and Novel Neuroprotective Strategies. <i>Reviews in the Neurosciences</i> , 2005, 16, 181-212.	1.4	74
591	Dyslipidemia and lipid-lowering therapy in the elderly. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 453-463.	0.6	2
592	The Non-Amyloidogenic Pathway: Structure and Function of β -Secretases. , 2005, 38, 105-127.		169
593	Biological Markers of Age-Related Memory Deficits. <i>CNS Drugs</i> , 2006, 20, 153-166.	2.7	111
594	Association of diagnosis of ischaemic heart disease, diabetes mellitus and heart failure with cognitive function in the elderly population. <i>European Journal of General Practice</i> , 2006, 12, 114-119.	0.9	17
595	Diabetes mellitus and dementia. <i>Diabetes and Metabolism</i> , 2006, 32, 403-414.	1.4	231
597	Alzheimer's disease. <i>Lancet, The</i> , 2006, 368, 387-403.	6.3	3,074
598	Oxidative stress in Alzheimer's disease. <i>Pathophysiology</i> , 2006, 13, 195-208.	1.0	288

#	ARTICLE	IF	CITATIONS
599	Cholesterol and 24S-hydroxycholesterol trafficking in Alzheimer's disease. Expert Review of Neurotherapeutics, 2006, 6, 683-693.	1.4	20
601	Statin use and the risk of Alzheimer's disease: The MIRAGE Study. , 2006, 2, 96-103.		48
602	Commentary on "Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery." Atorvastatin's effect in Alzheimer's dementia (LEADe) study. , 2006, 2, 282-283.		1
603	APOE Genotype and Cholesterol Levels in Lewy Body Dementia and Alzheimer Disease: Investigating Genotype's Phenotypic Effect on Disease Risk. American Journal of Geriatric Psychiatry, 2006, 14, 1022-1031.	0.6	35
604	Position Statement of the American Association for Geriatric Psychiatry Regarding Principles of Care for Patients With Dementia Resulting From Alzheimer Disease. American Journal of Geriatric Psychiatry, 2006, 14, 561-573.	0.6	236
605	Successful Mental Health Aging: Results From a Longitudinal Study of Older Australian Men. American Journal of Geriatric Psychiatry, 2006, 14, 27-35.	0.6	93
606	The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. Journal of Neuroinflammation, 2006, 3, 30.	3.1	195
607	Statins of Different Brain Penetrability Differentially Affect CSF PLTP Activity. Dementia and Geriatric Cognitive Disorders, 2006, 22, 392-398.	0.7	56
608	The involvement of lipid rafts in Alzheimer's disease (Review). Molecular Membrane Biology, 2006, 23, 111-122.	2.0	182
609	Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials. Journal of Clinical Oncology, 2006, 24, 4808-4817.	0.8	154
610	Effects of lipids and aging on the neurotoxicity and neuronal loss caused by intracerebral injections of the amyloid- β peptide in the rat. Experimental Neurology, 2006, 197, 41-55.	2.0	20
611	High cholesterol content in neurons increases BACE, β -amyloid, and phosphorylated tau levels in rabbit hippocampus. Experimental Neurology, 2006, 200, 460-467.	2.0	144
612	Amyloid excess in Alzheimer's disease: What is cholesterol to be blamed for?. FEBS Letters, 2006, 580, 5525-5532.	1.3	67
613	Circulating biomarkers of cognitive decline and dementia. Clinica Chimica Acta, 2006, 364, 91-112.	0.5	124
614	Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells. International Journal of Biochemistry and Cell Biology, 2006, 38, 1314-1329.	1.2	59
615	The ATP-binding cassette transporter ABCA2 as a mediator of intracellular trafficking. Biomedicine and Pharmacotherapy, 2006, 60, 587-592.	2.5	35
616	Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. Journal of Clinical Epidemiology, 2006, 59, 819-828.	2.4	115
617	Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Medical Hypotheses, 2006, 67, 251-269.	0.8	81

#	ARTICLE	IF	CITATIONS
618	Toward prevention of alzheimers disease â€œ Potential nutraceutical strategies for suppressing the production of amyloid beta peptides. <i>Medical Hypotheses</i> , 2006, 67, 682-697.	0.8	33
619	Influence of cholesterol and lovastatin on Î±-form of secreted amyloid precursor protein and expression of Î±7 nicotinic receptor on astrocytes. <i>Neurochemistry International</i> , 2006, 49, 459-465.	1.9	27
620	Influence of lysosomal acid lipase polymorphisms on chromosome 10 on the risk of Alzheimer's disease and cholesterol metabolism. <i>Neuroscience Letters</i> , 2006, 402, 262-266.	1.0	11
621	PPARD haplotype influences cholesterol metabolism but is no risk factor of Alzheimer's disease. <i>Neuroscience Letters</i> , 2006, 408, 57-61.	1.0	21
622	Effects of statins beyond lipid lowering: Potential for clinical benefits. <i>International Journal of Cardiology</i> , 2006, 109, 7-15.	0.8	121
623	Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. <i>Neurobiology of Aging</i> , 2006, 27, 1632-1643.	1.5	86
625	Preservation of the blood brain barrier integrity may underlie neuroprotective effects of statins in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2006, 10, 407-408.	1.2	8
627	Processing of Amyloid Precursor Protein as a Biochemical Link Between Atherosclerosis and Alzheimers Disease. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2006, 6, 21-34.	0.2	26
628	Effects of Eugenol on the Central Nervous System: Its Possible Application to Treatment of Alzheimers Disease, Depression, and Parkinsons Disease. <i>Current Bioactive Compounds</i> , 2006, 2, 57-66.	0.2	32
630	Pharmacological Evidence for the Potential of <i>Daucus carota</i> in the Management of Cognitive Dysfunctions. <i>Biological and Pharmaceutical Bulletin</i> , 2006, 29, 1154-1161.	0.6	33
631	Statins inhibit the dimerization of Î²-secretase via both isoprenoid- and cholesterol-mediated mechanisms. <i>Biochemical Journal</i> , 2006, 399, 205-214.	1.7	45
632	Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. <i>Journal of Alzheimer's Disease</i> , 2006, 10, 399-406.	1.2	97
633	La Lunga Attesa: Towards a Molecular Approach to Neuroimaging and Therapeutics in Alzheimer's Disease. <i>Neuroradiology Journal</i> , 2006, 19, 453-474.	0.6	12
634	LR11/SorLA Expression Is Reduced in Sporadic Alzheimer Disease but not in Familial Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 866-872.	0.9	131
635	Are Cerebrovascular White Matter Lesions an Early Sign of Vascular Cognitive Impairment and Vascular Dementia?. <i>Vascular Disease Prevention</i> , 2006, 3, 159-164.	0.2	0
636	Lovastatin Modulates Increased Cholesterol and Oxysterol Levels and Has a Neuroprotective Effect on Rat Hippocampal Neurons After Kainate Injury. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 652-663.	0.9	56
637	Lipid metabolism in Alzheimerâ€™s and Parkinsonâ€™s disease. <i>Future Lipidology</i> , 2006, 1, 441-453.	0.5	14
639	Medications and Diet. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, S89-S96.	0.6	13

#	ARTICLE	IF	CITATIONS
640	High-Dose Statin Treatment Does Not Alter Plasma Marker for Brain Cholesterol Metabolism in Patients With Moderately Elevated Plasma Cholesterol Levels. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 812-816.	1.0	43
641	Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism. <i>Vascular Disease Prevention</i> , 2006, 3, 235-245.	0.2	0
642	Pharmacological treatment of non-Alzheimer dementias. <i>Current Opinion in Psychiatry</i> , 2006, 19, 642-648.	3.1	4
644	Cholesterol Depletion Reduces the Internalization of β -Amyloid Peptide in SH-SY5Y Cells*. <i>Tsinghua Science and Technology</i> , 2006, 11, 447-451.	4.1	1
645	Albumin gene encoding free fatty acid and β -amyloid transporter is genetically associated with Alzheimer disease. <i>Psychiatry and Clinical Neurosciences</i> , 2006, 60, S34.	1.0	5
646	Comprehensive studies of cognitive impairment of the elderly with type 2 diabetes. <i>Geriatrics and Gerontology International</i> , 2006, 6, 159-164.	0.7	8
647	The effects of ABCA1 on cholesterol efflux and A β levels in vitro and in vivo. <i>Journal of Neurochemistry</i> , 2006, 98, 792-800.	2.1	101
648	The Cellular Biochemistry of Cholesterol and Statins: Insights into the Pathophysiology and Therapy of Alzheimer's Disease. <i>CNS Neuroscience & Therapeutics</i> , 2004, 10, 127-146.	4.0	48
649	Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2006, 114, 63-70.	1.0	91
650	Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2006, 114, 71-77.	1.0	100
651	Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. <i>Acta Neurologica Scandinavica</i> , 2006, 114, 3-7.	1.0	110
652	Effect of statins on beta-amyloid metabolism in humans: potential importance for the development of senile plaques in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2006, 114, 87-92.	1.0	14
653	Cholesterol, statins and tau. <i>Acta Neurologica Scandinavica</i> , 2006, 114, 93-101.	1.0	20
654	The role of pleiotropic effects of statins in dementia. <i>Acta Neurologica Scandinavica</i> , 2006, 114, 115-118.	1.0	15
655	Cholinesterase Inhibitor Blockade and its Prevention by Statins of Sympathetic α 7-nAChR-Mediated Cerebral Nitrogenic Neurogenic Vasodilation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2006, 26, 1562-1576.	2.4	27
656	Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. <i>Molecular Psychiatry</i> , 2006, 11, 721-736.	4.1	334
657	Noncovalent interaction between amyloid- β -peptide (1-40) and oleuropein studied by electrospray ionization mass spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2006, 17, 568-575.	1.2	75
658	LRP in Amyloid-beta Production and Metabolism. <i>Annals of the New York Academy of Sciences</i> , 2006, 1086, 35-53.	1.8	116

#	ARTICLE	IF	CITATIONS
659	The Role of Gonadotropins in Alzheimer's Disease: Potential Neurodegenerative Mechanisms. <i>Endocrine</i> , 2006, 29, 257-270.	2.2	28
660	Changes in Cholesterol Metabolism are Associated With PS1 and PS2 Gene Regulation in SK-N-BE. <i>Journal of Molecular Neuroscience</i> , 2006, 30, 311-322.	1.1	11
661	Cholesterol Distribution, Not Total Levels, Correlate With Altered Amyloid Precursor Protein Processing in Statin-Treated Mice. <i>NeuroMolecular Medicine</i> , 2006, 8, 319-328.	1.8	52
662	NEURODEGENERATIVE DISEASES: New Concepts of Pathogenesis and Their Therapeutic Implications. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2006, 1, 151-170.	9.6	346
663	Is the LDL Receptor Involved in Cortical Amyloid Protein Clearance?. <i>Neurochemical Research</i> , 2006, 31, 839-847.	1.6	15
664	C677T Methyltetrahydrofolate Reductase and Angiotensin Converting Enzyme Gene Polymorphisms in Patients with Alzheimer's Disease in Iranian Population. <i>Neurochemical Research</i> , 2006, 31, 1079-1083.	1.6	22
665	Polymorphism in neuropeptide Y influences CSF cholesterol levels but is no major risk factor of Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2006, 113, 231-238.	1.4	9
666	Effect of pravastatin on plasma sterols and oxysterols in men. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 9-14.	0.8	29
667	Effects of atorvastatin on higher functions. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 259-265.	0.8	46
668	Cholesterol inhibits the insertion of the Alzheimer's peptide A β (25-35) in lipid bilayers. <i>European Biophysics Journal</i> , 2006, 35, 523-531.	1.2	54
669	Lipid-lowering drugs. <i>Cellular and Molecular Life Sciences</i> , 2006, 63, 1165-1178.	2.4	174
670	Low-density lipoprotein reduction: Is the risk worth the benefit?. <i>Current Atherosclerosis Reports</i> , 2006, 8, 19-25.	2.0	1
671	Other than potency, are all statins the same?. <i>Current Atherosclerosis Reports</i> , 2006, 8, 26-31.	2.0	1
672	Mutant presenilin 2 causes abnormality in the brain lipid profile in the development of Alzheimer's disease. <i>Archives of Pharmacal Research</i> , 2006, 29, 884-889.	2.7	10
673	Oxidized plasma high-density lipoprotein is decreased in Alzheimer's disease. <i>Free Radical Biology and Medicine</i> , 2006, 41, 1542-1547.	1.3	14
674	Cellular mechanism of U18666A-mediated apoptosis in cultured murine cortical neurons: Bridging Niemann-Pick disease type C and Alzheimer's disease. <i>Cellular Signalling</i> , 2006, 18, 1844-1853.	1.7	61
675	Statin Safety: An Overview and Assessment of the Data-2005. <i>American Journal of Cardiology</i> , 2006, 97, S6-S26.	0.7	226
676	Cholesterol-enriched diet affects spatial learning and synaptic function in hippocampal synapses. <i>Brain Research</i> , 2006, 1103, 88-98.	1.1	43

#	ARTICLE	IF	CITATIONS
677	Lipid metabolism in cognitive decline and dementia. <i>Brain Research Reviews</i> , 2006, 51, 275-292.	9.1	165
678	Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. <i>Lancet Neurology</i> , The, 2006, 5, 735-741.	4.9	822
679	Cholesterol and Alzheimer's disease— is there a relation?. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 138-147.	2.2	86
680	Isoprenoids and Alzheimer's disease: A complex relationship. <i>Neurobiology of Disease</i> , 2006, 22, 209-222.	2.1	72
681	Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A β in plasma. <i>Neurobiology of Disease</i> , 2006, 24, 114-127.	2.1	112
682	Pharmacological actions of <i>Thespesia populnea</i> relevant to Alzheimer's disease. <i>Phytomedicine</i> , 2006, 13, 677-687.	2.3	66
683	Short-Term Memory Loss Associated with Rosuvastatin. <i>Pharmacotherapy</i> , 2006, 26, 1190-1192.	1.2	48
684	The modular systems biology approach to investigate the control of apoptosis in Alzheimer's disease neurodegeneration. <i>BMC Neuroscience</i> , 2006, 7, S2.	0.8	42
685	Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT). <i>Diabetes/Metabolism Research and Reviews</i> , 2006, 22, 376-384.	1.7	136
686	Amyloid β oligomerization is induced by brain lipid rafts. <i>Journal of Cellular Biochemistry</i> , 2006, 99, 878-889.	1.2	105
687	Rho/ROCK pathway as a target of tumor therapy. <i>Journal of Neuroscience Research</i> , 2006, 83, 243-255.	1.3	50
688	Simvastatin enhances learning and memory independent of amyloid load in mice. <i>Annals of Neurology</i> , 2006, 60, 729-739.	2.8	138
689	Interventions for heart disease and their effects on Alzheimer's disease. <i>Neurological Research</i> , 2006, 28, 630-636.	0.6	33
690	Cardiac risk factors and potential treatments in Alzheimer's disease. <i>Neurological Research</i> , 2006, 28, 595-604.	0.6	44
691	Polymorphism in ABCA1 influences CSF 24S-hydroxycholesterol levels but is not a major risk factor of Alzheimer's disease. <i>International Journal of Molecular Medicine</i> , 2006, 17, 791.	1.8	7
692	Genetic Association Between USF 1 and USF 2 Gene Polymorphisms and Japanese Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2006, 61, 660-662.	1.7	8
693	Statins: Are They All the Same?. <i>Current Drug Therapy</i> , 2006, 1, 157-172.	0.2	0
694	Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. <i>BMJ: British Medical Journal</i> , 2006, 333, 999.	2.4	230

#	ARTICLE	IF	CITATIONS
695	Therapeutic Perspectives in Alzheimers Disease. Recent Patents on CNS Drug Discovery, 2006, 1, 119-127.	0.9	25
696	Treating vascular risk factors and maintaining vascular health: Is this the way towards successful cognitive ageing and preventing cognitive decline?. Postgraduate Medical Journal, 2006, 82, 101-105.	0.9	49
697	Roles of Cholesterol and Lipids in the Etiopathogenesis of Alzheimer's Disease. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-17.	3.0	47
698	Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease. Current Pharmaceutical Design, 2006, 12, 719-738.	0.9	29
699	Studies on the Effect of the Apolipoprotein E Genotype on the Lipid Profile in Alzheimers Disease. Current Alzheimer Research, 2006, 3, 157-160.	0.7	13
700	Lipid Lowering Therapy in the Elderly: Is there a Benefit?. Current Pharmaceutical Design, 2006, 12, 3945-60.	0.9	10
701	Apolipoprotein E Recycling. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 442-448.	1.1	115
703	Mechanisms for Cellular Cholesterol Transport: Defects and Human Disease. Physiological Reviews, 2006, 86, 1237-1261.	13.1	185
704	Simvastatin-Induced Decline in Cognition. Annals of Pharmacotherapy, 2006, 40, 1880-1883.	0.9	43
705	Brain Cholesterol Synthesis in Mice Is Affected by High Dose of Simvastatin but Not of Pravastatin. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 1146-1152.	1.3	128
706	Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. Journal of Psychopharmacology, 2006, 20, 732-755.	2.0	145
707	The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 233-239.	0.9	74
708	Handbook of Multiple Sclerosis. , 0, , .		9
709	Neuroprotection in Vascular Dementia. Cerebrovascular Diseases, 2006, 21, 106-117.	0.8	48
710	Hematologic Risk Factors of Vascular Disease and Their Relation to Dementia. Dementia and Geriatric Cognitive Disorders, 2006, 21, 335-352.	0.7	21
711	Can statins put the brakes on Alzheimer's disease?. Expert Opinion on Investigational Drugs, 2006, 15, 1479-1485.	1.9	24
712	Therapeutic approaches to Alzheimer's disease. Brain, 2006, 129, 2840-2855.	3.7	310
713	Retinal Degenerations. , 2007, , .		7

#	ARTICLE	IF	CITATIONS
714	Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. Expert Review of Neurotherapeutics, 2007, 7, 473-485.	1.4	41
715	The ABCA2 Transporter: Intracellular Roles in Trafficking and Metabolism of LDL-Derived Cholesterol and Sterol-Related Compounds. Current Drug Metabolism, 2007, 8, 47-57.	0.7	43
716	Liver X Receptor-Mediated Gene Regulation and Cholesterol Homeostasis in Brain: Relevance to Alzheimers Disease Therapeutics. Current Alzheimer Research, 2007, 4, 179-184.	0.7	65
717	Role of LXR and ABCA1 in the Pathogenesis of Alzheimers Disease -Implications for a New Therapeutic Approach. Current Alzheimer Research, 2007, 4, 171-178.	0.7	50
718	The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease. Current Genomics, 2007, 8, 509-530.	0.7	82
719	Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology, 2007, 69, 878-885.	1.5	212
720	Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions. Current Neuropharmacology, 2007, 5, 232-243.	1.4	55
721	Statins prevent cholinesterase inhibitor blockade of sympathetic $\hat{\pm}$ 7-nAChR-mediated currents in rat superior cervical ganglion neurons. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H1737-H1744.	1.5	24
722	The Therapeutic Potential of Statins in Neurological Disorders. Current Medicinal Chemistry, 2007, 14, 103-112.	1.2	58
723	Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications. Current Pharmaceutical Design, 2007, 13, 3622-3636.	0.9	87
724	Association of statin use with cognitive decline in elderly African Americans. Neurology, 2007, 69, 1873-1880.	1.5	69
725	Soluble tumour necrosis factor- $\hat{\pm}$ receptor type 1 as a biomarker of response to phototherapy in patients with psoriasis. Biomarkers, 2007, 12, 599-607.	0.9	9
726	Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect. Current Drug Therapy, 2007, 2, 39-51.	0.2	3
727	New treatment options for vascular dementia. Aging Health, 2007, 3, 209-222.	0.3	3
728	Cardiovascular Risk Factors for Alzheimer's Disease. The American Journal of Geriatric Cardiology, 2007, 16, 143-149.	0.7	128
729	Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert Review of Neurotherapeutics, 2007, 7, 547-556.	1.4	24
730	Optic Neuritis and Vaccination Investigation: Failure to Consider Significant Sex Differences and Multiple Vaccine Combinations. Archives of Neurology, 2007, 64, 1673.	4.9	4
731	Optic Neuritis and Vaccination Investigation: Failure to Consider Significant Sex Differences and Multiple Vaccine Combinationsâ€™Reply. Archives of Neurology, 2007, 64, 1674.	4.9	1

#	ARTICLE	IF	CITATIONS
733	Prevention and Treatment of Dementia or Alzheimer's Disease by Statins: A Meta-Analysis. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 194-201.	0.7	82
734	Lipid-Lowering Agents and the Risk of Cognitive Impairment That Does Not Meet Criteria for Dementia, in Relation to Apolipoprotein E Status. <i>Neuroepidemiology</i> , 2007, 29, 201-207.	1.1	14
735	Clinical Trials of Amyloid-Based Therapies for Alzheimer's Disease. <i>CNS Spectrums</i> , 2007, 12, 7-10.	0.7	4
736	Alzheimer's Disease: Progress in the Development of Anti-amyloid Disease-Modifying Therapies. <i>CNS Spectrums</i> , 2007, 12, 113-123.	0.7	26
737	Pharmacotherapy of Alzheimer Disease. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 620-629.	0.9	30
738	Reversal of Memory Deficits by Atorvastatin and Simvastatin in Rats. <i>Yakugaku Zasshi</i> , 2007, 127, 1125-1137.	0.0	61
739	Regulation of the lipidation of β -secretase by statins. <i>Biochemical Society Transactions</i> , 2007, 35, 577-582.	1.6	14
740	Statins Differentially Affect Amyloid Precursor Protein Metabolism in Presymptomatic PS1 and Non-PS1 Subjects. <i>Archives of Neurology</i> , 2007, 64, 1672.	4.9	13
741	Cholesterol-Lowering Drugs And Alzheimer's Disease. <i>Future Lipidology</i> , 2007, 2, 423-432.	0.5	18
742	Primary Prevention and Delay of Onset of AD/Dementia. <i>Canadian Journal of Neurological Sciences</i> , 2007, 34, S84-S89.	0.3	13
743	Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid- β proteins. <i>Seminars in Cell and Developmental Biology</i> , 2007, 18, 638-648.	2.3	52
744	Impact of HMG-CoA reductase inhibition on brain pathology. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 342-349.	4.0	56
745	Structure and functions of the human amyloid precursor protein: The whole is more than the sum of its parts. <i>Progress in Neurobiology</i> , 2007, 82, 11-32.	2.8	155
746	The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid- β 1-42 in the rat hippocampus in vivo. <i>Neuropharmacology</i> , 2007, 52, 136-145.	2.0	60
747	Squalestatin protects neurons and reduces the activation of cytoplasmic phospholipase A2 by β 1-42. <i>Neuropharmacology</i> , 2007, 53, 222-231.	2.0	45
748	Amyloid beta-protein and lipid metabolism. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2007, 1768, 1991-2001.	1.4	38
749	Cholesterol and Cloquinol modulation of β 1-42 interaction with phospholipid bilayers and metals. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2007, 1768, 3135-3144.	1.4	32
750	Lipid-protein interactions, regulation and dysfunction of brain cholesterol. <i>Biochemical and Biophysical Research Communications</i> , 2007, 354, 627-633.	1.0	68

#	ARTICLE	IF	CITATIONS
751	Amyloid beta as a regulator of lipid homeostasis. Trends in Molecular Medicine, 2007, 13, 337-344.	3.5	72
752	Effects of statins on $\alpha 7$ nicotinic receptor, cholinesterase and $\alpha 7$ -form of secreted amyloid precursor peptide in SH-SY5Y cells. Neurochemistry International, 2007, 50, 800-806.	1.9	26
753	The effect of statin on the aortic gene expression profiling. International Journal of Cardiology, 2007, 114, 71-77.	0.8	16
754	The safety of statins in clinical practice. Lancet, The, 2007, 370, 1781-1790.	6.3	705
755	Links Between Amyloid and Tau Biology in Alzheimer's Disease and Their Cholinergic Aspects. , 2007, , 597-656.		2
756	Environmental and dietary risk factors in Alzheimer's disease. Expert Review of Neurotherapeutics, 2007, 7, 887-900.	1.4	93
759	Effects of Statins on Cognitive Function in Patients with Alzheimer's Disease in Galantamine Clinical Trials. Drugs and Aging, 2007, 24, 57-61.	1.3	25
760	evaluating clinical research. , 2007, , .		0
761	Statins Reduce Amyloid- β Production through Inhibition of Protein Isoprenylation. Journal of Biological Chemistry, 2007, 282, 26832-26844.	1.6	156
762	Mechanisms of Disease: new therapeutic strategies for Alzheimer's disease "targeting APP processing in lipid rafts. Nature Clinical Practice Neurology, 2007, 3, 374-382.	2.7	86
763	Effect of HMG-CoA Reductase Inhibitors on β -Amyloid Peptide Levels. CNS Drugs, 2007, 21, 449-462.	2.7	53
764	Regulation of β -Secretase Activity in Alzheimer's Disease. Biochemistry, 2007, 46, 2553-2563.	1.2	45
765	Effects of short term atorvastatin treatment on cerebral hemodynamics in CADASIL. Journal of the Neurological Sciences, 2007, 260, 100-105.	0.3	21
766	Environmental vascular risk factors: New perspectives for stroke prevention. Journal of the Neurological Sciences, 2007, 262, 60-70.	0.3	39
767	Role of HMG-CoA Reductase Inhibitors in Neurological Disorders. Drugs, 2007, 67, 2111-2120.	4.9	34
769	Pharmacologic Treatment of Alzheimer's Disease: An Update. Indian Journal of Psychological Medicine, 2007, 29, 27-37.	0.6	0
770	Alzheimer's disease prevention " The emerging role of lipids and diet. Oleagineux Corps Gras Lipides, 2007, 14, 182-185.	0.2	1
771	Changes in Cholesterol Metabolism in Peripheral Cells of Alzheimer Disease Patients and Their Relatives. Nature Precedings, 2007, , .	0.1	1

#	ARTICLE	IF	CITATIONS
772	Molecular genetics of Alzheimer's disease and other adult-onset dementias. , 0, , 439-453.		0
773	A novel intronic polymorphism of ABCA1 gene reveals risk for sporadic Alzheimer's disease in Chinese. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 1007-1013.	1.1	26
774	A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis. International Journal of Cancer, 2007, 121, 2331-2339.	2.3	39
775	Alzheimer's disease in Down syndrome: Neurobiology and risk. Mental Retardation and Developmental Disabilities Research Reviews, 2007, 13, 237-246.	3.5	227
776	ApoER2 expression increases A β production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of β -secretase activity. Molecular Neurodegeneration, 2007, 2, 14.	4.4	66
777	The Alzheimer's disease Beta-secretase enzyme, BACE1. Molecular Neurodegeneration, 2007, 2, 22.	4.4	386
778	Immortal time bias in observational studies of drug effects. Pharmacoepidemiology and Drug Safety, 2007, 16, 241-249.	0.9	462
779	Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. Journal of Neurochemistry, 2007, 101, 77-86.	2.1	72
780	Effects of human apolipoprotein E isoforms on the amyloid β protein concentration and lipid composition in brain low-density membrane domains. Journal of Neurochemistry, 2007, 101, 949-958.	2.1	7
781	A specific inhibitor of cholesterol biosynthesis, BM15.766, reduces the expression of β -secretase and the production of amyloid- β in vitro. Journal of Neurochemistry, 2007, 102, 1276-1291.	2.1	11
782	Oxysterols, cholesterol homeostasis, and Alzheimer disease. Journal of Neurochemistry, 2007, 102, 1727-1737.	2.1	159
783	Alzheimer's disease: the lipid connection. Journal of Neurochemistry, 2007, 103, 159-170.	2.1	178
784	Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. European Journal of Neurology, 2007, 14, e1-e26.	1.7	499
785	Alzheimer's Disease: The Vascular Connection. International Journal of Stroke, 2007, 2, 243-244.	2.9	5
786	Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Medicine, 2007, 5, 20.	2.3	334
787	Effect of Atorvastatin on Cognitive Function in Patients from the Lipid Lowering and Onset of Renal Disease (LORD) Trial. Pharmacotherapy, 2007, 27, 183-190.	1.2	34
788	Serum surfactant protein D is correlated to development of dementia and augmented mortality. Clinical Immunology, 2007, 123, 333-337.	1.4	16
789	The Inflammation Hypothesis and Its Potential Relevance to Statin Therapy. American Journal of Cardiology, 2007, 99, 732-738.	0.7	108

#	ARTICLE	IF	CITATIONS
790	Alzheimer's Disease: cholesterol, membrane rafts, isoprenoids and statins. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 383-392.	1.6	119
791	Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 1227-1238.	1.6	123
792	Gugulipid, an extract of <i>Commiphora whightii</i> with lipid-lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2007, 86, 797-805.	1.3	101
793	Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD). <i>Neurobiology of Disease</i> , 2007, 28, 16-29.	2.1	130
794	Neurodegeneration in autoimmune demyelination: Recent mechanistic insights reveal novel therapeutic targets. <i>Journal of Neuroimmunology</i> , 2007, 184, 17-26.	1.1	42
795	Alzheimer Diseaseâ€”No Target for Statin Treatment. A Mini Review. <i>Neurochemical Research</i> , 2007, 32, 695-706.	1.6	24
796	Alzheimerâ€™s Disease and Cholesterol: The Fat Connection. <i>Neurochemical Research</i> , 2007, 32, 739-750.	1.6	75
797	Statins and dementia. <i>Current Atherosclerosis Reports</i> , 2007, 9, 154-161.	2.0	29
798	Plasma 24S Hydroxycholesterol Response to Statins in Alzheimerâ€™s Disease Patients: Effects of Gender, CYP46, and ApoE Polymorphisms. <i>Journal of Molecular Neuroscience</i> , 2007, 33, 51-55.	1.1	16
799	Mevalonate pathway: A review of clinical and therapeutical implications. <i>Clinical Biochemistry</i> , 2007, 40, 575-584.	0.8	471
800	Statinsâ€”Treatment Option for Central Nervous System Autoimmune Disease?. <i>Neurotherapeutics</i> , 2007, 4, 693-700.	2.1	21
801	Cholesterol Potentiates Î² ² -Amyloid-Induced Toxicity in Human Neuroblastoma Cells: Involvement of Oxidative Stress. <i>Neurochemical Research</i> , 2008, 33, 1509-1517.	1.6	41
802	Neuropsychological Contributions to the Early Identification of Alzheimerâ€™s Disease. <i>Neuropsychology Review</i> , 2008, 18, 73-90.	2.5	166
803	Substrate specificity of Î²-secretase and other intramembrane proteases. <i>Cellular and Molecular Life Sciences</i> , 2008, 65, 1311-1334.	2.4	267
804	Metal effects on the membrane interactions of amyloid-Î² peptides. <i>European Biophysics Journal</i> , 2008, 37, 333-344.	1.2	45
805	Decreased nicotinic receptors and cognitive deficit in rats intracerebroventricularly injected with beta-amyloid peptide(1-42) and fed a high-cholesterol diet. <i>Journal of Neuroscience Research</i> , 2008, 86, 183-193.	1.3	31
806	Diseases of protein aggregation and the hunt for potential pharmacological agents. <i>Biotechnology Journal</i> , 2008, 3, 165-192.	1.8	40
807	Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways. <i>Journal of Neurochemistry</i> , 2008, 104, 1190-1200.	2.1	29

#	ARTICLE	IF	CITATIONS
808	Statins reduce neuronal β -synuclein aggregation in <i>in vitro</i> models of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2008, 105, 1656-1667.	2.1	147
809	Lovastatin inhibits amyloid precursor protein (APP) cleavage through reduction of APP distribution in Lubrol WX extractable low density lipid rafts. <i>Journal of Neurochemistry</i> , 2008, 105, 1536-1549.	2.1	37
810	Docosahexaenoic acid disrupts <i>in vitro</i> amyloid β_{40} fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats. <i>Journal of Neurochemistry</i> , 2008, 107, 1634-1646.	2.1	76
811	Current and future therapy in Alzheimer's disease. <i>Fundamental and Clinical Pharmacology</i> , 2008, 22, 265-274.	1.0	128
812	CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk. <i>Brain Research</i> , 2008, 1232, 1-6.	1.1	26
813	Fatty acids, lipid metabolism and Alzheimer pathology. <i>European Journal of Pharmacology</i> , 2008, 585, 176-196.	1.7	94
814	Seladin-1/DHCR24 protects neuroblastoma cells against $A\beta$ toxicity by increasing membrane cholesterol content. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 1990-2002.	1.6	64
815	Regulation of β -amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease. <i>Mechanisms of Ageing and Development</i> , 2008, 129, 649-655.	2.2	62
816	Mild cognitive impairment. <i>Psychiatry (Abingdon, England)</i> , 2008, 7, 36-38.	0.2	2
817	The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy. <i>Journal of the Neurological Sciences</i> , 2008, 271, 87-90.	0.3	31
818	Use of Statins and the Risk of Parkinson's Disease. <i>Drug Safety</i> , 2008, 31, 399-407.	1.4	62
819	Point: Lipoproteins are significant factors in Alzheimer's disease: Dementia is impacted by blood plasma lipoproteins. <i>Journal of Clinical Lipidology</i> , 2008, 2, 391-393.	0.6	1
821	Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease. <i>Neuroscience Letters</i> , 2008, 448, 166-169.	1.0	28
822	Cardiovascular risk factors and dementia. <i>American Journal of Geriatric Pharmacotherapy</i> , 2008, 6, 100-118.	3.0	183
823	Mechanisms of $A\beta$ mediated neurodegeneration in Alzheimer's disease. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 181-198.	1.2	220
824	Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain. <i>Biochimie</i> , 2008, 90, 426-436.	1.3	101
825	Current approaches in the treatment of Alzheimer's disease. <i>Biomedicine and Pharmacotherapy</i> , 2008, 62, 199-207.	2.5	139
826	Statins in tumor suppression. <i>Cancer Letters</i> , 2008, 260, 11-19.	3.2	156

#	ARTICLE	IF	CITATIONS
827	Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions. <i>NeuroImage</i> , 2008, 40, 1214-1221.	2.1	30
828	The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. <i>Alzheimer's and Dementia</i> , 2008, 4, 145-153.	0.4	56
830	Effects of Cardiovascular Medications on Rate of Functional Decline in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 883-892.	0.6	108
831	Cholesterol as a Risk Factor for Dementia and Cognitive Decline: A Systematic Review of Prospective Studies With Meta-Analysis. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 343-354.	0.6	337
832	Preventing Alzheimer's Disease. <i>CNS Drugs</i> , 2008, 22, 887-902.	2.7	16
833	Statin Adverse Effects. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 373-418.	1.0	564
834	Alzheimer's disease: epidemiology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 195-205.	1.0	18
835	Perspectives of Alzheimer's disease treatments. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 273-290.	1.0	2
836	Independent Inhibition of Alzheimer Disease β - and γ -Secretase Cleavage by Lowered Cholesterol Levels. <i>Journal of Biological Chemistry</i> , 2008, 283, 11302-11311.	1.6	110
837	Direct and Potent Regulation of β -Secretase by Its Lipid Microenvironment. <i>Journal of Biological Chemistry</i> , 2008, 283, 22529-22540.	1.6	240
838	Cognitive Performance and Plasma Levels of Homocysteine, Vitamin B ₁₂ , Folate and Lipids in Patients with Alzheimer Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 384-390.	0.7	38
839	Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. <i>Neurology</i> , 2008, 71, 344-350.	1.5	221
840	Plasma Lipid Levels in the Elderly Are Not Associated with the Risk of Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 232-237.	0.7	80
841	Small Molecules that Promote Neurogenesis in vitro. <i>Recent Patents on CNS Drug Discovery</i> , 2008, 3, 200-208.	0.9	21
842	Independent Cognitive Effects of Atrophy and Diffuse Subcortical and Thalamico-Cortical Cerebrovascular Disease in Dementia. <i>Stroke</i> , 2008, 39, 822-830.	1.0	77
843	ACAT as a Drug Target for Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2008, 5, 212-214.	0.8	42
844	Chapter 4 Alzheimer's Disease in Adults with Down Syndrome. <i>International Review of Research in Mental Retardation</i> , 2008, 36, 103-145.	0.7	75
845	Alzheimer's and Non-Alzheimer's Dementia: A Critical Review of Pharmacological and Nonpharmacological Strategies. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2008, 23, 150-161.	0.9	28

#	ARTICLE	IF	CITATIONS
846	Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. <i>Neurology</i> , 2008, 70, 1795-1802.	1.5	182
847	The Selective Alzheimer's Disease Indicator-1 Gene (<i>Seladin-1/DHCR24</i>) Is a Liver X Receptor Target Gene. <i>Molecular Pharmacology</i> , 2008, 74, 1716-1721.	1.0	42
848	Geranylgeranyl pyrophosphate stimulates β -secretase to increase the generation of $A\beta^{25-35}$ and APP β CTF β^{3} . <i>FASEB Journal</i> , 2008, 22, 47-54.	0.2	54
849	A Pivotal Role for Interleukin-4 in Atorvastatin-associated Neuroprotection in Rat Brain. <i>Journal of Biological Chemistry</i> , 2008, 283, 1808-1817.	1.6	78
850	BACE1 Structure and Function in Health and Alzheimers Disease. <i>Current Alzheimer Research</i> , 2008, 5, 100-120.	0.7	87
851	Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort. <i>Current Alzheimer Research</i> , 2008, 5, 416-421.	0.7	106
852	Risk Factors of Alzheimers Disease Among Iranian Population. <i>Current Alzheimer Research</i> , 2008, 5, 70-72.	0.7	11
853	Simvastatin Protects against Amyloid β and HIV-1 Tat-Induced Promoter Activities of Inflammatory Genes in Brain Endothelial Cells. <i>Molecular Pharmacology</i> , 2008, 73, 1424-1433.	1.0	39
854	Statin-Induced Heme Oxygenase-1 Increases NF- κ B Activation and Oxygen Radical Production in Cultured Neuronal Cells Exposed to Lipopolysaccharide. <i>Toxicological Sciences</i> , 2008, 102, 150-159.	1.4	25
855	Novel Systemic Markers for Patients with Alzheimer Disease? " A Pilot Study. <i>Current Alzheimer Research</i> , 2008, 5, 358-366.	0.7	35
856	Vascular factors and prevention of dementia. <i>International Review of Psychiatry</i> , 2008, 20, 344-356.	1.4	39
857	Total cholesterol and the risk of Parkinson disease. <i>Neurology</i> , 2008, 70, 1972-1979.	1.5	191
858	Treatment of Vascular Dementia: The Route of Prevention. <i>European Neurology</i> , 2008, 60, 217-223.	0.6	26
859	Estrogens and Alzheimer's Disease: Is Cholesterol a Link?. <i>Endocrinology</i> , 2008, 149, 4253-4255.	1.4	3
860	Non-cholinergic drug development for Alzheimer's disease. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 745-760.	2.5	4
861	Potential therapeutic role of statins in neurological disorders. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 827-837.	1.4	21
862	Beyond Cholesterol: Statin Benefits in Alzheimer's Disease. , 2007, , 53-80.		1
863	Simvastatin-Induced Heme Oxygenase-1 Increases Apoptosis of Neuro 2A Cells in Response to Glucose Deprivation. <i>Toxicological Sciences</i> , 2008, 101, 112-121.	1.4	37

#	ARTICLE	IF	CITATIONS
864	Increase in phosphorylation of Akt and its downstream signaling targets and suppression of apoptosis by simvastatin after traumatic brain injury. <i>Journal of Neurosurgery</i> , 2008, 109, 691-698.	0.9	77
865	Prevention of amyloid β -induced memory impairment by fluvastatin, associated with the decrease in amyloid β accumulation and oxidative stress in amyloid β injection mouse model. <i>International Journal of Molecular Medicine</i> , 2008, , .	1.8	16
866	Potential Mechanisms Linking Cholesterol to Alzheimer's Disease-like Pathology in Rabbit Brain, Hippocampal Organotypic Slices, and Skeletal Muscle. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 673-684.	1.2	60
867	Recent Advances in Liver X Receptor Biology and Chemistry. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 781-791.	1.0	34
868	Cholesterol lowering and beyond: role of statins in Alzheimer's disease. <i>Aging Health</i> , 2008, 4, 171-180.	0.3	3
869	Children of Persons With Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 6-20.	0.6	24
870	The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 605-615.	0.9	103
871	Comparison of the Mini Mental State Examination and depressive symptoms between high cardiovascular risk and healthy community elderly groups. <i>Dementia E Neuropsychologia</i> , 2008, 2, 294-299.	0.3	2
873	A doença de Alzheimer: aspectos fisiopatológicos e farmacológicos. <i>Revista De Psiquiatria Do Rio Grande Do Sul</i> , 2008, 30, .	0.3	31
874	Taking the Next Steps in the Treatment of Alzheimer's Disease: <i>Disease-Modifying Agents</i>. <i>CNS Spectrums</i> , 2008, 13, 11-14.	0.7	0
875	Vascular risk factors, cognitive decline, and dementia. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 363-381.	1.0	264
877	Policosanol to Manage Dyslipidemia in Older Adults. , 2009, , 117-134.		4
878	Statins in Neurological Disorders: Mechanisms and Therapeutic Value. <i>Scientific World Journal</i> , The, 2009, 9, 1242-1259.	0.8	32
879	Potential Anti-Dementia Agents in Traditional Chinese Medicine. <i>Natural Product Communications</i> , 2009, 4, 1934578X0900400.	0.2	3
880	Cholesterol-modifying strategies for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 695-709.	1.4	33
881	Optimizing the Start Time of Statin Therapy for Patients with Diabetes. <i>Medical Decision Making</i> , 2009, 29, 351-367.	1.2	71
882	An Open Pilot Study Exploring the Efficacy of Fluvastatin, Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Genotype 1b in High Viral Loads. <i>Intervirolgy</i> , 2009, 52, 43-48.	1.2	77
883	Long-Term Statin Therapy and CSF Cholesterol Levels: Implications for Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 519-524.	0.7	24

#	ARTICLE	IF	CITATIONS
884	Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. <i>Journal of Lipid Research</i> , 2009, 50, 2095-2102.	2.0	32
885	Statins Reduce the Neurofibrillary Tangle Burden in a Mouse Model of Tauopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 314-325.	0.9	79
886	Anti-Amyloid Treatments in Alzheimers Disease. <i>Recent Patents on CNS Drug Discovery</i> , 2009, 4, 143-148.	0.9	10
887	Cholesterol Oxidation Products and Disease: An Emerging Topic of Interest in Medicinal Chemistry. <i>Current Medicinal Chemistry</i> , 2009, 16, 685-705.	1.2	121
888	Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 546-551.	0.5	63
889	Statins for all: the new premed?. <i>British Journal of Anaesthesia</i> , 2009, 103, 99-107.	1.5	32
890	Effects of Achieving an LDL-Cholesterol Level of ≤ 70 mg/dL Compared With the Goal of ≤ 100 mg/dL Using Simvastatin or Atorvastatin on Cognitive Processes in High-Risk Diabetic Patients. , 2009, 19, 271-279.		1
891	DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APP ^{swE} /PS1 ^{dE9} mice. <i>Neurobiology of Disease</i> , 2009, 33, 482-498.	2.1	161
892	Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. <i>Neurobiology of Disease</i> , 2009, 35, 406-414.	2.1	112
893	Lovastatin potentiates the antidepressant efficacy of fluoxetine in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 92, 88-92.	1.3	30
894	Statin-associated Adverse Cognitive Effects: Survey Results from 171 Patients. <i>Pharmacotherapy</i> , 2009, 29, 800-811.	1.2	166
895	Membrane-targeted strategies for modulating APP and A β -mediated toxicity. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 249-261.	1.6	4
896	Transcriptional profiles of receptors and transporters involved in brain cholesterol homeostasis at the blood-brain barrier: Use of an in vitro model. <i>Brain Research</i> , 2009, 1249, 34-42.	1.1	73
897	Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk. <i>Brain Research</i> , 2009, 1280, 166-171.	1.1	38
898	The influence of age on the association between cholesterol and cognitive function. <i>Experimental Gerontology</i> , 2009, 44, 112-122.	1.2	63
899	Translational medicine perspective in development of disease modifying therapies for Alzheimer's disease: biomarkers to buy down the risk. <i>Drug Development Research</i> , 2009, 70, 60-69.	1.4	2
900	W7FW14F apomyoglobin amyloid aggregates-mediated apoptosis is due to oxidative stress and AKT inactivation caused by Ras and Rac. <i>Journal of Cellular Physiology</i> , 2009, 221, 412-423.	2.0	23
901	Novel N-terminal Cleavage of APP Precludes A β ² Generation in ACAT-Defective AC29 Cells. <i>Journal of Molecular Neuroscience</i> , 2009, 37, 6-15.	1.1	23

#	ARTICLE	IF	CITATIONS
902	Vascular dementia: A review of recent evidence for prevention and treatment. <i>Current Neurology and Neuroscience Reports</i> , 2009, 9, 437-442.	2.0	23
904	Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps. <i>Psychopharmacology</i> , 2009, 202, 15-36.	1.5	31
905	Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. <i>BMC Medical Genomics</i> , 2009, 2, 2.	0.7	421
906	Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 99-109.	1.1	200
907	Do statins protect against upper gastrointestinal bleeding?. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 460-465.	1.1	18
908	Activity-Regulated Cytoskeleton-Associated Protein in Rodent Brain is Down-Regulated by High Fat Diet <i>in vivo</i> and by 27-Hydroxycholesterol <i>in vitro</i> . <i>Brain Pathology</i> , 2009, 19, 69-80.	2.1	78
909	Statins and fibrate target CAC1 from side effects to CLC pharmacology. <i>British Journal of Pharmacology</i> , 2009, 156, 1204-1205.	2.7	2
910	Haptoglobin binds apolipoprotein E and influences cholesterol esterification in the cerebrospinal fluid. <i>Journal of Neurochemistry</i> , 2009, 110, 255-263.	2.1	41
911	Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2009, 111, 1275-1308.	2.1	211
912	A free radical-generating system induces the cholesterol biosynthesis pathway: a role in Alzheimer's disease. <i>Aging Cell</i> , 2009, 8, 128-139.	3.0	36
913	Greasing the wheels of A β clearance in Alzheimer's Disease: The role of lipids and apolipoprotein E. <i>BioFactors</i> , 2009, 35, 239-248.	2.6	94
914	Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 13-17.	0.9	319
915	Atorvastatin efficiency after traumatic brain injury in rats. <i>World Neurosurgery</i> , 2009, 72, 146-152.	1.3	31
916	Age-related influence of the HDL receptor SR-BI on synaptic plasticity and cognition. <i>Neurobiology of Aging</i> , 2009, 30, 407-419.	1.5	26
917	Epistasis in sporadic Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 1333-1349.	1.5	111
918	Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. <i>Seminars in Cell and Developmental Biology</i> , 2009, 20, 191-200.	2.3	105
919	Oxysterols and neurodegenerative diseases. <i>Molecular Aspects of Medicine</i> , 2009, 30, 171-179.	2.7	250
920	Cytotoxic effects of oxysterols associated with human diseases: Induction of cell death (apoptosis) <i>Tj ETQq1 1 0.784314 rgBT /Overl</i> <i>Medicine</i> , 2009, 30, 153-170.	2.7	242

#	ARTICLE	IF	CITATIONS
921	Cholesterol, lipoproteins, and cognitive impairment. <i>Journal of Clinical Lipidology</i> , 2009, 3, 368-371.	0.6	2
922	Therapeutic potential of statins in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2009, 283, 230-234.	0.3	99
923	The Nutritional Significance of Lipid Rafts. <i>Annual Review of Nutrition</i> , 2009, 29, 257-282.	4.3	88
924	Non-Atheroprotective Effects of Statins. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 361-370.	1.0	40
925	Statins for the prevention of dementia. , 2009, , CD003160.		131
926	Lipid Management in the Geriatric Patient. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 185-206.	1.2	5
927	Neuroprotective Effects of Statins in an In Vitro Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 503-517.	1.2	21
928	Statins and the risk of Parkinson disease: an update on the controversy. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 261-271.	1.0	17
929	Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease: drugs targeting β -amyloid and tau protein. <i>Aging Clinical and Experimental Research</i> , 2009, 21, 386-406.	1.4	47
930	Mild cholesterol depletion reduces amyloid β production by impairing APP trafficking to the cell surface. <i>Journal of Neurochemistry</i> , 2009, 110, 220-230.	2.1	60
931	Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum. <i>CNS Neuroscience and Therapeutics</i> , 2009, 15, 358-374.	1.9	129
932	Mild cognitive impairment in stroke patients with ischemic cerebral small-vessel disease: a forerunner of vascular dementia?. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1201-1217.	1.4	69
933	Increased Atherogenic Lipoproteins are Associated With Cognitive Impairment. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 11-17.	0.6	35
934	Use of Statins and Risk of Hospitalization With Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 18-22.	0.6	22
935	On Cholesterol Levels and Statins in Cognitive Decline and Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 303-305.	0.6	10
936	Neuropathology in the Adult Changes in Thought Study: A Review. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 703-711.	1.2	65
938	Alzheimer's disease: from pathogenesis to novel therapeutic approaches. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 259-277.	0.2	1
939	Treatment of latent stage Alzheimer's disease with statins?. <i>Aging Health</i> , 2009, 5, 29-32.	0.3	1

#	ARTICLE	IF	CITATIONS
940	A Potential Role for Alterations of Zinc and Zinc Transport Proteins in the Progression of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 471-483.	1.2	80
941	Immunomodulator Activity of 3-Hydroxy-3-Methylglutaryl-CoA Inhibitors. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2009, 7, 279-294.	0.4	34
942	The nutritional and clinical significance of lipid rafts. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2010, 13, 156-166.	1.3	67
943	Predicting memory decline as a risk factor for Alzheimer's disease in older post-menopausal women: <i>quod erat demonstrandum</i>?. <i>International Psychogeriatrics</i> , 2010, 22, 332-335.	0.6	2
944	Cholesterol, Alzheimers Disease, Prion Disorders: A menage a trois?. <i>Current Drug Targets</i> , 2010, 11, 1018-1031.	1.0	15
945	Management of Hypercholesterolemia in Older Persons for the Prevention of Cardiovascular Disease. <i>Cardiology in Review</i> , 2010, 18, 132-140.	0.6	18
947	Caffeine Protects Against Disruptions of the Blood-Brain Barrier in Animal Models of Alzheimer's and Parkinson's Diseases. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S127-S141.	1.2	106
948	Lipids and Cognition. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 737-747.	1.2	96
949	Long-Term Statin Therapy is Associated with Better Episodic Memory in Aged Familial Hypercholesterolemia Patients in Comparison with Population Controls. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 611-617.	1.2	16
950	Changes in Cognition and Amyloid- β Processing with Long Term Cholesterol Reduction using Atorvastatin in Aged Dogs. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 135-150.	1.2	34
951	Leptin Reduces the Accumulation of A β and Phosphorylated Tau Induced by 27-Hydroxycholesterol in Rabbit Organotypic Slices. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1007-1019.	1.2	120
952	Current Treatment and Recent Clinical Research in Alzheimer's Disease. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 3-16.	1.9	68
953	Dyslipidemia in the Elderly: Should it Be Treated?. <i>Clinical Cardiology</i> , 2010, 33, 4-9.	0.7	44
954	Chapter 1. The Amyloid Hypothesis of Alzheimer's Disease and Prospects for Therapeutics. <i>RSC Drug Discovery Series</i> , 2010, , 3-18.	0.2	0
955	Alzheimer Disease. <i>Disease-a-Month</i> , 2010, 56, 484-546.	0.4	391
956	Targeting inflammation to slow or delay functional decline: where are we?. <i>Biogerontology</i> , 2010, 11, 603-614.	2.0	29
957	Exploring new indications for statins beyond atherosclerosis: Successes and setbacks. <i>Journal of Cardiology</i> , 2010, 55, 155-162.	0.8	29
958	A functional polymorphism in the HMCCR promoter affects transcriptional activity but not the risk for Alzheimer disease in Swedish populations. <i>Brain Research</i> , 2010, 1344, 185-191.	1.1	14

#	ARTICLE	IF	CITATIONS
959	Simvastatin enhances immune responses to AÎ² vaccination and attenuates vaccination-induced behavioral alterations. <i>Brain Research</i> , 2010, 1356, 102-111.	1.1	7
960	Systematic review: role of health promotion in vascular dementia. <i>Journal of Nursing and Healthcare of Chronic Illness</i> , 2010, 2, 88-101.	0.5	7
962	CNS Drug Targets in Development and Future Perspectives. , 0, , 245-286.		0
963	The effects of cholesterol on learning and memory. <i>Neuroscience and Biobehavioral Reviews</i> , 2010, 34, 1366-1379.	2.9	87
964	Statin use and depressive symptoms in a prospective study of communityâ€living older persons. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 942-948.	0.9	23
965	Neuriteâ€like structures induced by mevalonate pathway blockade are due to the stability of cell adhesion foci and are enhanced by the presence of APP. <i>Journal of Neurochemistry</i> , 2010, 114, 832-842.	2.1	5
966	The Development of New Therapeutics for Alzheimer's Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 475-486.	2.3	94
967	Semisynthesis of novel monacolin J derivatives: hypocholesterolemic and neuroprotective activities. <i>Journal of Antibiotics</i> , 2010, 63, 499-505.	1.0	8
968	Systematic review of statins for the prevention of vascular dementia or dementia. <i>Geriatrics and Gerontology International</i> , 2010, 10, 199-208.	0.7	25
970	Vascular Pharmacotherapy and Dementia. <i>Current Vascular Pharmacology</i> , 2010, 8, 44-50.	0.8	3
971	Treatment of Alzheimers Disease: Symptomatic and Disease-Modifying Approaches. <i>Current Aging Science</i> , 2010, 3, 46-56.	0.4	41
972	Total Cholesterol and the Risk of Parkinson's Disease: A Review for Some New Findings. <i>Parkinson's Disease</i> , 2010, 2010, 1-6.	0.6	21
973	Alzheimer's Disease: A General Introduction and Pathomechanism. <i>Journal of Alzheimer's Disease</i> , 2010, 22, S5-S19.	1.2	143
974	Cognitive decline: the relevance of diabetes, hyperlipidaemia and hypertension. <i>British Journal of Diabetes and Vascular Disease</i> , 2010, 10, 115-122.	0.6	18
975	Oxysterols in biological systems: The gastrointestinal tract, liver, vascular wall and central nervous system. <i>Free Radical Research</i> , 2010, 44, 47-73.	1.5	38
976	Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 220-226.	0.6	57
977	Oleuropein in Olive and its Pharmacological Effects. <i>Scientia Pharmaceutica</i> , 2010, 78, 133-154.	0.7	477
978	Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease. <i>Neurology</i> , 2010, 74, 956-964.	1.5	365

#	ARTICLE	IF	CITATIONS
979	Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. <i>BMJ: British Medical Journal</i> , 2010, 340, c2197-c2197.	2.4	435
980	Type 2 Diabetes, Related Conditions, in Relation and Dementia: An Opportunity for Prevention?. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 723-736.	1.2	89
981	Amyloid- β as a Modulator of Synaptic Plasticity. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 741-763.	1.2	225
982	Cholesterol, Lipids, Amyloid Beta, and Alzheimers. <i>Current Alzheimer Research</i> , 2010, 7, 262-270.	0.7	36
983	Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. <i>BMJ: British Medical Journal</i> , 2010, 340, b5465-b5465.	2.4	393
984	Diet and Age Interactions with Regards to Cholesterol Regulation and Brain Pathogenesis. <i>Current Gerontology and Geriatrics Research</i> , 2010, 2010, 1-14.	1.6	24
985	Liver X Receptor Agonist Treatment Ameliorates Amyloid Pathology and Memory Deficits Caused by High-Fat Diet in APP23 Mice. <i>Journal of Neuroscience</i> , 2010, 30, 6862-6872.	1.7	155
986	Statins and the Squalene Synthase Inhibitor Zaragozic Acid Stimulate the Non-Amyloidogenic Pathway of Amyloid- β Protein Precursor Processing by Suppression of Cholesterol Synthesis. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1215-1231.	1.2	41
987	Vascular risk factors and dementia. <i>British Journal of Cardiac Nursing</i> , 2010, 5, 240-246.	0.0	6
988	Endocrine Aspects of Healthy Brain Aging. <i>Clinics in Geriatric Medicine</i> , 2010, 26, 57-74.	1.0	9
989	How does diabetes accelerate Alzheimer disease pathology?. <i>Nature Reviews Neurology</i> , 2010, 6, 551-559.	4.9	362
990	Interactions of estradiol and insulin-like growth factor-I signalling in the nervous system. <i>Progress in Brain Research</i> , 2010, 181, 251-272.	0.9	83
991	Can Statins Prevent or Help Treat Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 925-933.	1.2	64
992	APOE and cholesterol homeostasis in Alzheimer's disease. <i>Trends in Molecular Medicine</i> , 2010, 16, 469-477.	3.5	143
993	Cardioprotective and neuroprotective roles of oleuropein in olive. <i>Saudi Pharmaceutical Journal</i> , 2010, 18, 111-121.	1.2	109
994	Niemann-Pick type C cells show cholesterol dependent decrease of APP expression at the cell surface and its increased processing through the β -secretase pathway. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 682-691.	1.8	30
995	A second class of nuclear receptors for oxysterols: Regulation of ROR α and ROR β activity by 24S-hydroxycholesterol (cerebrosterol). <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 917-923.	1.2	114
996	Alterations of cholesterol precursor levels in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 945-950.	1.2	53

#	ARTICLE	IF	CITATIONS
997	Intracellular cholesterol homeostasis and amyloid precursor protein processing. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 853-859.	1.2	32
998	Membrane rafts in Alzheimer's disease beta-amyloid production. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 860-867.	1.2	240
999	Brain cholesterol in normal and pathological aging. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 934-944.	1.2	131
1000	ACAT inhibition and amyloid beta reduction. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 960-965.	1.2	56
1001	Role of amyloid beta in lipid homeostasis. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 966-974.	1.2	65
1002	Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 831-838.	1.2	32
1003	Rosuvastatin reduces microglia in the brain of wild type and ApoE knockout mice on a high cholesterol diet; Implications for prevention of stroke and AD. <i>Biochemical and Biophysical Research Communications</i> , 2010, 402, 367-372.	1.0	13
1004	Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice. <i>Neuroscience</i> , 2010, 166, 435-444.	1.1	68
1005	Effect of Statins on Serum Prostate-specific Antigen Levels. <i>Urology</i> , 2010, 76, 1048-1051.	0.5	17
1006	Classification of Alzheimer's Disease and Parkinson's Disease by Using Machine Learning and Neural Network Methods. , 2010, , .		43
1007	Role of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's Disease. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 82-102.	1.9	181
1008	Cholesterol and statins in Alzheimer's disease: Current controversies. <i>Experimental Neurology</i> , 2010, 223, 282-293.	2.0	94
1009	Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid- β 40 administration in mice: Evidence for dissociation between cognitive deficits and neuronal damage. <i>Experimental Neurology</i> , 2010, 226, 274-284.	2.0	94
1010	Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. <i>NeuroImage</i> , 2010, 49, 169-176.	2.1	61
1011	Statins for the treatment of dementia. , 2010, , CD007514.		68
1012	Reduction of Brain β -Amyloid ($A\beta$) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments (APP-CTFs) and $A\beta$ Clearance. <i>Journal of Biological Chemistry</i> , 2010, 285, 22091-22102.	1.6	95
1013	Prevention of Alzheimer's disease in high risk groups: statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein E epsilon 4. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 31.	3.0	7
1014	Simvastatin is the Statin that Most Efficiently Protects Against Kainate-Induced Excitotoxicity and Memory Impairment. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 161-174.	1.2	62

#	ARTICLE	IF	CITATIONS
1015	Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases. <i>Molecular Diagnosis and Therapy</i> , 2011, 15, 83-102.	1.6	25
1016	Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: A novel mechanism of action. <i>Pharmacological Research</i> , 2011, 63, 172-180.	3.1	86
1017	Current and Emerging Drug Treatment Options for Alzheimer's Disease. <i>Drugs</i> , 2011, 71, 2031-2065.	4.9	196
1018	Review of Cerebral Microangiopathy and Alzheimer's Disease: Relation between White Matter Hyperintensities and Microbleeds. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 367-378.	0.7	47
1019	Targeting liver X receptors in human health: deadlock or promising trail?. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 219-232.	1.5	73
1021	Alzheimer's disease: Cholesterol a menace?. <i>Brain Research Bulletin</i> , 2011, 86, 1-12.	1.4	29
1022	Statins and prostate cancer: Molecular and clinical aspects. <i>European Journal of Cancer</i> , 2011, 47, 819-830.	1.3	64
1023	Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats. <i>Behavioural Brain Research</i> , 2011, 216, 220-228.	1.2	16
1024	Coenzyme Q10 and cognition in atorvastatin treated dogs. <i>Neuroscience Letters</i> , 2011, 501, 92-95.	1.0	15
1025	The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly?. <i>International Journal of Cardiology</i> , 2011, 150, 123-129.	0.8	34
1026	Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases. <i>Experimental Neurology</i> , 2011, 230, 27-34.	2.0	127
1027	Atorvastatin and A β (1-40): Not as Simple as Cholesterol Reduction in Brain and Relevance to Alzheimer Disease. <i>Experimental Neurology</i> , 2011, 228, 15-18.	2.0	9
1028	Vascular Dementia and Vascular Cognitive Decline. , 2011, , 252-267.		0
1030	Mild Cognitive Impairment and Dementia. <i>Deutsches A&#x0308;rztblatt International</i> , 2011, 108, 743-50.	0.6	147
1032	Genetic Risk Factors: Their Function and Comorbidities in Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-2.	1.1	1
1033	Treatment of dyslipidemia in the elderly. <i>Journal of Geriatric Cardiology</i> , 2011, 8, 55-64.	0.2	16
1034	Mechanisms of Amyloid-Beta Peptide Uptake by Neurons: The Role of Lipid Rafts and Lipid Raft-Associated Proteins. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-11.	1.1	81
1035	Clinical practice guideline for dementia by Clinical Research Center for Dementia of South Korea. <i>Journal of the Korean Medical Association</i> , 2011, 54, 861.	0.1	26

#	ARTICLE	IF	CITATIONS
1036	Lipid Rafts: Linking Alzheimer's Amyloid- β Production, Aggregation, and Toxicity at Neuronal Membranes. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-14.	1.1	156
1037	Function and Comorbidities of Apolipoprotein E in Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-22.	1.1	33
1038	Future Targeted Disease Modifying Drugs for Alzheimer's Disease. <i>Recent Patents on CNS Drug Discovery</i> , 2011, 6, 65-76.	0.9	1
1039	Dietary Cholesterol and Its Effect on Tau Protein: A Study in Apolipoprotein E-Deficient and P301L Human Tau Mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 292-301.	0.9	30
1040	Current conceptions of the etiology and risk factors for Alzheimer's disease and their possible implications on the design of dementia clinical trials. <i>Clinical Investigation</i> , 2011, 1, 1491-1503.	0.0	0
1041	Endolysosome Mechanisms Associated with Alzheimer's Disease-like Pathology in Rabbits Ingesting Cholesterol-Enriched Diet. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1289-1303.	1.2	35
1042	Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other Dementias. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 699-708.	1.2	195
1043	Interaction between 24-hydroxycholesterol, oxidative stress, and amyloid- β in amplifying neuronal damage in Alzheimer's disease: three partners in crime. <i>Aging Cell</i> , 2011, 10, 403-417.	3.0	85
1044	Does Caring for a Spouse with Dementia Promote Cognitive Decline? A Hypothesis and Proposed Mechanisms. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 900-908.	1.3	111
1045	Axo-axonal interaction in autonomic regulation of the cerebral circulation. <i>Acta Physiologica</i> , 2011, 203, 25-35.	1.8	17
1046	Linking lipids to Alzheimer's disease: cholesterol and beyond. <i>Nature Reviews Neuroscience</i> , 2011, 12, 284-296.	4.9	751
1047	Parallel findings in age-related macular degeneration and Alzheimer's disease. <i>Progress in Retinal and Eye Research</i> , 2011, 30, 217-238.	7.3	236
1048	Nitric oxide involvement in consolidation, but not retrieval phase of cognitive performance enhanced by atorvastatin in mice. <i>European Journal of Pharmacology</i> , 2011, 666, 122-130.	1.7	15
1049	Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. <i>Brain Research</i> , 2011, 1371, 161-170.	1.1	88
1050	Atorvastatin improved scopolamine-induced impairment in memory acquisition in mice: Involvement of nitric oxide. <i>Brain Research</i> , 2011, 1386, 89-99.	1.1	25
1051	Statins as Neuroprotectants: A Comparative In Vitro Study of Lipophilicity, Blood-Brain-Barrier Penetration, Lowering of Brain Cholesterol, and Decrease of Neuron Cell Death. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 307-318.	1.2	181
1052	Disease-modifying treatments for Alzheimer's disease. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 203-216.	1.5	110
1053	The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer's disease in rats. <i>Journal of Neural Transmission</i> , 2011, 118, 1641-1649.	1.4	44

#	ARTICLE	IF	CITATIONS
1054	Red mold fermented products and Alzheimer's disease: a review. <i>Applied Microbiology and Biotechnology</i> , 2011, 91, 461-469.	1.7	28
1055	Rosuvastatin and Thapsigargin Modulate β -Secretase Gene Expression and APP Processing in a Human Neuroglioma Model. <i>Journal of Molecular Neuroscience</i> , 2011, 43, 461-469.	1.1	6
1056	Progress in the development of new drugs in Alzheimer's disease. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 45-57.	1.5	34
1057	Evaluation of the global association between cholesterol-associated polymorphisms and Alzheimer's disease suggests a role for rs3846662 and HMCCR splicing in disease risk. <i>Molecular Neurodegeneration</i> , 2011, 6, 62.	4.4	11
1058	Alzheimers Disease: From Pathogenesis to Disease-Modifying Approaches. <i>CNS and Neurological Disorders - Drug Targets</i> , 2011, 10, 163-174.	0.8	33
1059	Exploiting the Diversity of the Heat-Shock Protein Family for Primary and Secondary Tauopathy Therapeutics. <i>Current Neuropharmacology</i> , 2011, 9, 623-631.	1.4	25
1060	Therapeutic Interventions Targeting Beta Amyloid Pathogenesis in an Aging Dog Model. <i>Current Neuropharmacology</i> , 2011, 9, 651-661.	1.4	17
1061	A Hyperlipidemic Diet Induces Structural Changes in Cerebral Blood Vessels. <i>Current Neurovascular Research</i> , 2011, 8, 131-144.	0.4	9
1062	Lipid-lowering Drug Therapy in Elderly Patients. <i>Current Pharmaceutical Design</i> , 2011, 17, 877-893.	0.9	29
1063	A Review of Transcranial Magnetic Stimulation in Vascular Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 71-80.	0.7	47
1064	Low Cholesterol Triggers Membrane Microdomain-dependent CD44 Shedding and Suppresses Tumor Cell Migration. <i>Journal of Biological Chemistry</i> , 2011, 286, 1999-2007.	1.6	144
1065	Cholesterol Level and Statin Use in Alzheimer Disease. <i>Archives of Neurology</i> , 2011, 68, 1385.	4.9	166
1066	Antiapoptotic Drugs: A Therapeutic Strategy for the Prevention of Neurodegenerative Diseases. <i>Current Pharmaceutical Design</i> , 2011, 17, 230-245.	0.9	48
1067	Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. <i>Journal of Epidemiology and Community Health</i> , 2011, 65, 949-957.	2.0	96
1068	β -Secretase, Apolipoprotein E and Cellular Cholesterol Metabolism. <i>Current Alzheimer Research</i> , 2012, 9, 189-199.	0.7	8
1069	Mechanisms and Clinical Evidence of the Pleiotropic Effects of the Hydroxy-Methyl-Glutaryl-CoA Reductase Inhibitors in Central Nervous System Disorders: A Comprehensive Review. <i>International Journal of Neuroscience</i> , 2012, 122, 619-629.	0.8	19
1070	Dual Effects of Statins on A β Metabolism: Upregulation of the Degradation of APP-CTF and A β Clearance. <i>Neurodegenerative Diseases</i> , 2012, 10, 305-308.	0.8	12
1071	Sterol Lipid Metabolism in Down Syndrome Revisited: Down Syndrome Is Associated with a Selective Reduction in Serum Brassicasterol Levels. <i>Current Gerontology and Geriatrics Research</i> , 2012, 2012, 1-11.	1.6	13

#	ARTICLE	IF	CITATIONS
1072	Adult Changes in Thought Study: Dementia is an Individually Varying Convergent Syndrome with Prevalent Clinically Silent Diseases that may be Modified by Some Commonly Used Therapeutics. <i>Current Alzheimer Research</i> , 2012, 9, 718-723.	0.7	51
1073	The Role of Lipid Rafts in Cancer Cell Adhesion and Migration. <i>International Journal of Cell Biology</i> , 2012, 2012, 1-6.	1.0	107
1074	Lipid Rafts and Alzheimer's Disease: Protein-Lipid Interactions and Perturbation of Signaling. <i>Frontiers in Physiology</i> , 2012, 3, 189.	1.3	161
1075	The Effects of Statins on Prevention of Stroke and Dementia. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2012, 32, 240-249.	1.2	10
1076	Epidemiological of and risk factors for Alzheimer's disease: A review. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2012, 156, 108-114.	0.2	91
1077	Breast Cancer Cell Targeting by Prenylation Inhibitors Elucidated in Living Animals with a Bioluminescence Reporter. <i>Clinical Cancer Research</i> , 2012, 18, 4136-4144.	3.2	10
1078	Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. <i>Journal of Experimental Medicine</i> , 2012, 209, 2501-2513.	4.2	138
1079	Effects of Atorvastatin on Cerebral Blood Flow in Middle-Aged Adults at Risk for Alzheimer's Disease: A Pilot Study. <i>Current Alzheimer Research</i> , 2012, 9, 990-997.	0.7	27
1080	Lipids in Alzheimer's disease and their potential for therapy. <i>Clinical Lipidology</i> , 2012, 7, 65-78.	0.4	12
1081	KIF6 719Arg Allele is Associated with Statin Effects on Cholesterol Levels in Amnesic Mild Cognitive Impairment and Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 111-116.	1.2	6
1082	Lipid Lowering Agents, Cognitive Decline, and Dementia: The Three-City Study. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 629-637.	1.2	66
1083	Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 241-281.	1.2	51
1084	Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease. <i>Neurological Research</i> , 2012, 34, 601-610.	0.6	42
1085	Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 981-987.	1.0	63
1086	Regulation of Cerebral Cholesterol Metabolism in Alzheimer Disease. <i>Journal of Investigative Medicine</i> , 2012, 60, 576-582.	0.7	30
1087	Low-density lipoprotein receptor-related protein 1: A physiological A β homeostatic mechanism with multiple therapeutic opportunities. , 2012, 136, 94-105.		99
1088	The Controversies of Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2012, 60, 875-881.	1.2	140
1089	Cholesterol and Alzheimer's disease: A still poorly understood correlation. <i>IUBMB Life</i> , 2012, 64, 931-935.	1.5	40

#	ARTICLE	IF	CITATIONS
1090	Effects of statins and cholesterol on memory functions in mice. <i>Metabolic Brain Disease</i> , 2012, 27, 443-451.	1.4	21
1091	The effects of statins on mood: a review of the literature. <i>European Journal of Cardiovascular Nursing</i> , 2012, 11, 85-96.	0.4	38
1092	Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. <i>DMM Disease Models and Mechanisms</i> , 2012, 5, 746-55.	1.2	254
1093	Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. <i>Neurobiology of Aging</i> , 2012, 33, 2306-2320.	1.5	41
1094	Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation. <i>Neuroscience</i> , 2012, 202, 1-9.	1.1	58
1095	A high cholesterol diet ameliorates hippocampus-related cognitive and pathological deficits in ovariectomized mice. <i>Behavioural Brain Research</i> , 2012, 230, 251-258.	1.2	13
1096	The Effect of HMG-CoA Reductase Inhibitors on Cognition in Patients With Alzheimer's Dementia: A Prospective Withdrawal and Rechallenge Pilot Study. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012, 10, 296-302.	3.0	65
1097	Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain. <i>Journal of the Neurological Sciences</i> , 2012, 322, 59-63.	0.3	30
1098	Lipid Metabolism and Neuroinflammation in Alzheimer's Disease: A Role for Liver X Receptors. <i>Endocrine Reviews</i> , 2012, 33, 715-746.	8.9	67
1099	Isoprenoids and Related Pharmacological Interventions: Potential Application in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2012, 46, 64-77.	1.9	43
1100	Amyloid- β^2 Production: Major Link Between Oxidative Stress and BACE1. <i>Neurotoxicity Research</i> , 2012, 22, 208-219.	1.3	91
1101	Statins in Unconventional Secretion of Insulin-Degrading Enzyme and Degradation of the Amyloid- β^2 Peptide. <i>Neurodegenerative Diseases</i> , 2012, 10, 309-312.	0.8	22
1102	Age-Dependent Rescue by Simvastatin of Alzheimer's Disease Cerebrovascular and Memory Deficits. <i>Journal of Neuroscience</i> , 2012, 32, 4705-4715.	1.7	146
1103	Restoration of dietary-fat induced blood-brain barrier dysfunction by anti-inflammatory lipid-modulating agents. <i>Lipids in Health and Disease</i> , 2012, 11, 117.	1.2	47
1104	Simvastatin Blocks Blood-Brain Barrier Disruptions Induced by Elevated Cholesterol Both In Vivo and In Vitro. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-7.	1.1	28
1105	Overview of Pharmacoepidemiological Databases in the Assessment of Medicines Under Real-Life Conditions. , 0, , .		5
1106	4.5 Literatur. , 2012, , .		0
1107	The Kynurenine Pathway. , 2012, , .		5

#	ARTICLE	IF	CITATIONS
1108	Effect of Diabetes on Dementia and Its Preventive Strategies. <i>Journal of Korean Diabetes</i> , 2012, 13, 140.	0.1	0
1109	Peripheral cholesterol, metabolic disorders and Alzheimer's disease. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 181.	0.9	19
1110	Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer. <i>Pharmacological Reviews</i> , 2012, 64, 102-146.	7.1	370
1111	Is Statin-Associated Cognitive Impairment Clinically Relevant? A Narrative Review and Clinical Recommendations. <i>Annals of Pharmacotherapy</i> , 2012, 46, 549-557.	0.9	100
1112	The role of APP proteolytic processing in lipid metabolism. <i>Experimental Brain Research</i> , 2012, 217, 365-375.	0.7	59
1113	Biliverdin reductase: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. <i>Journal of Neurochemistry</i> , 2012, 120, 135-146.	2.1	63
1114	Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid β peptide in mice. <i>Experimental Neurology</i> , 2012, 233, 767-775.	2.0	70
1115	The interactions of atorvastatin and fluvastatin with carbamazepine, phenytoin and valproate in the mouse maximal electroshock seizure model. <i>European Journal of Pharmacology</i> , 2012, 674, 20-26.	1.7	14
1116	Modulation of <i>in vitro</i> activity of zymogenic and mature recombinant human β -secretase by dietary plants. <i>FEBS Journal</i> , 2012, 279, 1291-1305.	2.2	9
1117	The link between altered cholesterol metabolism and Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2012, 1259, 54-64.	1.8	108
1118	Combined treatment of β immunization with statin in a mouse model of Alzheimer's disease. <i>Journal of Neuroimmunology</i> , 2012, 244, 70-83.	1.1	12
1119	Selective liver X receptor modulators (SLiMs): What use in human health?. <i>Molecular and Cellular Endocrinology</i> , 2012, 351, 129-141.	1.6	102
1120	Targeting metabolic inflammation in Parkinson's disease: Implications for prospective therapeutic strategies. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2012, 39, 577-585.	0.9	27
1121	Risk factors associated with cognitive decline in the elderly with type 2 diabetes: Baseline data analysis of the Japanese elderly diabetes intervention trial. <i>Geriatrics and Gerontology International</i> , 2012, 12, 103-109.	0.7	40
1122	One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 49-58.	1.3	31
1123	The analytical determination of isoprenoid intermediates from the mevalonate pathway. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 402, 671-685.	1.9	20
1124	Statins Reduce Amyloid β -Peptide Production by Modulating Amyloid Precursor Protein Maturation and Phosphorylation Through a Cholesterol-Independent Mechanism in Cultured Neurons. <i>Neurochemical Research</i> , 2013, 38, 589-600.	1.6	20
1125	Genetic Variants in Alzheimer's Disease. , 2013, , .		9

#	ARTICLE	IF	CITATIONS
1126	Genetics of Alzheimer Disease. , 2013, , 1-20.		0
1127	Impact of a multi-nutrient diet on cognition, brain metabolism, hemodynamics, and plasticity in apoE4 carrier and apoE knockout mice. Brain Structure and Function, 2013, 219, 1841-68.	1.2	27
1128	Statins in the prevention of dementia and Alzheimer's disease: A meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiology and Drug Safety, 2013, 22, 345-358.	0.9	96
1129	The influence of vascular risk factors on cognitive decline in patients with dementia: A systematic review. Maturitas, 2013, 76, 113-117.	1.0	48
1130	Substitution of membrane cholesterol with β -sitosterol promotes nonamyloidogenic cleavage of endogenous amyloid precursor protein. Neuroscience, 2013, 247, 227-233.	1.1	30
1131	Poor Oral Health as a Chronic, Potentially Modifiable Dementia Risk Factor: Review of the Literature. Current Neurology and Neuroscience Reports, 2013, 13, 384.	2.0	99
1132	Multiplex biomarkers in blood. Alzheimer's Research and Therapy, 2013, 5, 31.	3.0	33
1133	Role of statins in Alzheimer's disease: a retrospective meta-analysis for commonly investigated clinical parameters in RCTs. International Journal of Neuroscience, 2013, 123, 521-525.	0.8	14
1134	Can lifestyle modification improve neurocognition? Rationale and design of the ENLIGHTEN clinical trial. Contemporary Clinical Trials, 2013, 34, 60-69.	0.8	18
1136	Alzheimer's Disease, Cholesterol, and Statins: The Junctions of Important Metabolic Pathways. Angewandte Chemie - International Edition, 2013, 52, 1110-1121.	7.2	56
1137	CYP46A1 intron-2T/C polymorphism and Alzheimer's disease: An updated meta-analysis of 16 studies including 3960 cases and 3828 controls. Neuroscience Letters, 2013, 549, 18-23.	1.0	9
1138	Current and future treatments for Alzheimer's disease. Therapeutic Advances in Neurological Disorders, 2013, 6, 19-33.	1.5	478
1139	Statins and Cognition: A Systematic Review and Meta-analysis of Short- and Long-term Cognitive Effects. Mayo Clinic Proceedings, 2013, 88, 1213-1221.	1.4	181
1140	Do the Frequencies of Adverse Events Increase, Decrease, or Stay the Same with Long-Term Use of Statins?. Current Atherosclerosis Reports, 2013, 15, 301.	2.0	24
1141	Role of Cholesterol in APP Metabolism and Its Significance in Alzheimer's Disease Pathogenesis. Molecular Neurobiology, 2013, 47, 37-63.	1.9	102
1142	Atorvastatin prevents cell damage via modulation of oxidative stress, glutamate uptake and glutamine synthetase activity in hippocampal slices subjected to oxygen/glucose deprivation. Neurochemistry International, 2013, 62, 948-955.	1.9	28
1143	Association of statin use with risk of dementia: A meta-analysis of prospective cohort studies. Geriatrics and Gerontology International, 2013, 13, 817-824.	0.7	47
1144	Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions?. Metabolic Brain Disease, 2013, 28, 341-353.	1.4	60

#	ARTICLE	IF	CITATIONS
1145	Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease. <i>Brain Research</i> , 2013, 1513, 103-116.	1.1	49
1146	Molecular Basis of Etiological Implications in Alzheimer's Disease: Focus on Neuroinflammation. <i>Molecular Neurobiology</i> , 2013, 48, 412-428.	1.9	71
1147	Type 2 Diabetes as a Risk Factor for Alzheimer's Disease: The Confounders, Interactions, and Neuropathology Associated With This Relationship. <i>Epidemiologic Reviews</i> , 2013, 35, 152-160.	1.3	252
1149	Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 547-658.	1.2	21
1150	Representativeness and optimal use of body mass index (BMI) in the UK Clinical Practice Research Datalink (CPRD). <i>BMJ Open</i> , 2013, 3, e003389.	0.8	121
1151	The Cache County Study on Memory in Aging: Factors affecting risk of Alzheimer's disease and its progression after onset. <i>International Review of Psychiatry</i> , 2013, 25, 673-685.	1.4	51
1152	The Role of ABCA1 Gene Sequence Variants on Risk of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 897-906.	1.2	45
1153	Statins stimulate the production of a soluble form of the receptor for advanced glycation end products. <i>Journal of Lipid Research</i> , 2013, 54, 3052-3061.	2.0	47
1154	Observational data for comparative effectiveness research: An emulation of randomised trials of statins and primary prevention of coronary heart disease. <i>Statistical Methods in Medical Research</i> , 2013, 22, 70-96.	0.7	192
1155	Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 349-357.	2.2	43
1156	Oatp1a4 and an L-Thyroxine-Sensitive Transporter Mediate the Mouse Blood-Brain Barrier Transport of Amyloid- β Peptide. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 555-561.	1.2	19
1157	Three-Dimensional Structure of Xanthones. , 2013, , 371-414.		0
1158	ROLE OF STATINS IN THE DEVELOPMENT AND PROGRESSION OF AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2013, 33, 414-422.	1.0	39
1159	Statins and Cognitive Function. <i>Annals of Internal Medicine</i> , 2013, 159, 688.	2.0	212
1160	A review of the potential therapeutic role of statins in the treatment of Alzheimer's disease: current research and opinion. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 55.	1.0	14
1161	Molecular mechanisms of neuropathological changes in Alzheimer's disease: a review. <i>Folia Neuropathologica</i> , 2013, 1, 1-9.	0.5	128
1162	Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 64.	1.7	53
1163	KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnesic Mild Cognitive Impairment and Alzheimer's Disease Patients. <i>International Journal of Alzheimer's Disease</i> , 2013, 2013, 1-6.	1.1	3

#	ARTICLE	IF	CITATIONS
1164	Muscular effects of statins in the elderly female: a review. <i>Clinical Interventions in Aging</i> , 2013, 8, 47.	1.3	63
1165	Emerging Therapeutic Strategies in Alzheimer's Disease. , 0, , .		1
1166	The effect of ACTH ₄₋₁₀ and HMG-CoA reductase inhibitor in moderate head injury: clinical outcome and serum Bcl-2 concentration. <i>Medical Journal of Indonesia</i> , 0, , 221.	0.2	0
1167	Effects of Statins on Incident Dementia in Patients with Type 2 DM: A Population-Based Retrospective Cohort Study in Taiwan. <i>PLoS ONE</i> , 2014, 9, e88434.	1.1	25
1168	Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges. <i>Frontiers in Pharmacology</i> , 2014, 5, 47.	1.6	32
1169	Human isoprenoid synthase enzymes as therapeutic targets. <i>Frontiers in Chemistry</i> , 2014, 2, 50.	1.8	37
1170	Imaging of cerebrovascular pathology in animal models of Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 32.	1.7	71
1171	Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 71.	1.7	43
1172	Cognitive Impairment and Age-Related Vision Disorders: Their Possible Relationship and the Evaluation of the Use of Aspirin and Statins in a 65 Years-and-Over Sardinian Population. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 309.	1.7	25
1173	Examination of the FDA Warning for Statins and Cognitive Dysfunction. <i>Journal of Pharmacovigilance</i> , 2014, 02, .	0.2	15
1174	Sepsis in the Central Nervous System and Antioxidant Strategies with Nacetylcysteine, Vitamins and Statins. <i>Current Neurovascular Research</i> , 2014, 11, 83-90.	0.4	18
1175	Statin treatment affects cytokine release and phagocytic activity in primary cultured microglia through two separable mechanisms. <i>Molecular Brain</i> , 2014, 7, 85.	1.3	45
1176	Statin use and risk of depression: a Swedish national cohort study. <i>BMC Psychiatry</i> , 2014, 14, 348.	1.1	66
1177	LDL receptor knock-out mice show impaired spatial cognition with hippocampal vulnerability to apoptosis and deficits in synapses. <i>Lipids in Health and Disease</i> , 2014, 13, 175.	1.2	26
1178	Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives. , 2014, , 3-39.		5
1179	Molecular Mechanisms Underlying the Effects of Statins in the Central Nervous System. <i>International Journal of Molecular Sciences</i> , 2014, 15, 20607-20637.	1.8	133
1180	Statins for the treatment of dementia. <i>The Cochrane Library</i> , 2014, , CD007514.	1.5	109
1181	Cyclopamine Modulates β -Secretase-mediated Cleavage of Amyloid Precursor Protein by Altering Its Subcellular Trafficking and Lysosomal Degradation. <i>Journal of Biological Chemistry</i> , 2014, 289, 33258-33274.	1.6	11

#	ARTICLE	IF	CITATIONS
1182	Simvastatin Treatment Preserves Synaptic Plasticity in A β 2PPswe/PS1dE9 Mice. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 315-329.	1.2	19
1183	Long-Term Statin Use and Dementia Risk in Taiwan. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014, 27, 165-171.	1.2	15
1184	Associations Between Serum Cholesterol Levels and Cerebral Amyloidosis. <i>JAMA Neurology</i> , 2014, 71, 195.	4.5	201
1185	Insulin resistance, neuroinflammation, and Alzheimer's disease. <i>Reviews in the Neurosciences</i> , 2014, 25, 509-25.	1.4	51
1186	Effect of Dementia on the Use of Drugs for Secondary Prevention of Ischemic Heart Disease. <i>Journal of Aging Research</i> , 2014, 2014, 1-8.	0.4	5
1187	Selective benefits of simvastatin in bitransgenic APPSwe,Ind/TGF- β 1 mice. <i>Neurobiology of Aging</i> , 2014, 35, 203-212.	1.5	26
1188	Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, S3-S10.	1.5	87
1189	An assessment by the Statin Cognitive Safety Task Force: 2014 update. <i>Journal of Clinical Lipidology</i> , 2014, 8, S5-S16.	0.6	92
1190	Long-term atorvastatin treatment leads to alterations in behavior, cognition, and hippocampal biochemistry. <i>Behavioural Brain Research</i> , 2014, 267, 6-11.	1.2	24
1191	Statins and Vascular Dementia: A Review. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S315-S320.	1.2	21
1192	Influence of cognitive impairment on the management of ischaemic stroke. <i>Revue Neurologique</i> , 2014, 170, 177-186.	0.6	4
1193	Cardiovascular manifestations of neurologic disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 119, 3-17.	1.0	16
1194	Statins more than cholesterol lowering agents in Alzheimer disease: Their pleiotropic functions as potential therapeutic targets. <i>Biochemical Pharmacology</i> , 2014, 88, 605-616.	2.0	73
1195	Neuropsychiatric Adverse Events Associated with Statins: Epidemiology, Pathophysiology, Prevention and Management. <i>CNS Drugs</i> , 2014, 28, 249-272.	2.7	52
1196	Statins use and risk of depression: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2014, 160, 62-67.	2.0	81
1197	Atorvastatin prevents amyloid- β 2 peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 716-726.	2.8	32
1198	Glimepiride reduces CD14 expression and cytokine secretion from macrophages. <i>Journal of Neuroinflammation</i> , 2014, 11, 115.	3.1	25
1199	Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 202.	0.7	15

#	ARTICLE	IF	CITATIONS
1200	Cholesterol in brain disease: sometimes determinant and frequently implicated. <i>EMBO Reports</i> , 2014, 15, 1036-1052.	2.0	224
1201	Simvastatin Treatment Enhances NMDAR-Mediated Synaptic Transmission by Upregulating the Surface Distribution of the GluN2B Subunit. <i>Cellular and Molecular Neurobiology</i> , 2014, 34, 693-705.	1.7	22
1202	Lipid metabolism in Alzheimer's disease. <i>Neuroscience Bulletin</i> , 2014, 30, 331-345.	1.5	83
1203	Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. <i>BMC Medicine</i> , 2014, 12, 51.	2.3	149
1204	Dietary modulators of statin efficacy in cardiovascular disease and cognition. <i>Molecular Aspects of Medicine</i> , 2014, 38, 1-53.	2.7	13
1205	Statin use and incident dementia: A nationwide cohort study of Taiwan. <i>International Journal of Cardiology</i> , 2014, 173, 305-310.	0.8	36
1206	Increased risk of dementia in people with previous exposure to general anesthesia: A nationwide population-based case-control study. <i>Alzheimer's and Dementia</i> , 2014, 10, 196-204.	0.4	108
1207	Statins in neurological disorders: An overview and update. <i>Pharmacological Research</i> , 2014, 88, 74-83.	3.1	65
1208	Bidirectional links between Alzheimer's disease and Niemann-Pick type C disease. <i>Neurobiology of Disease</i> , 2014, 72, 37-47.	2.1	68
1209	Multistage Screening Reveals Chameleon Ligands of the Human Farnesyl Pyrophosphate Synthase: Implications to Drug Discovery for Neurodegenerative Diseases. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5764-5776.	2.9	29
1210	The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: It's time for reconciliation. <i>Neurobiology of Disease</i> , 2014, 62, 144-159.	2.1	109
1212	P2-030: INVESTIGATING THE ROLE OF CLU, PICALM, AND CR1 IN ALZHEIMER'S DISEASE. , 2014, 10, P481-P481.		0
1213	Cholesterol, Statins, and Dementia: What the Cardiologist Should Know. <i>Clinical Cardiology</i> , 2015, 38, 243-250.	0.7	47
1215	LDL-lipids from patients with hypercholesterolaemia and Alzheimer's disease are inflammatory to microvascular endothelial cells: mitigation by statin intervention. <i>Clinical Science</i> , 2015, 129, 1195-1206.	1.8	53
1216	Lovastatin Differentially Affects Neuronal Cholesterol and Amyloid β Production <i>in Vivo</i> and <i>in Vitro</i> . <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 631-641.	1.9	15
1217	Cholesterol-induced astrocyte activation is associated with increased amyloid precursor protein expression and processing. <i>Glia</i> , 2015, 63, 2010-2022.	2.5	30
1218	The Mevalonate Pathway in Alzheimer's Disease – Cholesterol and Non-Sterol Isoprenoids. , 2015, , .		8
1219	Statin Use, Incident Dementia and Alzheimer Disease in Elderly African Americans. <i>Ethnicity and Disease</i> , 2015, 25, 345.	1.0	42

#	ARTICLE	IF	CITATIONS
1220	Statins and memory loss: An Australian perspective. <i>Australasian Medical Journal</i> , 2015, 8, 73-79.	0.1	10
1221	Role of Liver X Receptor in AD Pathophysiology. <i>PLoS ONE</i> , 2015, 10, e0145467.	1.1	36
1222	Lipid Lowering Effects of Hydroalcoholic Extract of <i>Anethum graveolens</i> L. and Dill Tablet in High Cholesterol Fed Hamsters. <i>Cholesterol</i> , 2015, 2015, 1-7.	1.6	37
1223	Nonhuman Primate Models of Human Disease. , 2015, , 257-277.		1
1224	Cholesterol lowering: role in cancer prevention and treatment. <i>Biological Chemistry</i> , 2015, 396, 1-11.	1.2	147
1225	Apolipoprotein E ϵ 4 as a genetic determinant of Alzheimer's disease heterogeneity. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2015, 5, 9.	0.7	4
1226	Data Resource Profile: Clinical Practice Research Datalink (CPRD). <i>International Journal of Epidemiology</i> , 2015, 44, 827-836.	0.9	1,969
1227	Prescribing for Australians living with dementia: study protocol using the Delphi technique. <i>BMJ Open</i> , 2015, 5, e008048.	0.8	33
1228	Statins and Cognitive Function: an Updated Review. <i>Current Cardiology Reports</i> , 2015, 17, 4.	1.3	16
1229	Statins: An Update on Clinical Issues and Selected Adverse Effects. <i>Journal for Nurse Practitioners</i> , 2015, 11, 287-294.	0.4	3
1230	Statins and Reduction of Oxidative Stress in the Aged Brain. , 2015, , 753-760.		3
1231	Molecular dynamics simulation study reveals potential substrate entry path into β -secretase/presenilin-1. <i>Journal of Structural Biology</i> , 2015, 191, 120-129.	1.3	41
1232	Statins for Treating Alzheimer's Disease: Truly Ineffective?. <i>European Neurology</i> , 2015, 73, 360-366.	0.6	15
1233	Angiotensin receptor blockers and risk of dementia: cohort study in UK Clinical Practice Research Datalink. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 337-350.	1.1	24
1234	Decreased prevalence of dementia associated with statins: a national population-based study. <i>European Journal of Neurology</i> , 2015, 22, 912-918.	1.7	24
1235	The relation of saturated fats and dietary cholesterol to childhood cognitive flexibility. <i>Appetite</i> , 2015, 93, 51-56.	1.8	40
1236	Atorvastatin Prevents Cognitive Deficits Induced by Intracerebroventricular Amyloid- β 40 Administration in Mice: Involvement of Glutamatergic and Antioxidant Systems. <i>Neurotoxicity Research</i> , 2015, 28, 32-42.	1.3	25
1237	Statins and Cognitive Side Effects. <i>Cardiology Clinics</i> , 2015, 33, 245-256.	0.9	12

#	ARTICLE	IF	CITATIONS
1238	Statins enhance cognitive performance in object location test in albino Swiss mice: Involvement of beta-adrenoceptors. <i>Physiology and Behavior</i> , 2015, 143, 27-34.	1.0	9
1239	The Association of Statin Use with Age-Related Macular Degeneration Progression. <i>Ophthalmology</i> , 2015, 122, 2490-2496.	2.5	25
1241	Dose-specific effect of simvastatin on hypoxia-induced HIF-1 β and BACE expression in Alzheimer's disease cybrid cells. <i>BMC Neurology</i> , 2015, 15, 127.	0.8	25
1242	Do statins cause or prevent dementia?. <i>European Journal of Neurology</i> , 2015, 22, 885-886.	1.7	4
1243	Monascus-fermented monascin and ankaflavin improve the memory and learning ability in amyloid β -protein intracerebroventricular-infused rat via the suppression of Alzheimer's disease risk factors. <i>Journal of Functional Foods</i> , 2015, 18, 387-399.	1.6	28
1244	Benzodiazepine Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis. <i>Drug Safety</i> , 2015, 38, 909-919.	1.4	76
1245	Statins and the risk of dementia in patients with atrial fibrillation: A nationwide population-based cohort study. <i>International Journal of Cardiology</i> , 2015, 196, 91-97.	0.8	31
1246	Do statins prevent Alzheimer's disease? A narrative review. <i>European Journal of Internal Medicine</i> , 2015, 26, 666-669.	1.0	30
1247	Simvastatin prevents β -amyloid $_{25-35}$ -impaired neurogenesis in hippocampal dentate gyrus through α 7nAChR-dependent cascading PI3K-Akt and increasing BDNF via reduction of farnesyl pyrophosphate. <i>Neuropharmacology</i> , 2015, 97, 122-132.	2.0	60
1248	Diabetes and Cognitive Dysfunction. , 2015, , 189-201.		3
1249	The CCAAT/enhancer-binding protein delta/miR135a/thrombospondin 1 axis mediates PGE2-induced angiogenesis in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1356-1368.	1.5	33
1250	Lower Risk of Alzheimer's Disease Mortality with Exercise, Statin, and Fruit Intake. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 1121-1129.	1.2	19
1251	Impact on Cognitive Function- Are All Statins the Same?. <i>Current Atherosclerosis Reports</i> , 2015, 17, 466.	2.0	7
1252	HMGR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study. <i>Molecular Psychiatry</i> , 2015, 20, 867-873.	4.1	51
1253	Reduction of Oxidative/Nitrosative Stress in Brain and its Involvement in the Neuroprotective Effect of n-3 PUFA in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016, 13, 123-134.	0.7	43
1254	Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial. <i>Trials</i> , 2016, 17, 370.	0.7	18
1255	Atorvastatin May Correct Dyslipidemia in Adult Patients at Risk for Alzheimer's Disease Through an Anti-Inflammatory Pathway. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 80-85.	0.8	8
1256	Simvastatin and atorvastatin facilitates amyloid β -protein degradation in extracellular spaces by increasing neprilysin secretion from astrocytes through activation of MAPK/ERK1/2 pathways. <i>Glia</i> , 2016, 64, 952-962.	2.5	60

#	ARTICLE	IF	CITATIONS
1257	Effectiveness of atorvastatin in suppressing <i>MUC5AC</i> gene expression in human airway epithelial cells. <i>International Forum of Allergy and Rhinology</i> , 2016, 6, 1159-1166.	1.5	7
1258	Statins for the prevention of dementia. <i>The Cochrane Library</i> , 2016, 2016, CD003160.	1.5	212
1259	Inhibition of Cholesterol Biosynthesis Reduces β -Secretase Activity and Amyloid- β Generation. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1057-1068.	1.2	22
1260	Evolution of primary care databases in UK: a scientometric analysis of research output. <i>BMJ Open</i> , 2016, 6, e012785.	0.8	43
1261	A segmentation technique to detect the Alzheimer's disease using image processing. , 2016, , .		8
1262	Risk factors for dementia diagnosis in German primary care practices. <i>International Psychogeriatrics</i> , 2016, 28, 1059-1065.	0.6	79
1263	Could drugs inhibiting the mevalonate pathway also target cancer stem cells?. <i>Drug Resistance Updates</i> , 2016, 25, 13-25.	6.5	80
1264	Neurovascular and Cognitive failure in Alzheimer's Disease: Benefits of Cardiovascular Therapy. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 219-232.	1.7	39
1265	Influenza infections and risk of Alzheimer's disease. <i>Brain, Behavior, and Immunity</i> , 2016, 57, 187-192.	2.0	18
1266	Effects of rs3846662 Variants on HMGR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology. <i>Journal of Molecular Neuroscience</i> , 2016, 58, 109-119.	1.1	10
1267	Neurochemical Aspects of Alzheimer Disease. , 2016, , 1-76.		1
1269	Medication appropriateness tool for comorbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel. <i>Internal Medicine Journal</i> , 2016, 46, 1189-1197.	0.5	38
1270	In vitro 6-hydroxydopamine-induced toxicity in striatal, cerebrocortical and hippocampal slices is attenuated by atorvastatin and MK-801. <i>Toxicology in Vitro</i> , 2016, 37, 162-168.	1.1	19
1271	Remembering Statins: Do Statins Have Adverse Cognitive Effects?. <i>Diabetes Care</i> , 2016, 39, S253-S259.	4.3	29
1272	Dose-Dependent Neuroprotection and Neurotoxicity of Simvastatin through Reduction of Farnesyl Pyrophosphate in Mice Treated with Intracerebroventricular Injection of β -Secretase Inhibitor. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 501-516.	1.2	14
1273	Simvastatin-induced cognitive dysfunction: two case reports. <i>Journal of Medical Case Reports</i> , 2016, 10, 83.	0.4	24
1274	Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease. <i>Neurological Sciences</i> , 2016, 37, 1403-1435.	0.9	60
1275	Are microRNAs the Molecular Link Between Metabolic Syndrome and Alzheimer's Disease?. <i>Molecular Neurobiology</i> , 2016, 53, 2320-2338.	1.9	27

#	ARTICLE	IF	CITATIONS
1276	Simvastatin enhances NMDA receptor GluN2B expression and phosphorylation of GluN2B and GluN2A through increased histone acetylation and Src signaling in hippocampal CA1 neurons. <i>Neuropharmacology</i> , 2016, 107, 411-421.	2.0	26
1277	Statins and Cognitive Side Effects. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 101-116.	1.2	6
1278	Pharmacological modulation of dietary lipid-induced cerebral capillary dysfunction: Considerations for reducing risk for Alzheimer's disease. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2016, 53, 166-183.	2.7	11
1279	Therapeutic Potentials of Curcumin for Alzheimer Disease. , 2016, , .		13
1280	<i>Monascus purpureus</i> NTU 568 fermented product improves memory and learning ability in rats with aluminium-induced Alzheimer's disease. <i>Journal of Functional Foods</i> , 2016, 21, 167-177.	1.6	15
1281	Glimepiride protects neurons against amyloid- β^2 -induced synapse damage. <i>Neuropharmacology</i> , 2016, 101, 225-236.	2.0	37
1282	Vascular Dementia and Cognitive Impairment. , 2016, , 253-267.e7.		0
1283	Potential of tocotrienols in the prevention and therapy of Alzheimer's disease. <i>Journal of Nutritional Biochemistry</i> , 2016, 31, 1-9.	1.9	33
1284	Lecithin-cholesterol acyltransferase in brain: Does oxidative stress influence the 24-hydroxycholesterol esterification?. <i>Neuroscience Research</i> , 2016, 105, 19-27.	1.0	23
1285	Regulation of Calcium-Independent Phospholipase A2 Expression by Adrenoceptors and Sterol Regulatory Element Binding Protein—Potential Crosstalk Between Sterol and Glycerophospholipid Mediators. <i>Molecular Neurobiology</i> , 2016, 53, 500-517.	1.9	4
1286	Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism and Alzheimer Disease Risk: a Meta-Analysis. <i>Molecular Neurobiology</i> , 2017, 54, 1173-1186.	1.9	69
1287	Association Between Exercise Capacity and Late Onset of Dementia, Alzheimer Disease, and Cognitive Impairment. <i>Mayo Clinic Proceedings</i> , 2017, 92, 211-217.	1.4	26
1288	Resveratrol Intervenes Cholesterol- and Isoprenoid-Mediated Amyloidogenic Processing of A β PP in Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, S3-S23.	1.2	27
1289	PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges. <i>Heart Lung and Circulation</i> , 2017, 26, 786-798.	0.2	2
1290	The level of 24-Hydroxycholesteryl Esters is an Early Marker of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 825-833.	1.2	15
1291	The effect of statins on rate of cognitive decline in mild cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 149-156.	1.8	17
1292	Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 10.	3.0	145
1293	Blood cholesterol in late-life and cognitive decline: a longitudinal study of the Chinese elderly. <i>Molecular Neurodegeneration</i> , 2017, 12, 24.	4.4	87

#	ARTICLE	IF	CITATIONS
1294	Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 7, 69-87.	1.2	283
1295	Role of Improved Vascular Health in the Declining Incidence of Dementia. <i>Stroke</i> , 2017, 48, 2013-2020.	1.0	37
1296	Do Statins Have Antidepressant Effects?. <i>CNS Drugs</i> , 2017, 31, 335-343.	2.7	22
1297	Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 225.	4.5	140
1298	A complex association between ABCA7 genotypes and blood lipid levels in Southern Chinese Han patients of sporadic Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2017, 382, 13-17.	0.3	14
1299	Secular Trends in the Incidence of Dementia in a Multi-Ethnic Community. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1065-1075.	1.2	44
1300	Statin Therapy in Patients With Low Serum Levels of Low-Density Lipoprotein Cholesterol. <i>American Journal of Cardiology</i> , 2017, 120, 1947-1954.	0.7	3
1301	Four Decades of Research in Alzheimer's Disease (1975-2014): A Bibliometric and Scientometric Analysis. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 763-783.	1.2	33
1302	Statins and Cognition in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 661-667.	1.5	13
1303	Amyloid plaques beyond A β : a survey of the diverse modulators of amyloid aggregation. <i>Biophysical Reviews</i> , 2017, 9, 405-419.	1.5	74
1304	Hypercholesterolaemia and vascular dementia. <i>Clinical Science</i> , 2017, 131, 1561-1578.	1.8	94
1305	Epidemiology and risk factors for dementia. , 0, , 44-56.		0
1306	Neurodegenerative Disorders. , 2017, , 1-16.		18
1307	Dementia ascertainment using existing data in UK longitudinal and cohort studies: a systematic review of methodology. <i>BMC Psychiatry</i> , 2017, 17, 239.	1.1	40
1308	Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 201-207.	0.8	57
1309	Neuroinflammation in Alzheimer's disease: Pleiotropic roles for cytokines and neuronal pentraxins. <i>Behavioural Brain Research</i> , 2018, 347, 49-56.	1.2	39
1310	Interaction between amyloidogenic proteins and biomembranes in protein misfolding diseases: Mechanisms, contributors, and therapy. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2018, 1860, 1876-1888.	1.4	20
1311	Systematic review of the efficacy of statins for the treatment of Alzheimer's disease. <i>Clinical Medicine</i> , 2018, 18, 54-61.	0.8	29

#	ARTICLE	IF	CITATIONS
1312	CYP46A1 and the APOE ϵ 4 Allele Polymorphisms Correlate with the Risk of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 8179-8187.	1.9	15
1313	Differences in statin associated neuroprotection corresponds with either decreased production of IL-1 β or TNF- α in an in vitro model of neuroinflammation-induced neurodegeneration. <i>Toxicology and Applied Pharmacology</i> , 2018, 344, 56-73.	1.3	36
1314	Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. <i>Scientific Reports</i> , 2018, 8, 5804.	1.6	118
1315	Isoprenoids and tau pathology in sporadic Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 65, 132-139.	1.5	24
1316	Amyloids of multiple species: are they helpful in survival?. <i>Biological Reviews</i> , 2018, 93, 1363-1386.	4.7	11
1317	Androgen deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?. <i>Cancer</i> , 2018, 124, 1326-1334.	2.0	39
1318	Effect of atorvastatin on behavioral alterations and neuroinflammation during epileptogenesis. <i>Epilepsy and Behavior</i> , 2018, 78, 109-117.	0.9	23
1319	Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2018, 53, 279-310.	2.3	95
1320	Risk Factors and Prevention in Alzheimer's Disease and Dementia. , 2018, , 93-112.		3
1321	Cognitive Function and Vascular Risk Factors Among Older African American Adults. <i>Journal of Immigrant and Minority Health</i> , 2018, 20, 612-618.	0.8	6
1322	Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review. <i>Medicinal Research Reviews</i> , 2018, 38, 1126-1158.	5.0	35
1323	Comparative effect of statins on the risk of incident Alzheimer disease. <i>Neurology</i> , 2018, 90, e179-e187.	1.5	32
1324	Angiotensin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. <i>Brain</i> , 2018, 141, 3377-3388.	3.7	32
1325	Connecting the brain cholesterol and renin-angiotensin systems: potential role of statins and RAS-modifying medications in dementia. <i>Journal of Internal Medicine</i> , 2018, 284, 620-642.	2.7	30
1326	Statins use and risk of dementia. <i>Medicine (United States)</i> , 2018, 97, e11304.	0.4	59
1327	Headache disorder and the risk of dementia: a systematic review and meta-analysis of cohort studies. <i>Journal of Headache and Pain</i> , 2018, 19, 95.	2.5	29
1328	Cholesterol level correlate with disability score in patients with relapsing-remitting form of multiple sclerosis. <i>Neuroscience Letters</i> , 2018, 687, 304-307.	1.0	24
1329	Mild cognitive impairment and progression to dementia in people with diabetes, prediabetes and metabolic syndrome: a systematic review and meta-analysis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2018, 53, 1149-1160.	1.6	166

#	ARTICLE	IF	CITATIONS
1330	Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1345-1352.	1.2	23
1331	A validation study of the CirCom comorbidity score in an English cirrhosis population using the Clinical Practice Research Datalink. <i>Clinical Epidemiology</i> , 2018, Volume 10, 107-120.	1.5	3
1332	The Function of Geranylgeraniol. <i>Oleoscience</i> , 2018, 18, 99-106.	0.0	1
1333	Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid- β^2 clearance in human astrocytes. <i>Journal of Biological Chemistry</i> , 2018, 293, 11341-11357.	1.6	49
1334	Small molecule biomarkers in Alzheimer's disease. <i>OCL - Oilseeds and Fats, Crops and Lipids</i> , 2018, 25, D404.	0.6	5
1335	Simvastatin Enhances Activity and Trafficking of $\alpha 7$ Nicotinic Acetylcholine Receptor in Hippocampal Neurons Through PKC and CaMKII Signaling Pathways. <i>Frontiers in Pharmacology</i> , 2018, 9, 362.	1.6	22
1336	The lysolipid transporter Mfsd2a regulates lipogenesis in the developing brain. <i>PLoS Biology</i> , 2018, 16, e2006443.	2.6	75
1337	The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. <i>Translational Neurodegeneration</i> , 2018, 7, 5.	3.6	147
1338	Medication use to manage comorbidities for people with dementia: a systematic review. <i>Journal of Pharmacy Practice and Research</i> , 2018, 48, 356-367.	0.5	12
1339	Proton Pump Inhibitor Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis. <i>Drug Safety</i> , 2018, 41, 1387-1396.	1.4	31
1340	Novel Phenoxazinones as potent agonist of PPAR- α : design, synthesis, molecular docking and in vivo studies. <i>Lipids in Health and Disease</i> , 2018, 17, 120.	1.2	12
1341	Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study. <i>Journal of Affective Disorders</i> , 2018, 238, 542-546.	2.0	18
1342	Does Treating Vascular Risk Factors Prevent Dementia and Alzheimer's Disease? A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 657-668.	1.2	72
1343	Predicting dementia from primary care records: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0194735.	1.1	70
1344	Regulation of Brain Cholesterol: What Role Do Liver X Receptors Play in Neurodegenerative Diseases?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3858.	1.8	42
1345	Genetics, Ageing and Human Health. , 2019, , 193-209.		0
1346	Emerging roles for high-density lipoproteins in neurodegenerative disorders. <i>BioFactors</i> , 2019, 45, 725-739.	2.6	29
1347	Atherosclerosis Pathogenesis and Microvascular Dysfunction. , 2019, , .		8

#	ARTICLE	IF	CITATIONS
1348	Treatment with Statins in Elderly Patients. <i>Medicina (Lithuania)</i> , 2019, 55, 721.	0.8	47
1349	Menopause, cognition and dementia – A review. <i>Post Reproductive Health</i> , 2019, 25, 200-206.	0.3	21
1350	Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study. <i>PLoS ONE</i> , 2019, 14, e0220254.	1.1	36
1351	Comparative benefits of simvastatin and exercise in a mouse model of vascular cognitive impairment and dementia. <i>FASEB Journal</i> , 2019, 33, 13280-13293.	0.2	14
1352	Association of Early-Onset Alzheimer Disease With Elevated Low-Density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of <i>APOB</i> . <i>JAMA Neurology</i> , 2019, 76, 809.	4.5	94
1353	Why Is Very High Cholesterol Content Beneficial for the Eye Lens but Negative for Other Organs?. <i>Nutrients</i> , 2019, 11, 1083.	1.7	26
1354	The value of international studies. <i>Adoption & Fostering</i> , 2019, 43, 3-5.	0.2	0
1355	Unraveling the Paradox of Statins with Human Neurons: New Leads in Alzheimer's Disease. <i>Cell Stem Cell</i> , 2019, 24, 347-349.	5.2	12
1356	Nanotechnology approaches for enhanced CNS delivery in treating Alzheimer's disease. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 51, 297-309.	1.4	22
1357	A Review and Hypothesized Model of the Mechanisms That Underpin the Relationship Between Inflammation and Cognition in the Elderly. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 56.	1.7	74
1358	Is Alzheimer's Disease Risk Modifiable?. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 795-819.	1.2	73
1359	Relations of magnesium intake to cognitive impairment and dementia among participants in the Women's Health Initiative Memory Study: a prospective cohort study. <i>BMJ Open</i> , 2019, 9, e030052.	0.8	18
1360	Significant association of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) rs3846662 and sirtuin 1 (SIRT1) rs7895833 and apolipoprotein E (APOE) hypermethylation with mild cognitive impairment (MCI). <i>Medicine (United States)</i> , 2019, 98, e16405.	0.4	3
1361	High exposure to statins decrease the risk of new-onset dementia. <i>Medicine (United States)</i> , 2019, 98, e16931.	0.4	11
1362	Case-control study examining the association between hip fracture risk and statins therapy in old people. <i>Medicine (United States)</i> , 2019, 98, e17476.	0.4	12
1363	Statin therapy: does sex matter?. <i>Menopause</i> , 2019, 26, 1425-1435.	0.8	33
1364	Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 276-283.	2.0	13
1365	In silico evidence of direct interaction between statins and β -amyloid. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 4710-4715.	1.2	16

#	ARTICLE	IF	CITATIONS
1366	Coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin. <i>Nutritional Neuroscience</i> , 2019, 22, 264-272.	1.5	29
1367	Association between Use of Statin and Risk of Dementia: A Meta-Analysis of Observational Studies. <i>Neuroepidemiology</i> , 2020, 54, 214-226.	1.1	68
1368	Cholesterol and Dementia: A Long and Complicated Relationship. <i>Current Aging Science</i> , 2020, 13, 42-51.	0.4	22
1369	Effect of atorvastatin on A β 1-42-induced alteration of SESN2, SIRT1, LC3II and TPP1 protein expressions in neuronal cell cultures. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 424-436.	1.2	18
1370	Effect of statins on amyloidosis in the rodent models of Alzheimer's disease: Evidence from the preclinical meta-analysis. <i>Brain Research</i> , 2020, 1749, 147115.	1.1	6
1371	Cognitive impairment in a primary healthcare population: a cross-sectional study on the island of Crete, Greece. <i>BMJ Open</i> , 2020, 10, e035551.	0.8	2
1372	From beta amyloid to altered proteostasis in Alzheimer's disease. <i>Ageing Research Reviews</i> , 2020, 64, 101126.	5.0	31
1373	The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8745.	1.8	42
1374	Quinovic Acid Impedes Cholesterol Dyshomeostasis, Oxidative Stress, and Neurodegeneration in an Amyloid- β -Induced Mouse Model. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-20.	1.9	15
1375	Lovastatin Differentially Regulates α 7 and α 4 Neuronal Nicotinic Acetylcholine Receptor Levels in Rat Hippocampal Neurons. <i>Molecules</i> , 2020, 25, 4838.	1.7	10
1376	Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer's Disease Patients and Correlates with Cognitive Performance. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 733-744.	1.2	7
1378	Blood Lipids and Cognitive Performance of Aging Polish Adults: A Case-Control Study Based on the PolSenior Project. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 590546.	1.7	11
1379	Sex-specific associations between lipids and cognitive decline in the middle-aged and elderly: a cohort study of Chinese adults. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 164.	3.0	14
1380	Cholesterol and Alzheimer's Disease Risk: A Meta-Meta-Analysis. <i>Brain Sciences</i> , 2020, 10, 386.	1.1	72
1381	Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 154.	1.7	9
1382	Benefits of physical exercise on cognition and glial white matter pathology in a mouse model of vascular cognitive impairment and dementia. <i>Glia</i> , 2020, 68, 1925-1940.	2.5	18
1383	Association of combination statin and antihypertensive therapy with reduced Alzheimer's disease and related dementia risk. <i>PLoS ONE</i> , 2020, 15, e0229541.	1.1	41
1384	The CC Genotype of Insulin-Induced Gene 2 rs7566605 Is a Protective Factor of Hypercholesteremia Susceptible to Mild Cognitive Impairment, Especially to the Executive Function of Patients with Type 2 Diabetes Mellitus. <i>BioMed Research International</i> , 2020, 2020, 1-7.	0.9	4

#	ARTICLE	IF	CITATIONS
1385	Pollution, Particles, and Dementia: A Hypothetical Causative Pathway. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 862.	1.2	17
1387	Examining the benefits and harms of Alzheimer's disease screening for family members of older adults: study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 202.	0.7	8
1388	Influence of Western diet and APOE genotype on Alzheimer's disease risk. <i>Neurobiology of Disease</i> , 2020, 138, 104790.	2.1	15
1389	High-Cholesterol Diet Decreases the Level of Phosphatidylinositol 4,5-Bisphosphate by Enhancing the Expression of Phospholipase C (PLC β 1) in Rat Brain. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1161.	1.8	6
1390	Impact of Statin Use on Dementia Incidence in Elderly Men and Women with Ischemic Heart Disease. <i>Biomedicines</i> , 2020, 8, 30.	1.4	12
1391	Effect of Combined Antihypertensive and Lipid-Lowering Therapies on Cognitive Function: A New Treatment Strategy?. <i>Cardiology Research and Practice</i> , 2020, 2020, 1-10.	0.5	11
1392	Transcranial Doppler could help to differentiate the types of dementia? A pilot study when CSF biomarkers are not available. <i>Journal of Neural Transmission</i> , 2020, 127, 899-904.	1.4	2
1393	Critical epidemiological literacy: understanding ideas better when placed in relation to alternatives. <i>Synthese</i> , 2021, 198, 2411-2438.	0.6	2
1394	Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 773-783.	1.1	3
1395	The changing pattern of statin use in people with dementia: A population-based study. <i>Journal of Clinical Lipidology</i> , 2021, 15, 192-201.	0.6	5
1396	Association Between Low-Density Lipoprotein Cholesterol Levels, Statin Use, and Dementia in Patients followed in German General Practices. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 37-46.	1.2	19
1397	Cholesterol-lowering drugs reduce APP processing to A β 2 by inducing APP dimerization. <i>Molecular Biology of the Cell</i> , 2021, 32, 247-259.	0.9	32
1398	Recent approaches to target apoptosis in neurological disorders. , 2021, , 217-283.		1
1399	Anti-inflammatory Effects of Statins in Lung Vascular Pathology: From Basic Science to Clinical Trials. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1303, 33-56.	0.8	1
1400	Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100012.	1.7	7
1401	Ginsenoside Rb1 protected PC12 cells from A β 25-35-induced cytotoxicity via PPAR β activation and cholesterol reduction. <i>European Journal of Pharmacology</i> , 2021, 893, 173835.	1.7	12
1402	Cordyceps cicadae NTTU 868 Mycelium with The Addition of Bioavailable Forms of Magnesium from Deep Ocean Water Prevents the A β 40 and Streptozotocin-Induced Memory Deficit via Suppressing Alzheimer's Disease Risk Factors and Increasing Magnesium Uptake of Brain. <i>Fermentation</i> , 2021, 7, 39.	1.4	5
1403	Cholesterol and Alzheimer's Disease; From Risk Genes to Pathological Effects. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 690372.	1.7	110

#	ARTICLE	IF	CITATIONS
1404	Promoting Successful Cognitive Aging: A Ten-Year Update. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 871-920.	1.2	65
1405	Host Directed Therapies for Tuberculous Meningitis. <i>Wellcome Open Research</i> , 0, 5, 292.	0.9	6
1406	Probiotics Fermentation Technology, a Novel Kefir Product, Ameliorates Cognitive Impairment in Streptozotocin-Induced Sporadic Alzheimer's Disease in Mice. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-18.	1.9	10
1407	Biomarkers for the Clinical Diagnosis of Alzheimer's Disease: Metabolomics Analysis of Brain Tissue and Blood. <i>Frontiers in Pharmacology</i> , 2021, 12, 700587.	1.6	11
1408	Simvastatin therapy attenuates memory deficits that associate with brain monocyte infiltration in chronic hypercholesterolemia. <i>Npj Aging and Mechanisms of Disease</i> , 2021, 7, 19.	4.5	2
1409	Mid- and Late-Life Migraine Is Associated with an Increased Risk of All-Cause Dementia and Alzheimer's Disease, but Not Vascular Dementia: A Nationwide Retrospective Cohort Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 990.	1.1	8
1410	Vascular Dementia and Cognitive Impairment. , 2022, , 221-236.e8.		1
1411	Adherence to Statins Use and Risk of Dementia among Patients with Diabetes and Comorbid Hyperlipidemia. <i>Inquiry (United States)</i> , 2021, 58, 004695802110192.	0.5	0
1412	Sex and APOE genotype differences related to statin use in the aging population. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12156.	1.8	6
1413	Clinical Practice Research Datalink (CPRD). <i>Springer Series on Epidemiology and Public Health</i> , 2021, , 57-65.	0.5	4
1414	Statins, toxicity, and their adverse effects via oxidative imbalance. , 2021, , 263-280.		0
1415	Possible Relationship Between Statin Use and Decreased Incidence of Dementia: Are We Ready for a New Indication for These Drugs?. <i>Archives of Internal Medicine</i> , 2001, 161, 1909-1910.	4.3	4
1416	Falls and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors. <i>Archives of Internal Medicine</i> , 2002, 162, 2381-2381.	4.3	3
1417	Report on Statins and Dementia Disputed. <i>Archives of Neurology</i> , 2001, 58, 1166-1167.	4.9	6
1418	Apolipoprotein E: A Novel Therapeutic Target for the Treatment of Alzheimer's Disease. <i>Advances in Behavioral Biology</i> , 2002, , 39-43.	0.2	6
1419	Cholesterol—A Janus-Faced Molecule in the Central Nervous System. , 2007, , 151-170.		2
1420	Cholesterol and β^2 -Amyloid. , 2007, , 93-111.		1
1421	Living Longer, Healthier Lives. , 2007, , 53-78.		2

#	ARTICLE	IF	CITATIONS
1422	Zinc and Zinc Transport and Sequestration Proteins in the Brain in the Progression of Alzheimer's Disease. <i>Advances in Neurobiology</i> , 2011, , 669-693.	1.3	1
1423	Clusterin. , 2013, , 25-51.		1
1424	Statins and Age-Related Maculopathy. , 2007, , 185-196.		1
1425	The A β -centric Pathway of Alzheimer's Disease. , 2007, , 5-36.		1
1426	Cholesterol and Alzheimer's Disease. , 2007, , 142-158.		1
1427	History and development of HMG-CoA reductase inhibitors. , 2002, , 1-17.		2
1428	Lipoprotein Genes and Diet in the Evolution of Human Intelligence and Longevity. , 2003, , 33-67.		3
1429	Neuroinflammation in Alzheimer's Disease: Potential Targets for Disease-Modifying Drugs. , 2002, , 159-178.		1
1430	Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer's disease. , 2020, , 469-504.		5
1431	Amyloid β -peptide1-40 increases neuronal membrane fluidity: role of cholesterol and brain region. <i>Journal of Lipid Research</i> , 2001, 42, 1292-1297.	2.0	87
1432	Oxidized cholesterol species as signaling molecules in the brain: diabetes and Alzheimer's disease. <i>Neuronal Signaling</i> , 2019, 3, NS20190068.	1.7	8
1433	What's New in Alzheimer's Disease?. <i>Home Healthcare Nurse</i> , 2003, 21, 8-14.	0.4	6
1434	Treatment of Patients with Lipid Disorders in the Primary Care Setting: New Treatment Guidelines and their Implications. <i>Southern Medical Journal</i> , 2003, 96, 266-275.	0.3	5
1435	Treatments for Alzheimer Disease. <i>Southern Medical Journal</i> , 2005, 98, 628-635.	0.3	25
1436	Preoperative Use of Statins Is Associated with Reduced Early Delirium Rates after Cardiac Surgery. <i>Anesthesiology</i> , 2009, 110, 67-73.	1.3	180
1437	Cognitive Function and Antihypertensive Treatment in the Elderly: A 6-Year Follow-up Study. <i>American Journal of Therapeutics</i> , 2010, 17, 358-364.	0.5	24
1438	Detangling Alzheimer's Disease. <i>Science of Aging Knowledge Environment: SAGE KE</i> , 2003, 2003, 2oa-2.	0.9	6
1440	Transient global amnesia associated with statin intake. <i>BMJ Case Reports</i> , 2009, 2009, bcr0620080033-bcr0620080033.	0.2	6

#	ARTICLE	IF	CITATIONS
1441	Cholesterol, lipid rafts, and disease. <i>Journal of Clinical Investigation</i> , 2002, 110, 597-603.	3.9	808
1442	Isoprenoids as mediators of the biological effects of statins. <i>Journal of Clinical Investigation</i> , 2002, 110, 285-288.	3.9	327
1443	Cholesterol, lipid rafts, and disease. <i>Journal of Clinical Investigation</i> , 2002, 110, 597-603.	3.9	468
1444	Isoprenoids as mediators of the biological effects of statins. <i>Journal of Clinical Investigation</i> , 2002, 110, 285-288.	3.9	210
1445	Alzheimer disease therapy: Can the amyloid cascade be halted?. <i>Journal of Clinical Investigation</i> , 2003, 111, 11-18.	3.9	125
1446	Liver X receptors and cholesterol metabolism: role in ventral midbrain development and neurodegeneration. <i>F1000prime Reports</i> , 2015, 7, 37.	5.9	15
1447	Simvastatin Inhibits Renal Cancer Cell Growth and Metastasis via AKT/mTOR, ERK and JAK2/STAT3 Pathway. <i>PLoS ONE</i> , 2013, 8, e62823.	1.1	121
1448	Chronic Pravastatin but Not Atorvastatin Treatment Impairs Cognitive Function in Two Rodent Models of Learning and Memory. <i>PLoS ONE</i> , 2013, 8, e75467.	1.1	45
1449	Statin Use and Cognitive Function: Population-Based Observational Study with Long-Term Follow-Up. <i>PLoS ONE</i> , 2014, 9, e115755.	1.1	13
1450	Statins Reduces the Risk of Dementia in Patients with Late-Onset Depression: A Retrospective Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0137914.	1.1	14
1451	The Use of a Bayesian Hierarchy to Develop and Validate a Co-Morbidity Score to Predict Mortality for Linked Primary and Secondary Care Data from the NHS in England. <i>PLoS ONE</i> , 2016, 11, e0165507.	1.1	5
1452	IMAGING VASCULAR DISEASE AND AMYLOID IN THE AGING BRAIN: IMPLICATIONS FOR TREATMENT. <i>Journal of prevention of Alzheimer's disease, The</i> , 2015, 2, 1-7.	1.5	25
1453	Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 638-649.	0.6	17
1454	Lipidomics and cognitive dysfunction – A Narrative review. <i>Turkish Journal of Biochemistry</i> , 2020, 45, 109-119.	0.3	2
1455	Neuroprotective Effect of Rosuvastatin on Ca1 & Ca3 Regions of Hippocampus in High Fat Diet and Stress Induced Rats. <i>International Journal of Neurology and Brain Disorders</i> , 2014, 1, 1-5.	0.0	3
1456	Cholesterol Homeostasis Imbalance and Brain Functioning: Neurological Disorders and Behavioral Consequences. <i>Journal of Neurology and Neurological Disorders</i> , 2014, 1, .	0.0	5
1457	III Diretrizes Brasileiras Sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. <i>Arquivos Brasileiros De Cardiologia</i> , 0, 77, 1-48.	0.3	164
1458	Is it possible to prevent dementia?. <i>Revista Brasileira De Psiquiatria</i> , 2002, 24, 22-27.	0.9	8

#	ARTICLE	IF	CITATIONS
1459	A study of the neuroprotective role of Punica granatum and rosuvastatin in scopolamine induced cognitive deficit in rats. <i>International Journal of Basic and Clinical Pharmacology</i> , 2017, 6, 1773.	0.0	5
1460	An exploration of the role of a fish-oriented diet in cognitive decline: a systematic review of the literature. <i>Oncotarget</i> , 2017, 8, 39877-39895.	0.8	21
1461	Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2018, 6, 435-435.	0.7	14
1462	Vascular dementia: prevention and treatment. <i>Clinical Interventions in Aging</i> , 2006, 1, 229-235.	1.3	48
1463	Ongoing clinical trials of the pleiotropic effects of statins. <i>Vascular Health and Risk Management</i> , 2005, 1, 29-40.	1.0	41
1464	Cholesterol Homeostasis Failure in the Brain: Implications for Synaptic Dysfunction and Cognitive Decline. <i>Current Medicinal Chemistry</i> , 2014, 21, 2788-2802.	1.2	48
1465	Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases. <i>Current Drug Metabolism</i> , 2011, 12, 742-749.	0.7	65
1466	The Complex Actions of Statins in Brain and their Relevance for Alzheimer's Disease Treatment: an Analytical Review. <i>Current Alzheimer Research</i> , 2014, 11, 1-1.	0.7	24
1467	The Role of Brain Cholesterol and its Oxidized Products in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016, 13, 198-205.	0.7	35
1468	ACAT1 as a Therapeutic Target and its Genetic Relationship with Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2019, 16, 699-709.	0.7	5
1469	Cardiovascular Dementia - A Different Perspective. <i>The Open Biochemistry Journal</i> , 2010, 4, 29-52.	0.3	21
1470	A High-fat and High-Cholesterol Diet Potentiates Oxidative Damage in Hippocampus of Mice Lacking Apolipoprotein E. <i>The Open Neurology Journal</i> , 2018, 12, 12-18.	0.4	4
1471	Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application. <i>Current Molecular Pharmacology</i> , 2017, 10, 115-140.	0.7	12
1472	Apolipoprotein E and cholesterol in aging and disease in the brain. <i>Future Lipidology</i> , 2008, 3, 505-530.	0.5	140
1473	Atorvastatin reduces the expression of aldo-keto reductases in HUVEC and PTEC. A new approach to influence the polyol pathway. <i>Clinical and Investigative Medicine</i> , 2009, 32, 219.	0.3	10
1475	Treatment of cognitive impairment in Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2003, 5, 35-43.	1.8	13
1476	Is the distinction between Alzheimer's disease and vascular dementia possible and relevant?. <i>Dialogues in Clinical Neuroscience</i> , 2003, 5, 7-15.	1.8	14
1477	Neuropsychiatric consequences of cardiovascular medications. <i>Dialogues in Clinical Neuroscience</i> , 2007, 9, 29-45.	1.8	92

#	ARTICLE	IF	CITATIONS
1478	Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 111-128.	1.8	855
1479	Alzheimer's disease: How does it start?. <i>Journal of Alzheimer's Disease</i> , 2002, 4, 497-512.	1.2	88
1480	Potential use of routine databases in health technology assessment. <i>Health Technology Assessment</i> , 2005, 9, 1-92, iii-iv.	1.3	68
1481	Increased basolateral sorting of carcinoembryonic antigen in a polarized colon carcinoma cell line after cholesterol depletion-Implications for treatment of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2008, 14, 1528.	1.4	14
1482	The Heart Protection Study: high-risk patients benefit from statins, regardless of LDL-C level.. <i>Cleveland Clinic Journal of Medicine</i> , 2003, 70, 991-997.	0.6	15
1483	Does this patient have Alzheimer disease? Diagnosing and treating dementia.. <i>Cleveland Clinic Journal of Medicine</i> , 2003, 70, 762-762.	0.6	3
1484	Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial.. <i>Cleveland Clinic Journal of Medicine</i> , 2008, 75, S87-S87.	0.6	16
1485	Alzheimer disease: Time to improve its diagnosis and treatment. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, 49-58.	0.6	53
1486	An evaluation of the effect of atorvastatin on memory and psychomotor functions in hypertensive patients. <i>Journal of Postgraduate Medicine</i> , 2011, 57, 291-297.	0.2	8
1487	Effect of <i>Prunus domestica</i> L. (mirabelle) on learning and memory in mice. <i>Ancient Science of Life: Journal of International Institute of Ayurveda</i> , 2013, 32, 139.	0.3	9
1488	Neuroprotective effects of statins against amyloid β^2 -induced neurotoxicity. <i>Neural Regeneration Research</i> , 2018, 13, 198.	1.6	31
1489	Frailty: A Core Geriatric Concept. <i>Journal of the Korean Geriatrics Society</i> , 2010, 14, 1-7.	0.3	9
1490	High Fibre Diets and Alzheimer's Disease. <i>Food and Nutrition Sciences (Print)</i> , 2014, 05, 410-424.	0.2	20
1491	Linking multiple pathogenic pathways in Alzheimer's disease. <i>World Journal of Psychiatry</i> , 2016, 6, 208.	1.3	19
1492	Classification of Neurodegenerative Disorders Based on Major Risk Factors Employing Machine Learning Techniques. <i>International Journal of Engineering and Technology</i> , 2010, 2, 350-355.	0.1	14
1493	Common Factors of Alzheimer's Disease and Rheumatoid Arthritis's Pathomechanism and Treatment. <i>Molecules</i> , 2021, 26, 6038.	1.7	9
1494	Mild Cognitive Impairment. <i>Advances in Behavioral Biology</i> , 2002, , 177-182.	0.2	0
1496	Long-chain polyunsaturated fatty acids. , 2002, , 135-174.		0

#	ARTICLE	IF	CITATIONS
1497	Cholesterol and Alzheimer's disease. <i>Neurology</i> , 2002, 59, 150-151.	1.5	0
1498	Alzheimer's Disease, <i>Epidemiology</i> , 2003, , 96-102.		0
1500	Psychiatrische Erkrankungen. , 2003, , 1265-1384.		0
1503	The Principle Syndromes of Dementia. , 2004, , 1216-1233.		0
1504	Alzheimer's Disease and Vascular Dementia. , 2004, , 103-130.		0
1505	Cognitive Disorders and Dementia. , 2005, , 201-217.		0
1507	Stroke Prevention, Blood Cholesterol and Statins. <i>Neurological Disease and Therapy</i> , 2005, , 123-150.	0.0	0
1508	Non-cholinergic therapies of dementia. , 2005, , 518-525.		0
1510	Statins. , 2005, , 425-450.		0
1511	Spinal Surgery. <i>Spinal Surgery</i> , 2006, 20, 99-104.		0
1512	Treatment and Management of the Elderly Patients with Alzheimer's Disease. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2006, 2, 145-147.	0.0	0
1513	Prescribing options for dementia. <i>Independent Nurse</i> , 2006, 2006, .	0.0	0
1514	Statins and Toxicity. , 2006, , 273-295.		1
1515	Drugs from Molecular Targets for CNS and Neurodegenerative Diseases. , 2006, , 225-241.		0
1518	Interpreting Clinical Studies of Putative Therapeutics for Alzheimer's Disease: The Case of Statins and NSAIDs. , 2007, , 296-308.		0
1519	Japanese Journal of Clinical Pharmacology and Therapeutics, 2007, 38, 189-195.		0
1520	Increase of Amyloid-Beta Peptide Generation in High Cholesterol Diet Rabbit Brain. <i>Biomolecules and Therapeutics</i> , 2007, 15, 34-39.	1.1	0
1521	Neuroprotection for Acute Spinal Cord Injury - Comparison of Simvastatin and Atorvastatin -. <i>The Journal of the Korean Orthopaedic Association</i> , 2008, 43, 551.	0.0	0

#	ARTICLE	IF	CITATIONS
1522	èªçŸŸç—†ã®ã°é~2ã«ã~ä1/2•ã,'ã—ãŸã,%ã,^ã,ã«?. Juntendo, Igaku, 2008, 54, 508-510.	0.1	0
1524	La maladie d'Alzheimer : des lésions cérébrales aux perspectives thérapeutiques. Bulletin De L'Academie Nationale De Medecine, 2008, 192, 363-380.	0.0	6
1526	Prévention de la dépendance : le défi de la longévité. Bulletin De L'Academie Nationale De Medecine, 2009, 193, 455-471.	0.0	3
1527	Efectos no hipolipemiantes de las estatinas. Acta Medica Costarricense, 2008, 49, .	0.1	1
1528	Methodological issues in using prescription and other databases in pharmacoepidemiology. Norsk Epidemiologi, 2009, 11, .	0.2	3
1529	Amyloidogenic Processing of APP in Lipid Rafts. The Open Biology Journal, 2010, 3, 21-31.	0.5	0
1530	The Search for Biomarkers in Alzheimer's Disease. Indonesian Biomedical Journal, 2010, 2, 4.	0.2	0
1532	Dislipemia y demencia. Alzheimer Realidades E Investigaci3n En Demencia, 2011, , 33-39.	0.1	0
1533	Lipid-lowering therapy in elderly patients: Focus on statins and outcome. Arterial Hypertension (Russian Federation), 2011, 17, 415-424.	0.1	1
1536	Les enjeux de la prévention. Gerontologie Et Societe, 2012, vol. 35 / HS n° 1, 27-40.	0.1	2
1538	Alzheimer's Disease: Approaches to Pathogenesis in the Genomic Age. , 0, , .		0
1539	Therapeutic Opportunities in Alzheimer Disease: Current Concepts. , 2012, , 767-788.		0
1540	The Current Status of Alzheimer's Disease Treatment. Frontiers in Neuroscience, 2012, , 117-161.	0.0	0
1541	The impact of simvastatin vs. atorvastatin on cognitive function in obese hypertensives. Arterial Hypertension (Russian Federation), 2012, 18, 228-234.	0.1	0
1543	Homage to Rita Levi-Montalcini. Molecular mechanisms of Alzheimer's disease: NGF modulation of APP processing. Adipobiology, 2014, 5, 7.	0.1	6
1544	Reconsidering markers of oxidative stress. Medical Journal of Indonesia, 2013, 22, 195.	0.2	0
1545	Can Microbes Play a Role in the Pathogenesis of Alzheimer Disease?. , 2014, , 129-146.		0
1546	Rational of Current Practice of Prescribing Statin to Treat Dyslipidaemia as Primary Prevention of Coronary Heart Disease in Elderly People. Ibrahim Cardiac Medical Journal, 2011, 1, 45-55.	0.1	0

#	ARTICLE	IF	CITATIONS
1547	STATINS AND MEMORY LOSS: THE AUSTRALIAN PERSPECTIVE. Australasian Medical Journal, 2015, 08, .	0.1	0
1550	Controversies over Statins-related Cognitive Impairment. International Journal of Cardiovascular and Cerebrovascular Disease, 2016, 4, 20-25.	0.1	0
1551	Factors associated with cognitive performance of non-demented elderly outpatients. PAJAR - Pan-American Journal of Aging Research, 2016, 4, 5.	0.1	1
1552	Risk Factors and Prevention in Light of Atherosclerosis Being a Microvascular Disease. , 2019, , 75-95.		0
1553	Improving the Quality of Life of Individuals with Dementia Using Personal Digital Media. Intelligent Systems Reference Library, 2020, , 311-334.	1.0	1
1554	Behavioral and Psychological Symptoms in Vascular Cognitive Impairment. Stroke Revisited, 2020, , 43-59.	0.2	0
1556	Doctorsâ€™ health & performance. , 2020, , 860-879.		0
1558	Ear, nose, and throat. , 2020, , 384-431.		0
1559	Cognitive Function Assessment in Patients on Moderate- or High-Intensity Statin Therapy. Journal of Clinical Medicine Research, 2020, 12, 255-265.	0.6	9
1560	Host Directed Therapies for Tuberculous Meningitis. Wellcome Open Research, 2020, 5, 292.	0.9	9
1561	Revisiting Alzheimerâ€™s Disease. , 2020, , 137-155.		0
1562	Molecular Modelling Based Design and Synthesis of Donepezil Like Derivatives As Acetylcholinesterase Inhibitors. SSRN Electronic Journal, 0, , .	0.4	1
1563	Synthesis and biological evaluation of novel Î²-cyclodextrin-fluvastatin conjugates. Results in Chemistry, 2021, 3, 100230.	0.9	0
1564	Progress in the development of new drugs in Alzheimerâ€™s disease. Journal of Nutrition, Health and Aging, 0, , .	1.5	0
1565	Demenzkerkrankungen. , 2005, , 1395-1402.		0
1566	Cholesterol Transport and Production in Alzheimerâ€™s Disease. , 2008, , 211-219.		1
1567	Cholesterol and AÎ² Production: Methods for Analysis of Altered Cholesterol De Novo Synthesis. , 2008, , 221-230.		0
1568	Alzheimer disease therapy: Can the amyloid cascade be halted?. Journal of Clinical Investigation, 2003, 111, 11-18.	3.9	57

#	ARTICLE	IF	CITATIONS
1569	Genetics and Neurobiology of Alzheimer's Disease and Frontotemporal Dementias. , 2006, , 1130-1141.		0
1570	Mouse Models of Alzheimer's Disease. , 2007, , 259-273.		0
1571	Therapy of vascular dementia: perspectives and milestones. Therapy: Open Access in Clinical Medicine, 2005, 2, 649-658.	0.2	1
1572	Demenzkerkrankungen. , 2007, , 1572-1580.		0
1573	Biomarkers of Alzheimer disease in plasma. Neurotherapeutics, 2004, 1, 226-234.	2.1	0
1574	Statins and the prevention of dementia. Cmaj, 2001, 165, 908-9.	0.9	6
1575	Diet and Alzheimer's disease: what the evidence shows. MedGenMed: Medscape General Medicine, 2004, 6, 48.	0.2	6
1580	Sensitivity and specificity of neuroimaging for the diagnosis of Alzheimer's disease. Dialogues in Clinical Neuroscience, 2003, 5, 89-99.	1.8	11
1582	Type 2 diabetes and ethnic disparities in cognitive impairment. Ethnicity and Disease, 2012, 22, 38-44.	1.0	37
1586	Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals. Current Opinion in Investigational Drugs, 2010, 11, 884-900.	2.3	28
1587	Biliverdin Reductase-A correlates with inducible nitric oxide synthase in atorvastatin treated aged canine brain. Neural Regeneration Research, 2013, 8, 1925-37.	1.6	11
1588	CHOLESTEROL AND NEURONAL SUSCEPTIBILITY TO BETA-AMYLOID TOXICITY. Cognitive Sciences, 2010, 5, 35-56.	0.0	5
1589	Systematic review of atorvastatin for the treatment of Alzheimer's disease. Neural Regeneration Research, 2012, 7, 1344-51.	1.6	4
1591	The Black Book of Psychotropic Dosing and Monitoring. Psychopharmacology Bulletin, 2018, 48, 64-153.	0.0	1
1594	Environmental Pyrethroid Exposure and Cognitive Dysfunction in U.S. Older Adults: The NHANES 2001-2002. International Journal of Environmental Research and Public Health, 2021, 18, 12005.	1.2	7
1595	An evidence-based review of neuronal cholesterol role in dementia and statins as a pharmacotherapy in reducing risk of dementia. Expert Review of Neurotherapeutics, 2021, 21, 1455-1472.	1.4	3
1597	Pre-hospital emergency medicine. , 2020, , 624-655.		0
1598	General practice. , 2020, , 774-841.		0

#	ARTICLE	IF	CITATIONS
1602	Eponymous syndromes. , 2020, , 842-859.		0
1604	Orthopaedics. , 2020, , 462-519.		1
1608	Gynaecology. , 2020, , 104-177.		0
1609	Risk Factors, Lifestyle Behaviors, and Vascular Brain Health. <i>Stroke</i> , 2022, 53, 394-403.	1.0	18
1611	Etiology and Histopathology of Alzheimerâ€™s Disease and Current Approaches. <i>Black Sea Journal of Health Science</i> , 0, , .	0.4	1
1612	The role of DHCR24 in the pathogenesis of AD: re-cognition of the relationship between cholesterol and AD pathogenesis. <i>Acta Neuropathologica Communications</i> , 2022, 10, 35.	2.4	12
1613	Adult atopic eczema and the risk of dementia: A population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 314-322.	0.6	8
1614	Molecular targets of statins and their potential side effects: Not all the glitter is gold. <i>European Journal of Pharmacology</i> , 2022, 922, 174906.	1.7	15
1615	Statin use and risk of dementia or Alzheimerâ€™s disease: a systematic review and meta-analysis of observational studies. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 804-814.	0.8	46
1619	Alzheimerâ€™s Disease: A Washing Machine on the Fritz. <i>Journal of Behavioral and Brain Science</i> , 2022, 12, 131-163.	0.2	1
1620	Sensitivity and specificity of neuroimaging for the diagnosis of Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2003, 5, 89-99.	1.8	25
1621	Therapeutic Targeting of Rab GTPases: Relevance for Alzheimerâ€™s Disease. <i>Biomedicines</i> , 2022, 10, 1141.	1.4	9
1622	Effects of HSYA on serum and brain cholesterol levels in AD rats based on quantitative proteomics. <i>International Journal of Neuroscience</i> , 2023, 133, 1411-1423.	0.8	0
1623	Use of Lipid-Lowering Drugs After Intracerebral Hemorrhage. <i>Stroke</i> , 2022, 53, 2161-2170.	1.0	11
1624	Cholesterol and Dementia: A Possible Therapeutic Approach. , 2022, , 357-385.		0
1625	Diabetes and cognitive dysfunction. , 2023, , 185-201.		2
1627	Cholesterol as a key player in amyloid Î²-mediated toxicity in Alzheimerâ€™s disease. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	21
1628	Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	78

#	ARTICLE	IF	CITATIONS
1629	Neuropharmacology in Alzheimer and Huntington Disease. , 2022, , 218-260.		0
1630	Statin contribution to middle cerebral artery blood flow velocity in older adults at risk for dementia. European Journal of Applied Physiology, 2022, 122, 2417-2426.	1.2	2
1631	Cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, .	3.0	6
1632	Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review. Brain Sciences, 2022, 12, 1290.	1.1	33
1634	A Call for Drug Therapies for the Treatment of Social Behavior Disorders in Dementia: Systematic Review of Evidence and State of the Art. International Journal of Molecular Sciences, 2022, 23, 11550.	1.8	2
1635	Potential of Therapeutic Small Molecules in Apoptosis Regulation in the Treatment of Neurodegenerative Diseases: An Updated Review. Molecules, 2022, 27, 7207.	1.7	7
1638	Association of statin therapy with progression of carotid arterial stiffness: the Multi-Ethnic Study of Atherosclerosis (MESA). Hypertension Research, 2023, 46, 679-687.	1.5	5
1639	A Review on Phyto-Therapeutic Approaches in Alzheimer's Disease. Journal of Functional Biomaterials, 2023, 14, 50.	1.8	5
1640	Oral Anticoagulants and the Risk of Dementia in Patients With Nonvalvular Atrial Fibrillation. Neurology, 2023, 100, .	1.5	7
1641	Longitudinal associations between use of antihypertensive, antidiabetic, and lipid-lowering medications and biological aging. GeroScience, 2023, 45, 2065-2078.	2.1	2
1645	Lipid-lowering therapy and the risk of dementia: lessons learned from two decades of controversy. European Heart Journal, 0, , .	1.0	0
1646	Pharmacoepidemiology Research Delivering Evidence About Drug Safety in Dementia. , 2022, , 1-15.		0
1660	Risikofaktoren und Prävention im Licht der Atherosklerose als Mikrozirkulationskrankheit. , 2023, , 81-102.		0
1661	Cognitive Enhancers and Treatments for Alzheimer's Disease. , 2023, , 1-42.		0
1666	The translational potential of cholesterol-based therapies for neurological disease. Nature Reviews Neurology, 2023, 19, 583-598.	4.9	3
1669	Pharmacoepidemiology Research Delivering Evidence About Drug Safety in Dementia. , 2023, , 1090-1104.		0
1671	Introduction to Alzheimer's Disease. , 2023, , 1-26.		0
1672	Statins' Effects on Alzheimer's Disease. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1673	Management of Cardiovascular Disease in the Elderly. , 2023, , 1-41.		0
1677	Management of Cardiovascular Disease in the Elderly. , 2024, , 343-383.		0